fluorouracil has been researched along with Lung Neoplasms in 1346 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy." | 9.30 | Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. ( Chen, J; Chen, X; Chua, MLK; Han, F; Hu, G; Hu, X; Li, J; Mai, H; Miao, J; Shao, X; Shen, G; Shi, M; Wang, L; Wu, S; Xie, C; Zhang, N; Zhao, C, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 9.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| " This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma." | 9.20 | Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 9.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 9.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 9.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 9.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 9.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 9.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 9.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 9.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 9.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 9.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 9.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis." | 9.11 | Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 9.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 9.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 9.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 9.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 9.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 9.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 9.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 9.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)." | 9.06 | 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 9.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 8.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 8.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| " Thus, this study was aimed to investigate the potential cytotoxic, antiproliferative and apoptosis-triggering effects of a newly developed SLN-Carmofur compound on human lung adenocarcinoma A549 cells." | 8.02 | Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment. ( Çömlekçi, E; Kutlu, HM; Vejselova Sezer, C, 2021) |
| " We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus." | 7.96 | Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020) |
| "The aim of this retrospective study was to analyse the efficacy of gemcitabine-oxaliplatin (gemox) or 5-fluorouracil-oxaliplatin (folfox) in the treatment of metastatic pulmonary carcinoid tumors." | 7.83 | Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. ( Arpin, D; Baudin, E; Berdelou, A; Bouledrak, K; Ducreux, M; Dussol, AS; Guigay, J; Hervieu, V; Lombard-Bohas, C; Planchard, D; Scoazec, JY; Souquet, PJ; Walter, T, 2016) |
| "When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis." | 7.83 | Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016) |
| "This study aimed to investigate the clinical application value of the 5-fluorouracil (5-FU) sustained-release particles implanted along the cardiac tangent direction into malignant pericardial effusion (MPCE)." | 7.81 | Therapeutic effects of 5-fluorouracil sustained-release particles in 81 malignant pericardial effusion patients. ( Cui, WC; Dong, L; Gao, Y; Ji, YL; Li, P; Li, RZ; Liang, XH; Pang, MX; Xue, LF, 2015) |
| "This study proposed a conception of individualized chemotherapy based on organ selectivity of drug distribution by retrospectively comparing the effect of vinorelbine and capecitabine in patients with metastatic breast cancer." | 7.80 | Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. ( Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 7.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| " This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC." | 7.79 | Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 7.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| "To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)." | 7.77 | A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 7.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 7.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 7.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 7.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 7.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| " We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy." | 7.75 | Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009) |
| "Umbilical cord matrix stem (UCMS) cells that were engineered to express interferon-beta (IFN-beta) were transplanted weekly for three weeks into MDA 231 breast cancer xenografts bearing SCID mice in combination with 5-fluorouracil (5-FU)." | 7.74 | Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. ( Ayuzawa, R; Edwards, SM; Marini, FC; Pyle, MM; Rachakatla, RS; Tamura, M; Troyer, D; Weiss, ML, 2008) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 7.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| "Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas." | 7.74 | Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 7.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 7.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 7.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 7.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP." | 7.70 | Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 7.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 7.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 7.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 7.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 7.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 7.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 7.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 7.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)." | 7.67 | Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 7.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients." | 7.67 | 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987) |
| "Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks." | 7.67 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986) |
| "Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)." | 7.66 | Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 7.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)." | 7.66 | 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 7.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)." | 7.66 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease." | 6.74 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES, 2009) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 6.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Patients with tracheal or major airway obstruction owing to inoperable carcinomas are at risk of developing respiratory failure or postobstructive pneumonia." | 6.71 | Intratumoural chemotherapy with 5-fluorouracil for palliation of bronchial cancer in patients with severe airway obstruction. ( Celikoğlu, F; Celikoğlu, SI, 2003) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 6.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 6.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 6.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 6.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 6.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 6.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "Ginsenoside Rg3 (Rg3) has a strong anticancer influence on colon cancer, breast cancer, lung cancer, and other malignant tumors." | 5.72 | Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells. ( Deng, Y; Du, Z; Shan, K; Yang, S; Yue, P, 2022) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 5.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 5.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 5.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 5.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| "We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy." | 5.30 | Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. ( Chen, J; Chen, X; Chua, MLK; Han, F; Hu, G; Hu, X; Li, J; Mai, H; Miao, J; Shao, X; Shen, G; Shi, M; Wang, L; Wu, S; Xie, C; Zhang, N; Zhao, C, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 5.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Patients with hepatic metastases have 5-FU TBCs about half that of those found in patients without hepatic involvement." | 5.26 | Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. ( Byfield, JE; Floyd, RA; Frankel, SS; Griffiths, JC; Hornbeck, CL, 1982) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| " This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma." | 5.20 | Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 5.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 5.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 5.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 5.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 5.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| " This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." | 5.13 | Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity." | 5.13 | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 5.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 5.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 5.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50." | 5.12 | A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. ( Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 5.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 5.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 5.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis." | 5.11 | Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004) |
| "Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC)." | 5.11 | Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. ( Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 5.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "The purpose of this study was to evaluate the prognostic value of quantitative dynamic FDG PET studies in patients with metastastic colorectal cancer receiving FOLFOX (fluorouracil, folinic acid and oxaliplatin) chemotherapy." | 5.10 | PET-FDG as predictor of therapy response in patients with colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Rudi, J; Strauss, LG, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 5.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 5.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 5.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 5.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 5.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 5.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 5.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Using a randomized prospective trial design, chemotherapy with 5-fluorouracil, vincristine, and mitomycin C (FOMi) was compared with cyclophosphamide, doxorubicin, and cisplatin (CAP) and with FOMi alternating with CAP (FOMi/CAP) in 452 eligible patients with metastatic large-cell undifferentiated and adenocarcinoma of the lung." | 5.06 | Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. ( Chen, TT; Coltman, CA; Fletcher, WS; Livingston, RB; Miller, TP; O'Bryan, RM; Stephens, RL; Vance, RB; Weiss, GB, 1986) |
| "Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)." | 5.06 | 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 5.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| " The early diagnosis was a choriocarcinoma, and combination chemotherapy (etoposide, kengshengmycin, methotrexate, leucovorin, vincristine, and cyclophosphamide [EMACO]) was administered." | 4.98 | Postmenopausal choriocarcinoma: a rare case report and review of the literature. ( Guo, N; Li, Q; Song, L; Wang, D; Yin, R, 2018) |
| "We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC)." | 4.90 | [A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. ( Akasu, I; Fukushima, G; Kataoka, H; Kondo, K; Magata, H; Marutsuka, H; Nakamura, K; Otani, K; Sato, Y; Yano, K; Yonei, A, 2014) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 4.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 4.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| "This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors." | 4.31 | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |
| " Thus, this study was aimed to investigate the potential cytotoxic, antiproliferative and apoptosis-triggering effects of a newly developed SLN-Carmofur compound on human lung adenocarcinoma A549 cells." | 4.02 | Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment. ( Çömlekçi, E; Kutlu, HM; Vejselova Sezer, C, 2021) |
| " We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus." | 3.96 | Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| "We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease." | 3.88 | KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018) |
| "Between November 2002 and January 2015, 14 patients with 29 unresectable pulmonary or mediastinal breast cancer metastases underwent transcatheter arterial chemoembolization using SAP-MS (50-100 μm) after injection of a combination of 2-4 types of anticancer drugs (eg, cisplatin [30 mg] + fluorouracil [500 mg], or epirubicin [40 mg] + mitomycin C [4 mg] + fluorouracil [500 mg])." | 3.85 | Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer. ( Hori, A; Hori, S; Kennoki, N; Yuki, T, 2017) |
| "We retrospectively investigated 156 patients with unresectable colorectal cancer who received oxaliplatin- or irinotecan-based first-line systemic chemotherapy with or without antibodies in our department between January 2007 and December 2015." | 3.85 | Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K, 2017) |
| "The aim of this retrospective study was to analyse the efficacy of gemcitabine-oxaliplatin (gemox) or 5-fluorouracil-oxaliplatin (folfox) in the treatment of metastatic pulmonary carcinoid tumors." | 3.83 | Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. ( Arpin, D; Baudin, E; Berdelou, A; Bouledrak, K; Ducreux, M; Dussol, AS; Guigay, J; Hervieu, V; Lombard-Bohas, C; Planchard, D; Scoazec, JY; Souquet, PJ; Walter, T, 2016) |
| "When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis." | 3.83 | Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016) |
| "This study aimed to investigate the clinical application value of the 5-fluorouracil (5-FU) sustained-release particles implanted along the cardiac tangent direction into malignant pericardial effusion (MPCE)." | 3.81 | Therapeutic effects of 5-fluorouracil sustained-release particles in 81 malignant pericardial effusion patients. ( Cui, WC; Dong, L; Gao, Y; Ji, YL; Li, P; Li, RZ; Liang, XH; Pang, MX; Xue, LF, 2015) |
| "This study proposed a conception of individualized chemotherapy based on organ selectivity of drug distribution by retrospectively comparing the effect of vinorelbine and capecitabine in patients with metastatic breast cancer." | 3.80 | Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. ( Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 3.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| " This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC." | 3.79 | Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 3.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| "Fourteen cases of metastatic brain tumors from lung cancer underwent biochemical modulation chemotherapy with daily administration of small doses of CDDP (5 or 10 mg/day) and continuous infusion of 5-FU (300 mg/day) for three tow six weeks." | 3.78 | [Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. ( Hagiwara, Y; Kanayama, T; Moriuchi, S; Nakagawa, H; Yamada, M, 1997) |
| "To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)." | 3.77 | A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011) |
| " The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer." | 3.77 | Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. ( Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| " We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC)." | 3.77 | Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. ( Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H, 2011) |
| "The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer." | 3.77 | Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. ( Boc, M; Ocvirk, J; Rebersek, M, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 3.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 3.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 3.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital." | 3.76 | Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 3.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 3.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)." | 3.75 | Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009) |
| " We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy." | 3.75 | Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "Umbilical cord matrix stem (UCMS) cells that were engineered to express interferon-beta (IFN-beta) were transplanted weekly for three weeks into MDA 231 breast cancer xenografts bearing SCID mice in combination with 5-fluorouracil (5-FU)." | 3.74 | Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. ( Ayuzawa, R; Edwards, SM; Marini, FC; Pyle, MM; Rachakatla, RS; Tamura, M; Troyer, D; Weiss, ML, 2008) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 3.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas." | 3.74 | Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| "The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue." | 3.74 | A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 3.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "A 35-year-old woman with taxane and anthracycline-resistant recurrent breast cancer with multiple lung metastasis and carcinomatous lymphangitis was treated with CMF as third-line chemotherapy." | 3.73 | [A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy]. ( Bando, H; Emori, N; Hiranuma, C; Ishiguro, K; Kadoya, S; Kinoshita, S; Koizumi, H; Morita, K; Murakami, N; Yamada, T; Yoshino, H, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 3.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases." | 3.72 | [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 3.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| " A postmenopausal woman was treated for stage II breast cancer with a modified radical mastectomy and adjuvant cyclophosphamide, doxorubicin, and 5-flurouracil followed by tamoxifen for 5 years." | 3.72 | Raloxifene rebound regression. ( Dosik, M; Kaufman, R, 2004) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT." | 3.71 | [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002) |
| "For patients with incurable stage IV colorectal cancer, minimally symptomatic primary tumours were left in situ and 5-fluorouracil-based chemotherapy was administered systemically." | 3.71 | Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. ( Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT, 2001) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)." | 3.70 | Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998) |
| " It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer." | 3.70 | A risk-benefit assessment of irinotecan in solid tumours. ( Rowinsky, EK; Siu, LL, 1998) |
| "The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was explored in the human MX-1 breast carcinoma and human H460 and Calu-6 non-small cell lung carcinoma xenografts to assess antitumor activity and toxicity (body weight loss)." | 3.70 | Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. ( Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA, 2000) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 3.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases." | 3.70 | [Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000) |
| "To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP." | 3.70 | Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 3.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 3.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 3.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 3.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)." | 3.68 | Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 3.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 3.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 3.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 3.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| " Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma." | 3.67 | [Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion]. ( Inoue, F; Mimura, H; Miyake, M; Mori, T; Orita, K; Takeda, I; Tanaka, N, 1988) |
| "When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity." | 3.67 | Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989) |
| "27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)." | 3.67 | Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989) |
| " This study provided evidence that the combination of DP and amphotericin B (AmB) significantly potentiated the inhibitory effect of 5-fluorouracil (FU) or methotrexate (MTX) against a panel of transplantable tumors including sarcoma 180, cervical carcinoma U14, and Lewis lung carcinoma in mice." | 3.67 | Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. ( Cao, SS; Zhen, YS, 1989) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 3.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients." | 3.67 | 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987) |
| "Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks." | 3.67 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates." | 3.67 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985) |
| "Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)." | 3.66 | Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| " The antitumor activity of this compound was superior to those of 5-FU and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur, Ftorafur) in the treatment of transplantable tumors, not only 5-FU-sensitive tumors such as adenocarcinoma 755, lymphosarcoma LS-1, and plasmacytoma X5563, but also 5-FU-resistant tumors such as Lewis lung carcinoma and Walker carcinosarcoma 256." | 3.66 | Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. ( Arakawa, M; Inomata, T; Sasagawa, K; Shimizu, F; Shinkai, K, 1981) |
| " Results of treatment of B16 melanoma and Lewis lung carcinoma with 3,4-dihydroxybenzohydroxamic acid are used to demonstrate this definition." | 3.66 | Drug activity and therapeutic synergism in cancer treatment. ( Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL, 1982) |
| "The combined effect of the polysaccharide levan (previously shown to exert a host-dependent as well as direct antitumoural activity) and the cytotoxic agents cyclophosphamide (CY), methotrexate (MTX), vincristine (VINC) and 5-fluoro-uracil (SFU) was studied in Lewis lung carcinoma and AKR lymphoma." | 3.66 | Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice. ( Leibovici, J; Stark, Y; Wolman, M, 1983) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 3.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)." | 3.66 | 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981) |
| "Antitumor activity of seven 5-fluorouracil derivatives having carbamoyl linkage with amino acid was examined against L-1210 leukemia, adenocarcinoma 755, ascites sarcoma 180, Ehrlich ascites carcinoma and Lewis lung carcinoma by oral administration." | 3.66 | Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration. ( Ando, N; Hoshi, A; Iigo, M; Inomata, M; Kuretani, K, 1981) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 3.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)." | 3.66 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979) |
| " Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections." | 3.65 | Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| " In squamous cell cancer of the lung 48 patients were administered methotrexate (90 mg per course), 18 patients with adenocarcinoma--5-fluoruracil, 29 patients with undifferentiated cancer-cyclophosphane (3 g of each substance)." | 3.65 | [Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)]. ( Abisatov, KhA; Khan, SV, 1976) |
| "Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms." | 3.65 | Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| " Our previous clinical study found that anlotinib combined with S-1 has better short-term ORR than the single-agent anlotinib of SCLC and other small-molecule vascular targeted drug therapies in the treatment of SCLC." | 3.11 | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer. ( Lan, Y; Lv, D; Meng, Y; Pi, W; Wang, W; Wu, X; Xia, X; Yang, H, 2022) |
| " Patients exhibiting EWL had worse survival and higher frequencies of adverse events." | 3.11 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control." | 2.79 | Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. ( Bressel, M; Chander, S; Cooray, P; Heriot, A; Hicks, R; Jefford, M; Leong, T; MacKay, JR; McClure, B; McKendrick, J; Michael, M; Ngan, SY; Steel, M; Zalcberg, J, 2014) |
| "Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15." | 2.78 | Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. ( El-Hadaad, HA; Wahba, HA, 2013) |
| "Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself." | 2.76 | Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. ( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative." | 2.76 | Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. ( Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T, 2011) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days." | 2.74 | Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. ( Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J, 2009) |
| "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease." | 2.74 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES, 2009) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 2.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Gemcitabine was given at 1,000 mg/m(2) weekly for 3 weeks followed by 1 week rest then 5-6 weeks of radiotherapy and concurrent CI 5FU (200 mg/m(2)/day)." | 2.73 | 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. ( Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y, 2008) |
| "Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients." | 2.73 | Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007) |
| "For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX)." | 2.72 | Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Patients with tracheal or major airway obstruction owing to inoperable carcinomas are at risk of developing respiratory failure or postobstructive pneumonia." | 2.71 | Intratumoural chemotherapy with 5-fluorouracil for palliation of bronchial cancer in patients with severe airway obstruction. ( Celikoğlu, F; Celikoğlu, SI, 2003) |
| "Treatment was given until disease progression or unacceptable toxicity." | 2.71 | A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 2.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| "From 2% to 10% of cancer patients treated with 5-fluorouracil (5-FU) will develop symptomatic cardiotoxicity." | 2.71 | 5-Fluorouracil induces arterial vasocontractions. ( Enderle, MD; Graeven, U; Pahlke, M; Petz, C; Schmiegel, W; Südhoff, T; Teschendorf, C, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| " Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed." | 2.71 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. ( Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005) |
| "To explore the efficacy and safety of CPT-11 combined with fluoropyrimidine in treatment for advanced or metastatic colorectal carcinoma." | 2.71 | [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. ( Wu, WQ; Yu, BM, 2005) |
| " Three of 7 (43%) patients treated with irinotecan 300 mg/m(2) and capecitabine 2,300 mg/d had course 1 dose-limiting toxicity (DLT) defining maximum tolerated dosage (MTD)." | 2.70 | Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. ( Baker, C; Chun, HG; Fehn, K; Goel, S; Hoffman, A; Hopkins, U; Jhawer, M; Landau, L; Makower, D; Mani, S; Rajdev, L; Wadler, S, 2002) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 2.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| "Music therapy combined with anti-tumor drugs, including chemotherapy and Chinese drugs, was given to 162 tumor patients according to syndrome differentiation to observe the change of self-rating depression scale (SDS), self-rating anxiety scale (SAS), minnesota multiphasic personality inventory (MMPI), Hamilton rating scale for depression (HAMD) and T lymphocyte subsets (immuno-histochemical assay), NK cell anti-tumor activity (NAG method), etc." | 2.70 | [Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients]. ( Cai, GR; Jiao, LP; Li, PW, 2001) |
| "To observe the complementary function of moxibustion and Guben Yiliu III (GBYL), a Chinese herbal composite preparation, in combination with chemotherapy." | 2.70 | [Study on effect of moxibustion and guben yiliu III combined with chemotherapy in treating middle-late stage malignant tumor]. ( Liu, J; Rao, XQ; Yu, RC, 2001) |
| "The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients." | 2.70 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. ( Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 2.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| " None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU." | 2.68 | [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995) |
| "Chemotherapy for squamous cell carcinoma with unknown primary (SCUP) has not been prospectively studied." | 2.68 | Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. ( Allred, C; Anand, V; Khansur, T; Little, D, 1995) |
| " In total, 158 courses (median: 4, range: 1 through 16; 81 and 58 courses at, respectively, a 40 and 50 to 55 mg/m2 daily dosage of C) were delivered using a multichannel programmable in-time pump (Intelliject, Aguettant) connected to a double lumen implanted venous side-port." | 2.68 | Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. ( Denis, B; Focan, C; Focan-Henrard, D; Kreutz, F; Levi, F, 1995) |
| "Women with resected T1-3N1,2 primary breast cancer and > or = 10 positive axillary lymph nodes referred for possible trial participation were evaluated for this report." | 2.68 | Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. ( Crump, M; Girouard, C; Goss, PE; Prince, M, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 2.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 2.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "The response rate was 56." | 2.68 | [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997) |
| " Frequent dosage modifications were required with the dose intensity of 5-FU and alpha interferon of 57% and 58%, respectively." | 2.67 | Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. ( Dreicer, R; Forest, PK; Williams, RD, 1994) |
| "61 cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy." | 2.67 | [Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy]. ( Chen, CH; Sun, GZ; Wang, GM, 1994) |
| " Significant hematological toxicity was documented but the most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths." | 2.67 | A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. ( Berchier, MC; Bureau, G; Dabouis, G; Klastersky, J; Libert, P; Ries, F; Schmerber, J; Sculier, JP; Thiriaux, J; Van Cutsem, O, 1994) |
| " QDBS syndrome is somehow related to immuno-deficiency and blood hypercoagulability, the method of Yiqi Huoxue (YQHX) which used to be combined with chemotherapy could not only reduce the toxic-side effects of chemotherapy, but also improve the cellular immune function and hemorheology." | 2.67 | [Studies of guben quyu No I combined with chemotherapy in treating cancer]. ( Peng, XM; Rao, XQ; Yu, RC, 1994) |
| " The most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths." | 2.67 | A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party. ( Berchier, MC; Bureau, G; Dabouis, G; Klastersky, J; Libert, P; Ries, F; Schmerber, J; Sculier, JP; Thiriaux, J; Van Cutsem, O, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 2.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991." | 2.67 | [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. ( Zhou, JC, 1993) |
| " Because of severe mucositis, the final 30 patients were treated with the same dosage of cisplatin but with the deletion on day 6 of leucovorin and 5-fluorouracil." | 2.67 | Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. ( Elias, A; Frei, E; Kalish, LA; Kass, F; Lynch, TJ; Shulman, L; Skarin, A; Strauss, G; Sugarbaker, D, 1994) |
| "A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy." | 2.67 | Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992) |
| "Seventeen patients with colorectal cancer who failed local chemotherapy received 5-FU as a 4-hour infusion, preceded by a bolus of FA and IFN." | 2.67 | A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ( Boese-Landgraf, J; Boewer, C; Hilgenfeld, RU; Hoksch, B; Knauf, WU; Kreuser, ED; Matthias, M; Oldenkott, B; Schalhorn, A; Zeitz, M, 1992) |
| "Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study." | 2.67 | Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. ( Aronson, FR; Deisseroth, AB; Gandara, DR; Luce, J; Paradise, C; Perez, EA; Rayner, A; Valone, FH, 1991) |
| "A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks." | 2.67 | Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. ( Droz, JP; Ducreux, M; Kac, J; Oliveira, J; Rougier, P; Theodore, C, 1991) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Eight patients with untreated squamous cell carcinoma of the esophagus accompanying distant metastases who were treated by one to five cycles of chemotherapy consisting of Cisplatin and 120 hour infusion of 5-Fluorouracil were reported." | 2.67 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases]. ( Sueyama, H, 1990) |
| "Among 13 patients with colorectal cancer, 4 partial responses were observed." | 2.67 | Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. ( Comis, RL; Cornfeld, MJ; O'Dwyer, PJ; Peter, R, 1990) |
| "5-Fluorouracil was infused 24 hours per day throughout the period of radiation at a dose of 300 mg/m2/day for a median of 42 days (range, 28-56 days)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| " The dosage schedule was cisplatinum 100 mg/m2 D1 and 5-FU 1 g/m2 D1 to D5 every 3 weeks for 3 courses before evaluation." | 2.66 | [Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer]. ( Abouz, D; Ayela, P; Berthaud, P; Frenay, M; Lagrange, JL; Le Chevalier, T; Pujol, JL; Rivière, A; Robillard, J, 1989) |
| " During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed." | 2.66 | [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. ( Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985) |
| "In patients with Stage I-II squamous cell carcinoma of the lung without regional lymph node metastases the used regimen of combined therapy had no significant effect." | 2.66 | Combined treatment including postoperative chemotherapy in lung cancer patients. ( Amiraliev, MA; Barchuk, AS; Glagolev, AN; Grigoryeva, SP; Kovalev, VN; Malay, EF; Trakhtenberg, AKh; Vidyak, IV; Zakharchenkov, AV; Zhiglov, MA, 1988) |
| "Ten of the gastric cancer patients (29%) had partial responses." | 2.66 | Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. ( Ahmed, S; Alvarez, CA; Cazap, EL; Estevez, RA; Gisselbrecht, C; Hannois, A; Lagarde, C; Schein, PS; Smith, FP; Woolley, PV, 1986) |
| "In well differentiated squamous cell carcinoma, a marked positive effect was obtained in 48." | 2.65 | [Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer]. ( Bidiak, IP; Kiseleva, ES; Pitskhelauri, VG; Trakhtenberg, AKh; Zholkiver, KI, 1984) |
| "Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control." | 2.48 | [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure]. ( Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K, 2012) |
| "Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy." | 2.47 | Surgical therapies in metastatic colorectal cancer with a potential for cure. ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011) |
| "He was diagnosed with interstitial pneumonitis." | 2.47 | [A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)]. ( Fukushima, M; Hamada, A; Ishizaka, T; Mukai, J; Nakagawa, M; Sawada, R; Takahashi, N; Yoshihara, Y, 2011) |
| " As a result, both the toxicity and efficacy of over 30 anticancer agents vary by more than 50% as a function of dosing time in experimental models." | 2.44 | Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. ( Baron, B; de la Valette, V; Focan, C; Focan-Henrard, D; Giacchetti, S; Karaboué, A; Kreutz, F; Lévi, F, 2007) |
| "Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors." | 2.41 | Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. ( Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M, 2000) |
| "Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist." | 2.40 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997) |
| "Cystosarcoma phyllodes is a rare tumor." | 2.38 | Malignant cystosarcoma phyllodes: an unusual presentation and review of the literature. ( Salamoun, WI, 1993) |
| "Altretamine is a National Cancer Institute-designated group C antineoplastic agent used in the treatment of advanced ovarian cancer." | 2.38 | Altretamine. ( Hansen, LA; Hughes, TE, 1991) |
| "Patients with cancer commonly suffer neurologic disabilities." | 2.37 | Neurologic complications of systemic cancer. ( Patchell, RA; Posner, JB, 1985) |
| "We diagnosed as having rectal cancer with multiple lung metastases." | 1.72 | [A Case of Rectal Cancer and Multiple Lung Metastases That Had Complete Response Treated by XELOX plus Bevacizumab after Primary Lesion Resection]. ( Aomatsu, K; Hiramatsu, S; On, O; Sugimoto, A, 2022) |
| " Therefore, this study determined whether C3G alone or C3G combined with 5-fluorouracil (5-FU) inhibits human lung LCC." | 1.72 | The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. ( Chang, GR; Liao, HJ; Lin, CF; Lin, TC; Liu, YW; Wu, CF; Wu, CY, 2022) |
| "Ginsenoside Rg3 (Rg3) has a strong anticancer influence on colon cancer, breast cancer, lung cancer, and other malignant tumors." | 1.72 | Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells. ( Deng, Y; Du, Z; Shan, K; Yang, S; Yue, P, 2022) |
| "Prostate and lung cancers are among the most common cancer types, and they still need more therapeutics." | 1.72 | Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells. ( Pereira, M; Vale, N, 2022) |
| " However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation." | 1.62 | Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment. ( Dang, N; Lin, Y; Sprangers, B; Waer, M, 2021) |
| "Lung cancer is the most common cause of cancer-related death in developed countries; therefore, the generation of effective targeted therapeutic regimens is essential." | 1.62 | Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. ( Abe, K; Fujiwara, T; Harigae, H; Kanehira, M; Kumata, S; Miyauchi, E; Noda, M; Ohkouchi, S; Oishi, H; Okada, Y; Sakurada, A; Suzuki, Y, 2021) |
| "Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy." | 1.56 | Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020) |
| " The results of this study demonstrated that UBE combined with fluorouracil attenuated multiple drug resistance and inhibited the expression of P-gp in lung cancer." | 1.56 | Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer. ( Ding, GG; Ling, XA; Wan, J; Wang, J; Wang, X, 2020) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 1.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Oral fluorouracil was also significantly associated with improved recurrence-free survival compared with VNR/CDDP, according to multivariable Cox regression analysis (hazard ratio, 0." | 1.48 | Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses. ( Fushimi, K; Hasegawa, W; Hiraishi, Y; Jo, T; Matsui, H; Michihata, N; Mitani, A; Nagase, T; Sakamoto, Y; Takeshima, H; Urushiyama, H; Yamauchi, Y; Yasunaga, H, 2018) |
| "A 56-year-old woman was diagnosed with rectal cancer and liver metastases(Stage IV), and underwent low anterior resection and laparoscopic partial hepatectomy." | 1.48 | [Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report]. ( Hayashi, H; Hyodo, M; Inoue, Y; Lefor, AK; Okada, M; Ota, G; Sato, H; Shinohara, S; Tsukahara, M; Yasuda, Y, 2018) |
| "Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD." | 1.48 | Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. ( Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B, 2018) |
| "Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | 1.46 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "Distinct metastasis accounts for the leading cause of mortality among patients with gastric cancer." | 1.46 | Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis. ( Wu, J; Xu, Q; Zhou, Y; Zhu, X, 2017) |
| "Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents." | 1.46 | Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma. ( Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN, 2017) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | 1.42 | [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| "Stage III colon cancer is currently treated as an entity with a unified therapeutic principle." | 1.42 | A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. ( Deng, G; He, J; Ma, J; Pei, H; Shen, H; Wu, X; Zeng, S; Zhang, S; Zhang, Y, 2015) |
| "HCT116/R, a HCT116 colon cancer cell subline carrying acquired resistance to 5-FU, showed increased expression and activation of HSP90's client proteins and transcriptional up-regulation of TYMS." | 1.42 | Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. ( Ahn, JY; Lee, HY; Lee, JS; Min, HY, 2015) |
| "The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. ( , 2015) |
| "A patient in his 70s was diagnosed with rectal cancer (pT3, pN1, cM0, and pStage IIIa) for which he underwent low anterior resection of the rectum and received adjuvant therapy with UFT/LV." | 1.42 | [A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab]. ( Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T, 2015) |
| "Approximately 20% of the patients with colorectal cancer have distant metastasis during diagnosis." | 1.42 | Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. ( Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S, 2015) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "Metastasized rectal cancer has long been considered incurable." | 1.40 | A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. ( Albertsson, M; Holmqvist, A; Jung, M; Sun, XF, 2014) |
| "Human esophageal cancer tissue microarray was analyzed for overexpression of IGF-II and its correlation with that of Id1 and phosphorylated AKT (p-AKT)." | 1.40 | Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy. ( Chan, KW; Cheung, AL; He, QY; Li, B; Li, YY; Ludwig, DL; Novosyadlyy, R; Tsao, SW, 2014) |
| "He was diagnosed with sigmoid cancer with multiple liver and lung metastases." | 1.40 | [A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs]. ( Hasegawa, Y; Hatanaka, M; Iwata, H, 2014) |
| "Lung cancer is one of the leading causes of cancer-related death in developed countries." | 1.40 | SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. ( Feng, Y; Lu, W; Zhang, M; Zuo, Y, 2014) |
| "Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs." | 1.40 | A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014) |
| "All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy." | 1.40 | Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014) |
| "Stage III rectal cancer was found in 64." | 1.39 | Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. ( Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ, 2013) |
| "Carbon monoxide was a mediator of HMOX1 effects on proliferation, migration, and miR-378 expression." | 1.39 | Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. ( Boczkowski, J; Ciesla, M; Collet, G; Dulak, J; Gil, T; Golda, S; Guichard, A; Jozkowicz, A; Kieda, C; Kozakowska, M; Kuzdzal, J; Loboda, A; Muchova, L; Skrzypek, K; Tertil, M; Vitek, L; Was, H; Weglarczyk, K, 2013) |
| "Among the 252 cases, there were 110 carcinoids (43." | 1.39 | [Neuroendocrine tumors: analysis of 252 cases]. ( Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP, 2013) |
| "Sorafenib can inhibit not only the tumor growth and lung metastsis in the nude mouse models, but also reduce the expression of multidrug resistance proteins P-gp and Topo IIa as well." | 1.39 | [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil]. ( Shen, HJ; Wang, YH; Xu, J, 2013) |
| "We report a case of advanced rectal cancer treated with chemotherapy, for which laparoscopic splenectomy had been effective for thrombocytopenia." | 1.39 | [Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer]. ( Arita, S; Koike, N; Ohshima, Y; Shinozaki, E; Takeuchi, T, 2013) |
| " The clinical efficacy and bevacizumab-related adverse reactions were observed." | 1.39 | [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. ( Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013) |
| "A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy." | 1.39 | Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. ( Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T, 2013) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "Clinicopathological data of 257 cM1 gastric cancer patients who underwent an operation at Seoul National University Hospital from January 1999 to December 2004 were reviewed." | 1.38 | The value of palliative gastrectomy in gastric cancer with distant metastasis. ( Chang, YR; Han, DS; Kim, SH; Kim, WH; Kong, SH; Lee, HJ; Yang, HK, 2012) |
| "The majority of brain metastases result from lung cancer, but the metastatic mechanism remains unclear." | 1.38 | Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. ( Cho, MH; Choi, KC; Kim, SU; Kim, YB; Lee, HJ; Yi, BR, 2012) |
| " Pharmacokinetic studies of BIIB036 in tumor-bearing mice revealed a half-life of approximately three days suggesting twice a week dosing would be necessary to maintain efficacy." | 1.38 | The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. ( Joseph, IB; Kelly, R; Michaelson, JS; Wortham, K; Yang, L; Zhang, X, 2012) |
| "She was diagnosed as advanced sigmoid colon cancer with multiple metastases of lung, liver, and left hydronephrosis." | 1.38 | [A case of pathologically by complete response in advanced sigmoid colon cancer with multiple metastases of lung and Liver, left hydronephrosis after chemotherapy including bevacizumab/FOLFOX6]. ( Hasegawa, H; Kubo, H; Miyahara, M; Nishiyama, M; Tada, K; Yamashita, Y, 2012) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 1.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| "The majority of patients with gastric cancer in developing countries present with advanced disease." | 1.38 | Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. ( Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M, 2012) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Sixteen months after the diagnosis of rectal cancer, the patient died." | 1.38 | [A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab]. ( Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Masuda, T; Matsuyama, T; Okazaki, S; Sugihara, K; Uetake, H; Yamauchi, S, 2012) |
| " This case demonstrates the successful treatment and CR of recurrent lung metastasis after surgery for rectal cancer using lung RFA therapy and long-term administration of FOLFIRI." | 1.38 | [A case report of recurrent lung metastasis after surgery for rectal cancer for which lung radiofrequency ablation therapy and long-term administration of FOLFIRI were effective]. ( Fukushima, M; Hoshino, M; Murakami, M; Naruse, H; Suzuki, N; Suzuki, S; Tominaga, K, 2012) |
| "Radiation pneumonitis was retrospectively graded using the Radiation Therapy Oncology Group (RTOG) scale by an observer blinded to the PET radiotoxicity score." | 1.37 | Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. ( Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP, 2011) |
| "Metastatic colorectal cancer has a low cure rate." | 1.37 | Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011) |
| "Two years later, he was diagnosed for rectal cancer and bilateral lung metastases by TBLB." | 1.37 | [A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Kurokawa, T; Nagahama, T; Nakamura, M; Okada, Y; Tei, S; Watayo, Y, 2011) |
| "Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-)." | 1.36 | Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. ( Arai, M; Asakage, M; Endo, J; Furukawa, Y; Muto, Y; Nozawa, H; Oka, T; Yamada, Y, 2010) |
| "Colonoscopy detected rectal cancer and sigmoid al polyps." | 1.36 | [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy]. ( Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S, 2010) |
| " For the pharmacokinetic study, two groups of male rats were administered either an aqueous solution of 5-FU (control group)/or a 5-FU-loaded PEG-hydrogel (treated group) at a dose of 100 mg/kg." | 1.36 | Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. ( Abd El-Aty, AM; Bae, GW; Bartlett, MG; Cho, HJ; Cho, SM; Kim, B; Kim, JS; Lee, CH; Lee, DG; Nho, K; Shin, HC; Yi, H; Yoon, SJ, 2010) |
| "A close inspection showed progressive stomach cancer with lymph node metastasis." | 1.36 | [A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6]. ( Ishida, T; Iwasaki, T; Kanemitsu, K; Okuda, T; Tanaka, K; Toyokawa, A, 2010) |
| "A 61-year-old female who had sigmoid colon cancer with unresectable multiple lung and liver metastases underwent sigmoidectomy." | 1.36 | [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure]. ( Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "The basaloid squamous cell carcinoma of the esophagus is highly malignant with poor prognosis." | 1.35 | [Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus]. ( Chen, JX; Tang, Q; Zheng, YD; Zhu, HN, 2008) |
| "Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here." | 1.35 | Fatal pneumonitis induced by oxaliplatin. ( Arévalo Lobera, S; Azkue Gabilondo, M; Basterretxea Badiola, L; Egaña Otaño, L; Elejoste Echeberría, I; La Casta Muñoa, A; Melé Olivé, M; Sagastibeltza Mariñelarena, N, 2008) |
| "Of 55 patients with colorectal cancer, 20 had no metastasis and the other 35 had distant metastasis." | 1.35 | Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. ( Akagi, Y; Hattori, S; Kage, M; Kawahara, A; Kuwano, M; Mizobe, T; Ono, M; Shirouzu, K; Yanagawa, T, 2009) |
| "To evaluate the efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm (GTN) patients, and investigate factors influencing the outcome of the surgery combined with chemotherapy." | 1.35 | [Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm]. ( Cao, Y; Feng, FZ; Li, L; Wan, XR; Xiang, Y; Yang, XY, 2008) |
| "Medical records of 62 patients with gestational trophoblastic neoplasia who underwent pulmonary lobectomy or limited resection were reviewed." | 1.35 | Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia. ( Cao, Y; Feng, F; Wan, X; Xiang, Y; Yang, X, 2009) |
| " The primary dose of oxaliplatin (L-OHP) ranged from 60 mg/m(2) to 85 mg/m(2), and adverse reactions and serum platinum concentration were monitored." | 1.35 | [The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy]. ( Fujita, M; Kataoka, Y; Katayama, T; Koide, T; Matsuda, H; Okuda, M; Yamagishi, Y, 2009) |
| "Rectovaginal fistula in long-standing Crohn's disease is possibly associated with malignant transformation to mucinous adenocarcinoma of the vagina." | 1.35 | Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases. ( Chi, DS; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB, 2009) |
| "Drug-induced interstitial pneumonitis was suspected, and Pneumocystis carini pneumonia was considered in the differential diagnosis." | 1.35 | [A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer]. ( Baba, N; Ishigami, S; Kitaguchi, K; Nakauchi, M; Nakayama, Y; Ohe, H; Sakikubo, M; Taira, K; Tamura, J; Ura, K; Yoshikawa, A, 2009) |
| "All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites)." | 1.35 | The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. ( Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J, 2008) |
| "Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6." | 1.35 | The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. ( Chida, K; Inui, N; Kaida, Y; Nakamura, H; Suda, T; Watanabe, H, 2008) |
| " The human lung carcinoma MV522 cell line and its corresponding xenograft model were used to evaluate the activity of irofulven in combination with these different agents." | 1.35 | Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. ( Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P, 2008) |
| " Based on the findings, the antitumor effects of a selected retinoid either alone or in combination with cisplatin were also investigated in a preclinical mouse melanoma model." | 1.35 | Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. ( Chan, SY; Ho, PC; Liu, X, 2008) |
| "A case of colorectal cancer in a 60-year-old man became resectable after downstaging was achieved with mFOLFOX 6 for multiple liver metastases from colorectal cancer." | 1.34 | [A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer]. ( Abe, T; Aoki, T; Ishizaki, T; Katsumata, K; Koyanagi, Y; Tsuchida, A; Wada, T, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | 1.34 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| " The dosage of FOLFOX 4 was reduced after three courses due to neutropenia and diarrhea." | 1.34 | [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy]. ( Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M, 2007) |
| "In vitro, human colon cancer cell lines were treated with anti-CEA MAb IgG1, hMN-14 (labetuzumab), to assess direct effects on proliferation, as well as antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC)." | 1.33 | Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. ( Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L, 2005) |
| " TFT is a good substrate for thymidine phosphorylase (TP), and the combination of TFT and a TP inhibitor (TPI), called TAS-102, has been developed to enhance the bioavailability of TFT in vivo, and is currently being studied in a phase I study." | 1.33 | Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. ( Comijn, EM; de Bruin, M; Fukushima, M; Peters, GJ; Temmink, OH, 2005) |
| " 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a." | 1.33 | [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "A 72-year-old man who had multiple hepatocellular carcinoma underwent eight times intrahepatic arterial chemotherapies of SMANCS and two times percutaneous ethanol injection (PEIT) therapies over three years, but new diffuse lesions appeared in the liver." | 1.33 | [A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU]. ( Arima, T; Horino, K; Inoue, M; Kimura, M; Kuhara, H; Nishimura, T; Uemura, K; Yamada, K, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "An in situ human hepatocellular carcinoma model was established in mice livers orthotopically." | 1.33 | Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history." | 1.33 | 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| " An eight-compartment pharmacokinetic model was used to describe the observed trends in concentrations of LNPs and total 5-FU and to estimate the released 5-FU concentration in the above tissues." | 1.33 | Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. ( Hitzman, CJ; Wattenberg, LW; Wiedmann, TS, 2006) |
| "Renal cell carcinoma is an uncommon tumor in adults." | 1.33 | Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma. ( Alcaide-García, J; Alés-Díaz, I; Benavides-Orgaz, M; Cobo-Dols, M; Gil-Calle, S; Gutiérrez-Calderón, V; Montesa-Pino, A; Villar-Chamorro, E, 2006) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "Most pulmonary metastases of hepatic cancer were hypervascular and the lipiodol deposited well in the nodules; during the follow-up, the nodules shrunk significantly and kept stable." | 1.33 | [Blood supply of pulmonary metastases and its clinical significance]. ( Chen, YX; Jiang, GM; Tian, F; Zhao, JW, 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| " 3DCRT was given with the field covering the tumor with a generous margin." | 1.33 | [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma]. ( Chen, Z; Cheng, WW; Jiang, GL; Lin, JH; Liu, LM; Meng, ZQ; Zhang, XJ; Zhou, ZH, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| " After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis." | 1.33 | [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. ( Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K, 2006) |
| "The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 1.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "Generalized metastases showed substantial progression." | 1.32 | Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome. ( Bonnekoh, B; Franke, I; Gollnick, H; Grundmann, JU; Weisshaar, E, 2003) |
| "Human esophageal cancer cells NEC and human lung adenocarcinoma cells GLC were cultured and then inoculated into the wells." | 1.32 | [The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells]. ( Huang, J; Jiao, SC; Lu, SX; Sun, Y, 2003) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 1.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| "5 patients with colorectal cancer with multiple liver metastases underwent resection of primary lesions." | 1.32 | [Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer]. ( Abe, N; Ishii, Y; Itou, T; Nakayama, K; Takahashi, M, 2003) |
| "We report a rectal cancer case with liver and lung metastases treated successfully with this protocol." | 1.32 | [A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT]. ( Ebuchi, M; Hasegawa, K; Kato, K; Maruyama, M; Nagahama, T; Shinoura, H; Takashima, I, 2003) |
| "The murine AT-84 orthotopic model of oral cancer was assessed to find how similar it is to human oral cancer." | 1.32 | Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. ( Hutchison, R; Kellman, RM; Lou, E; Shillitoe, EJ, 2003) |
| "Hemoptysis was negligible until he died 8 months later." | 1.32 | [Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases]. ( Ishigaki, T; Kitai, T; Kojima, N; Miki, A; Nishikawa, S; Nomura, A; Todo, G; Ukikusa, M, 2003) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | 1.32 | Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| "A 58-year-old man who had colon cancer with liver and multiple lung metastases underwent ileocecal resection on May 10, 2002." | 1.32 | [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. ( Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T, 2004) |
| "Infiltrating squamous cell carcinomas of the URT occurred in 92% of the controls and were reduced by 50% in animals receiving DFMO (P = 0." | 1.32 | Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. ( Estensen, RD; Wattenberg, LW; Wiedmann, TS, 2004) |
| " Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels." | 1.32 | S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. ( Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004) |
| "This report shows a case of advanced gastric cancer that responded to low-dose 5-FU plus CDDP." | 1.31 | [A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP]. ( Baba, H; Endo, K; Ikeda, Y; Ishio, T; Kawamoto, K; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2002) |
| "We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "Pathological study revealed primary pancreatic cancer with lung metastasis." | 1.31 | [Resection of pancreatic cancer and simultaneous lung metastasis--a case report of successful in tumor dormancy mainly by postoperative 5-fluorouracil-based chemotherapy]. ( Arii, S; Baba, H; Goseki, N; Kumagai, J; Nosaka, T; Takamatsu, S; Teramoto, K, 2002) |
| "Compared with adenocarcinoma, squamous cell carcinoma might be a favorable target for 5-FU-based chemotherapy in the treatment of nonsmall-cell lung cancer." | 1.31 | Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. ( Koga, T; Ninomiya, S; Takeo, S; Yano, T, 2002) |
| " Thus, by using a dosing schedule of cyclophosphamide that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, we show that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant." | 1.31 | Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. ( Browder, T; Butterfield, CE; Folkman, J; Kräling, BM; Marshall, B; O'Reilly, MS; Shi, B, 2000) |
| " Each 50% inhibitory concentration was calculated based on the dose-response curves." | 1.31 | Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. ( Hara, N; Nakanishi, Y; Osaki, S; Pei, XH; Takayama, K; Ueno, H, 2000) |
| "5-fluorouracil (5-FU) has been used widely, including in gastrointestinal cancer, breast cancer, and non-small cell lung cancer (NSCLC), and its efficacy has been reported to be associated with intratumoral expression of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD)." | 1.31 | Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. ( Fukushima, M; Hitomi, S; Huang, CL; Kobayashi, S; Wada, H; Yokomise, H, 2000) |
| "In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2." | 1.31 | Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Molders, N; Padrón, JM; Peters, GJ; Pinedo, HM; van Der Wilt, CL; van Groeningen, CJ; Wouters, D, 2000) |
| "A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West." | 1.31 | [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. ( Aiba, K; Akaza, H; Blackledge, G; Hinotsu, S; Isonishi, S; Kono, S; Mikami, O; Noguchi, S; Ogawa, O; Shibuya, M; Sone, S; Stribling, D; Tsuruo, T; Vose, B, 2000) |
| "Lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus-associated undifferentiated carcinoma, is a rare entity of pulmonary malignancy." | 1.31 | Chemoradiotherapy for advanced lymphoepithelioma-like carcinoma of the lung. ( Ho, JC; Lam, B; Lam, WK; Ooi, GC; Tsang, KW, 2000) |
| "In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration." | 1.31 | Quality of life in cancer patients treated by chemotherapy. ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Human colon cancer cells (KM12SM) were injected into the cecal wall of the nude rats." | 1.31 | [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. ( Akagi, Y; Kobayashi, H; Matono, K; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K, 2001) |
| "To the best of our knowledge no anaphylactic reaction secondary to folinic acid (FA) administration has ever been reported before." | 1.31 | Anaphylactic shock secondary to intravenous administration of folinic acid: a first report. ( Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E, 2002) |
| "Isoliquiritigenin is a chalcone isolated from licorice and shallots." | 1.31 | Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002) |
| " In order to assess the mode of action of lobaplatin when combined with 5-FU, two human cancer cell lines were treated with various combinations of 5-FU given for either 2 or 24h and lobaplatin." | 1.30 | Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines. ( Druyen, H; Harstrick, A; Heidemann, A; Seeber, S; Vanhoefer, U; Wilke, H, 1997) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "5-Fluorouracil, 2600 mg/m2, was administered concurrently with 100 mg/m2 leucovorin over 24 hours of continuous intravenous infusion." | 1.30 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience. ( Chen, PM; Chen, WS; Chiou, TJ; Fan, FS; Hsieh, RK; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, WS; Yen, CC, 1998) |
| "Bone metastasis of breast cancer generally tends to be multiple." | 1.30 | [Significance of full-thickness chest wall resection as a local treatment for sternum metastasis of breast cancer]. ( Hamazoe, R; Hirooka, Y; Kinugasa, Y; Murata, Y; Shiota, S; Sumi, K; Takahashi, S, 1998) |
| "Patients with metastatic breast cancer (MBC) have variable clinical courses." | 1.30 | Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. ( Adachi, I; Ando, M; Katsumata, N; Narabayashi, M; Omuro, Y; Watanabe, T; Yamamoto, N, 1998) |
| "Animals bearing established B16 melanoma or MB-49 bladder carcinoma were used to study the most effective scheduling of recombinant murine IL-12 (rmIL-12), along with systemic chemotherapy." | 1.30 | Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. ( Ara, G; Buxton, D; Leonard, J; Schaub, RG; Teicher, BA, 1997) |
| "Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study." | 1.30 | [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999) |
| "Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation." | 1.30 | Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil. ( Abe, A; Inada, K; Nakanishi, H; Tatematsu, M; Tsukamoto, T; Yasui, K, 1999) |
| "5 mg/kg), or cisplatin (4 mg/kg, by one shot) to TNP (120-140 mg/kg) with a 6-7 fractionated dosing schedule reduced s." | 1.29 | Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. ( Kakinuma, H; Kato, T; Matsuda, Y; Sato, K, 1994) |
| "The other five patients with advanced stomach cancer who could not have so good nutrition were receiving home parental nutrition (HPN, 1,200 kcal/day) and continuous or intermittent 5-FU infusion (250-500 mg/body/day) using Lentinan at the same time." | 1.29 | [Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer]. ( Chibai, M; Inomata, Y; Isshi, K; Nakamura, Y; Sakuyama, T; Shimono, S; Tadaoka, N; Takahashi, N; Takamura, S; Yamada, T, 1994) |
| "The another patient was 61 years old rectum cancer patient with lung and hepatic metastasis (stage V)." | 1.29 | [Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home]. ( Hayashi, K, 1994) |
| "levamisole/5-FU) treatment." | 1.29 | Enhancement of antitumor effects of combined chemoimmunotherapy. ( Fowler, WC; Gerçel-Taylor, C; Taylor, DD; Weese, JL, 1993) |
| "A 58-year-old woman with colon cancer, who had received oral 5-FU over 17 months after right hemicolectomy, was diagnosed as having a recurrence of the disease with multiple pulmonary metastasis." | 1.29 | [A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a]. ( Hirata, Y; Ichiki, Y; Kanaya, S; Nakamura, M; Nakano, S; Niho, Y, 1993) |
| "We assessed the antiproliferative effect of human recombinant interferon -alpha (IFN-alpha) or -beta in combination with 5-fluorouracil (5-FU), cisplatin, or cis- or trans-retinoic acid on two human nonsmall cell lung carcinoma cell lines (SK-LU-1 and SK-MES-1) and on one human small cell lung carcinoma cell line (NCI-H69)." | 1.29 | Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines. ( Arbaje, YM; Bittner, G; Schiller, JH; Storer, B; Yingling, JM, 1993) |
| "5-Fluorouracil (5-FU) is an agent with little intrinsic activity against NSCLC: However, there is increasing evidence that 5-FU is synergistic with cisplatin and vice versa." | 1.29 | Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. ( Elias, AD; Frei, E; Kalish, LA; Kass, F; Lynch, TJ; Shulman, LN; Skarin, A; Strauss, G; Sugarbaker, DJ, 1993) |
| "This case suggested that respiratory failure due to lymphangitis carcinomatosis can be a treatable condition." | 1.29 | Respiratory failure due to pulmonary lymphangitis carcinomatosis. ( Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y, 1993) |
| "Three patients with lung metastases of renal cell carcinoma (RCC) were treated with a combination of interferon-alpha, leucovorin and 5-fluorouracil." | 1.29 | [Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin]. ( Demura, T; Hirakawa, K; Hirano, T; Ohashi, N; Sindoh, J; Tabata, T; Togashi, M, 1996) |
| " Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508." | 1.29 | Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ( Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996) |
| " Amide 1 is effective after either oral or intraperitoneal dosing in acute, subacute, or chronic regimens." | 1.28 | N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis lung carcinoma. ( Fliri, AF; Kajiji, S; Pollack, VA; Schnur, RC, 1991) |
| " The bioavailability of UK-21 given p." | 1.28 | Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25. ( Kato, T; Kitaichi, K; Koda, A; Mori, H; Sakamoto, O, 1992) |
| " The 5-FU concentration was a determinant factor affecting modification of the effects of the drug combination from antagonism (with low 5-FU concentrations) to synergism (high 5-FU concentrations) (P less than 0." | 1.28 | [Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration]. ( Berille, J; Berlion, M; Bizzari, JP; Fischel, JL; Formento, P; Gioanni, J; Milano, G, 1992) |
| " This has been explored in non-Hodgkin lymphoma, osteogenic sarcoma and bladder cancer with improved results using intensive, weekly dosing schemas." | 1.28 | Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer. ( Comis, RL; Hudes, GR; Langer, CJ; Levy, MH; Litwin, S; O'Dwyer, PJ; Padavic-Shaller, K; Walczak, J, 1991) |
| "Monocytes from untreated breast cancer patients released significantly less hydrogen peroxide than controls (Breast = 75 +/- 17." | 1.28 | The effect of cancer and chemotherapy on monocyte function. ( Baughman, RP; Lower, EE, 1990) |
| "The choriocarcinoma was one of the most curable malignant neoplasms." | 1.28 | [The treatment of refractory choriocarcinoma]. ( Inaba, N; Matsui, H; Takamizawa, Y, 1990) |
| "Over a 2-year period, 17 patients with histologically proven squamous cell carcinoma of the bronchus, assessed as inoperable or incurable on surgical or medical grounds, were treated with palliative radiotherapy and a concurrent 120-h infusion of 5-flurouracil, at a dosage of 1 g/day." | 1.28 | The use of simultaneous radiotherapy and 5-flurouracil in patients with inoperable squamous cell lung cancer. ( Ash, DV; Kelly, SA; MacLeod, PM, 1989) |
| "A case of renal cell carcinoma with multiple lung metastases successfully treated with interferon (IFN) following nephrectomy is reported." | 1.28 | [A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta]. ( Horie, M; Kawada, Y; Kobayashi, S; Komeda, H; Kuriyama, M; Takahashi, Y; Yamada, S, 1989) |
| "One patient had lower esophageal cancer (T2N0M0) and the other had metastatic cancer of both lungs." | 1.28 | [5-FU intra-arterial infusion and simultaneous irradiation in the treatment of esophageal cancer and metastatic lung cancer]. ( Bohno, K; Ushijima, T, 1989) |
| " At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy)." | 1.27 | [The clinical effect of hyperthermia combined with induced hypertension chemotherapy]. ( Hayashida, S; Kobayashi, T; Sugimoto, K, 1984) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| " Long-term daily administration was shown to be more effective than intermittent dosage in the treatment of Lewis lung carcinoma." | 1.27 | [Antitumor effect of FU-O-G, new antitumor agent, following long term administration]. ( Arakawa, M; Inomata, T; Mizuno, H; Shimizu, F; Umezawa, T, 1984) |
| "Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined." | 1.27 | Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "5-fluorouracil that was less active in the used therapeutic doses did not cause similar changes in the LSA levels." | 1.27 | [Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents]. ( Bassalyk, LS; Kozlov, AM; Novikov, AM; Sof'ina, ZP, 1984) |
| "Tumor metastasis was examined after iv inoculation of highly metastatic variants of mouse tumors." | 1.27 | Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. ( Hori, K; Kawabata, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "However, against colo-rectal and stomach cancer, the response rate was only 25% (2/8) and 28." | 1.27 | [Chemotherapy and total body hyperthermia]. ( Kato, N; Yamanaka, N, 1985) |
| " From 1980 to 1982, 96 patients with SCLC were treated, 37 of whom by chemotherapy combined with surgery." | 1.27 | [Chemotherapy combined with selective resection in small cell lung cancer--analysis of 239 patients]. ( Cao, YF; Chen, YR; Fang, MS; Huang, OL; Liao, ML; Wu, SC; Wu, SF; Wu, SZ; Xu, CW; Yang, XF, 1986) |
| "7 of 8 with brain metastases treated by the same modality gave complete remission." | 1.27 | [Combination therapy of advanced choriocarcinoma--an analysis of 60 patients]. ( Cai, SM; Ding, YQ; Wang, RY, 1986) |
| " Our results show that all five drugs exhibited a dose-response relationship against tumor cells and GM-CFUC." | 1.27 | Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. ( Ajani, JA; Baker, FL; Blaauw, AA; Dicke, KA; Spitzer, G; Thielvoldt, D; Tomasovic, B; Umbach, G; Zander, AR, 1985) |
| "Etoposide has been added to this regimen, and 32 stage IIIM0 non-small cell lung cancer patients have been treated with the 3-drug regimen resulting in a 73% clinical partial remission rate." | 1.27 | Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. ( Bonomi, P; Faber, LP; Kittle, CF; Lee, MS; Pincus, M; Reddy, S; Rowland, KM; Taylor, SG; Warren, W, 1988) |
| " In tumor tissue, optimal doses of FUra or FdUrd resulted in lower (a) FdUMP levels (5- to 2-fold), (b) RNA-level antimetabolites (6- to 3-fold), and (c) DNA-level antimetabolites (10- to 4-fold) compared to an optimal dosage of FdCyd plus H4Urd." | 1.27 | Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. ( Boothman, DA; Briggle, TV; Greer, S, 1987) |
| "Nine patients had squamous cell carcinoma, two adenocarcinoma, and two large cell carcinoma." | 1.27 | [Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung]. ( Kikuchi, K; Ogata, T, 1986) |
| "The mitomycin C and BCNU were alternated monthly at the start of each FUDR cycle." | 1.27 | Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. ( Cohen, AM; Higgins, J; Schaeffer, N, 1986) |
| "Lymph node metastasis was not related to the concentration of 5-FU in the lymph nodes." | 1.27 | [Serum and tissue concentrations of UFT in patients with lung cancer]. ( Aota, M; Daitoh, N; Jinno, K; Nakayama, S; Yokomise, H, 1986) |
| "Esophageal cancer was treated with sequential intravenous cisplatin 100 mg/m2 (day 1) and 5-fluorouracil (5-FU) 40 mg/m2/hour X 120 (days 2-7)." | 1.27 | Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy. ( Barreras, L; Manten, H; Saldana, MJ; Sridhar, KS, 1988) |
| "In analysing the anticancer effects of TBHT according to cancer site, a high efficacy was observed in patients with their main tumor in the lung, liver and lymph nodes." | 1.27 | [Clinical results and problems of total-body thermochemotherapy]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T, 1988) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " If toxicity is intolerable, the dosage of CDDP and ADM was decreased in thirty percent." | 1.27 | [Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer]. ( Nakagawa, T; Nishimura, K; Ogawa, O; Taniguchi, T; Yoshimura, N, 1986) |
| "The treatment schedule for disseminated breast carcinoma has been developed." | 1.27 | [4-component chemotherapy and radiation therapy of breast cancer]. ( Aplevich, NN; Gritsaĭ, AA; Kondrat'eva, AP; Lichinitser, MR; Vyshinskaia, GV, 1986) |
| " This study demonstrates that sequential MTX and 5-FU in this dosage and schedule is ineffective in NSCCL." | 1.27 | Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung. ( Ponder, BA; Slevin, ML; Wood, CD; Wrigley, PF, 1985) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | 1.27 | A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. ( Ford, J; Margolese, R; Panasci, L, 1985) |
| " They received 5FU and cisplatin in the same dosage every 28 days for either recurrent or metastatic disease." | 1.27 | A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. ( Citrin, P; Dasmahapatra, KS; Hill, GJ; Mohit-Tabatabai, MA; Rush, BF; Yee, R, 1985) |
| "Patients with squamous cell carcinoma or good performance status were somewhat more likely to respond." | 1.27 | Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. ( Einstein, AB; Rudolph, RH; Weiden, PL, 1985) |
| "Phosphorylating activity in squamous cell carcinoma of the lung was similar to that in adenocarcinomas." | 1.26 | Metabolism of 5-fluorouracil in various human normal and tumor tissues. ( Fujii, S; Maehara, Y; Nagayama, S; Nakamura, H; Okazaki, H; Shirasaka, T, 1981) |
| "Seventeen patients with adenocystic carcinoma have received 34 adequate trials of chemotherapy at Princess Margaret Hospital since 1969." | 1.26 | Chemotherapy for adenocystic carcinoma. ( Sutherland, DJ; Tannock, IF, 1980) |
| "5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
| " Dose-response relationships of 3 triple-drug combinations and their component agents were explored, allowing the relative contributions of single agents in each combination to be assessed." | 1.26 | Experimental combination and single-agent chemotherapy in human lung-tumour xenografts. ( Jones, JM; Peckham, MJ; Shorthouse, AJ; Steel, GG, 1982) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| "Patients with hepatic metastases have 5-FU TBCs about half that of those found in patients without hepatic involvement." | 1.26 | Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. ( Byfield, JE; Floyd, RA; Frankel, SS; Griffiths, JC; Hornbeck, CL, 1982) |
| " Half-life values for the elimination of FU from plasma (mean, 123." | 1.26 | Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ( McDermott, BJ; Murphy, RF; van den Berg, HW, 1982) |
| "An unique combination treatment for cancer patients has been attempted in our department." | 1.26 | [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. ( Enomoto, K; Kodama, K; Okada, N; Sakurai, T; Suzuki, Y; Takimoto, M; Yokoi, H, 1982) |
| "Stomach cancer and colorectal cancer showed partial responses in 10." | 1.26 | [Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)]. ( , 1982) |
| " Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1." | 1.26 | [TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers]. ( Arimori, S; Furue, H; Ikenaga, M; Iketa, T; Komita, T; Nagao, T; Ohki, S; Satoh, H; Watanabe, K; Yamamoto, S, 1982) |
| "Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months." | 1.26 | Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981) |
| "The problems of defining response in prostatic cancer are discussed and a protocol for the future is outlined." | 1.26 | The non-hormone chemotherapy of prostatic cancer. ( Jones, MA; Williams, G, 1980) |
| "Oat cell carcinoma is the one variety of primary lung cancer which is sufficiently responsive to a variety of drugs and drug combinations that a very high rate of response and significant prolongation of survival can be consistently achieved." | 1.26 | Chemotherapy for lung cancer. ( Golbey, RB, 1978) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| "A fourth patient with previously treated epidermoid carcinoma of the anus presented with biopsy-proven pulmonary metastasis and was placed on the chemotherapeutic regimen alone." | 1.26 | Multi-modality therapy for epidermoid carcinoma of the anus. ( Newman, HK; Quan, SH, 1976) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "The topography of the neoplasm had no influence on the I." | 1.25 | Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors. ( Dubois, JB; Serrou, B, 1975) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours." | 1.25 | The influence of site of metastasis on tumour growth and response to chemotherapy. ( Bross, ID; Slack, NH, 1975) |
| " The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level." | 1.24 | The potentiation of radiation effects with 5-fluoro-uracil. ( FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 425 (31.58) | 18.7374 |
| 1990's | 262 (19.47) | 18.2507 |
| 2000's | 341 (25.33) | 29.6817 |
| 2010's | 275 (20.43) | 24.3611 |
| 2020's | 43 (3.19) | 2.80 |
| Authors | Studies |
|---|---|
| Schnur, RC | 1 |
| Fliri, AF | 1 |
| Kajiji, S | 1 |
| Pollack, VA | 1 |
| Bobek, M | 1 |
| An, SH | 1 |
| Skrincosky, D | 1 |
| De Clercq, E | 2 |
| Bernacki, RJ | 1 |
| Zou, ZR | 1 |
| Yi, YH | 1 |
| Wu, HM | 1 |
| Wu, JH | 1 |
| Liaw, CC | 3 |
| Lee, KH | 2 |
| Zhou, XW | 1 |
| Ma, HL | 1 |
| Zhang, X | 5 |
| Jing, SY | 1 |
| Miao, JY | 2 |
| Zhao, BX | 2 |
| Zhang, JF | 1 |
| Li, M | 2 |
| Cai, H | 1 |
| Huang, X | 1 |
| Xu, S | 2 |
| Shen, H | 2 |
| Zhang, P | 3 |
| Huang, Y | 5 |
| Jiang, J | 1 |
| Sun, Y | 5 |
| Jiang, B | 1 |
| Wu, X | 5 |
| Yao, H | 1 |
| Xu, J | 2 |
| Bistrović, A | 1 |
| Krstulović, L | 1 |
| Harej, A | 1 |
| Grbčić, P | 1 |
| Sedić, M | 1 |
| Koštrun, S | 1 |
| Pavelić, SK | 1 |
| Bajić, M | 1 |
| Raić-Malić, S | 1 |
| Zhao, TQ | 1 |
| Zhao, YD | 1 |
| Liu, XY | 1 |
| Wang, B | 3 |
| Li, ZH | 1 |
| He, ZX | 1 |
| Zhang, XH | 1 |
| Liang, JJ | 1 |
| Ma, LY | 1 |
| Liu, HM | 1 |
| Chen, L | 4 |
| Li, Q | 5 |
| Weng, B | 1 |
| Wang, J | 2 |
| Zhou, Y | 3 |
| Cheng, D | 1 |
| Sirirak, T | 1 |
| Qiu, P | 1 |
| Wu, J | 3 |
| Zhang, Y | 6 |
| Luo, YH | 1 |
| Piao, XJ | 1 |
| Shen, GN | 1 |
| Wang, JR | 1 |
| Feng, YC | 1 |
| Li, JQ | 1 |
| Xu, WT | 1 |
| Zhang, T | 2 |
| Wang, CY | 1 |
| Jin, CH | 1 |
| Li, N | 3 |
| Qu, G | 1 |
| Xue, J | 1 |
| Li, X | 3 |
| Zhao, X | 2 |
| Yan, Y | 1 |
| Gao, D | 2 |
| Zhang, L | 6 |
| Wang, P | 2 |
| Zhang, M | 4 |
| Zhao, B | 2 |
| Miao, J | 3 |
| Lin, Z | 2 |
| Wu, WC | 1 |
| Liu, YM | 1 |
| Liao, YH | 1 |
| Hsu, KC | 1 |
| Lien, ST | 1 |
| Chen, IC | 1 |
| Lai, MJ | 1 |
| Li, YH | 4 |
| Pan, SL | 1 |
| Chen, MC | 1 |
| Liou, JP | 1 |
| Song, JR | 1 |
| Wei, YL | 1 |
| Lu, FL | 1 |
| Li, DP | 1 |
| Mao, G | 1 |
| Mu, Z | 1 |
| Wu, DA | 1 |
| Dung, DTM | 1 |
| Park, EJ | 1 |
| Anh, DT | 1 |
| Hai, PT | 1 |
| Huy, LD | 1 |
| Jun, HW | 1 |
| Kwon, JH | 1 |
| Young Ji, A | 1 |
| Kang, JS | 1 |
| Tung, TT | 1 |
| Dung, PTP | 1 |
| Han, SB | 1 |
| Nam, NH | 1 |
| Ko, JC | 1 |
| Chen, JC | 2 |
| Wei, CL | 1 |
| Liu, LL | 1 |
| Chien, CC | 1 |
| Huang, IH | 1 |
| Hsieh, JM | 1 |
| Chiang, CS | 1 |
| Tseng, PY | 1 |
| Cheng, HH | 1 |
| Tsao, YC | 1 |
| Lin, YW | 1 |
| Gupta, R | 1 |
| Vishwakarma, L | 1 |
| Guleri, SK | 1 |
| Kumar, G | 1 |
| Asgharzadeh, F | 1 |
| Naghibzadeh, N | 1 |
| Hashemzehi, M | 1 |
| Mostafapour, A | 1 |
| Hassanian, SM | 1 |
| Avan, A | 1 |
| Khazaei, M | 1 |
| Hiramatsu, S | 1 |
| Sugimoto, A | 1 |
| On, O | 1 |
| Aomatsu, K | 1 |
| Wu, CF | 1 |
| Wu, CY | 1 |
| Lin, CF | 1 |
| Liu, YW | 1 |
| Lin, TC | 3 |
| Liao, HJ | 1 |
| Chang, GR | 1 |
| Xia, X | 1 |
| Pi, W | 1 |
| Lan, Y | 1 |
| Lv, D | 1 |
| Meng, Y | 1 |
| Yang, H | 1 |
| Wang, W | 1 |
| Shan, K | 1 |
| Deng, Y | 2 |
| Du, Z | 1 |
| Yue, P | 1 |
| Yang, S | 1 |
| Zhao, Y | 4 |
| Song, R | 1 |
| Jia, Y | 1 |
| Zhang, S | 3 |
| Wu, C | 3 |
| Zhang, R | 1 |
| Guo, Z | 1 |
| Pereira, M | 1 |
| Vale, N | 1 |
| Kamio, Y | 2 |
| Suzuki, T | 6 |
| Nakano, R | 1 |
| Musha, H | 1 |
| Takahashi, K | 5 |
| Ashino, K | 1 |
| Kanno, H | 1 |
| Kono, M | 1 |
| Nozu, S | 1 |
| Motoi, F | 1 |
| Kuhara, K | 1 |
| Usui, T | 2 |
| Kono, T | 1 |
| Shimojima, Y | 1 |
| Nishiguchi, R | 1 |
| Okayama, S | 2 |
| Asaka, S | 1 |
| Yokomizo, H | 3 |
| Shimakawa, T | 2 |
| Ohigashi, S | 1 |
| Shiozawa, S | 2 |
| Ni, X | 1 |
| Yang, Y | 5 |
| Fu, Z | 1 |
| Liu, R | 1 |
| Zhang, CY | 1 |
| Chen, X | 4 |
| Mathew, AA | 1 |
| Zakkariya, ZT | 1 |
| Ashokan, A | 1 |
| Manohar, M | 1 |
| Keechilat, P | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Qu, S | 1 |
| Wang, Q | 1 |
| Wang, Y | 1 |
| Li, L | 5 |
| Zhu, L | 1 |
| Kuang, X | 1 |
| Wang, X | 6 |
| Li, H | 4 |
| Zhao, L | 2 |
| Dai, H | 1 |
| Guijarro-Eguinoa, J | 1 |
| Arjona-Hernandez, S | 1 |
| Stewart, S | 1 |
| Pernia, O | 1 |
| Arias, P | 1 |
| Losantos-García, I | 1 |
| Rubio, T | 1 |
| Burdiel, M | 1 |
| Rodriguez-Antolin, C | 1 |
| Cruz-Castellanos, P | 1 |
| Higuera, O | 1 |
| Borobia, AM | 1 |
| Rodriguez-Novoa, S | 1 |
| de Castro-Carpeño, J | 1 |
| Ibanez de Caceres, I | 1 |
| Rosas-Alonso, R | 1 |
| Fukuda, K | 2 |
| Osumi, H | 2 |
| Yoshino, K | 1 |
| Nakayama, I | 2 |
| Fukuoka, S | 1 |
| Ogura, M | 2 |
| Wakatsuki, T | 2 |
| Ooki, A | 2 |
| Takahari, D | 3 |
| Chin, K | 3 |
| Yamaguchi, K | 3 |
| Shinozaki, E | 3 |
| Ogo, T | 1 |
| Ishihara, K | 1 |
| Nishino, M | 1 |
| Inokuch, M | 1 |
| Sakurai, U | 1 |
| Tang, Y | 1 |
| Sun, Z | 1 |
| Wu, S | 2 |
| Zhang, C | 1 |
| Cao, Y | 3 |
| Ganesh, K | 1 |
| O'Rourke, KP | 1 |
| Szeglin, BC | 1 |
| Zheng, Y | 1 |
| Sauvé, CG | 1 |
| Adileh, M | 1 |
| Wasserman, I | 1 |
| Marco, MR | 1 |
| Kim, AS | 1 |
| Shady, M | 1 |
| Sanchez-Vega, F | 1 |
| Karthaus, WR | 1 |
| Won, HH | 1 |
| Choi, SH | 3 |
| Pelossof, R | 1 |
| Barlas, A | 1 |
| Ntiamoah, P | 1 |
| Pappou, E | 1 |
| Elghouayel, A | 1 |
| Strong, JS | 1 |
| Chen, CT | 1 |
| Harris, JW | 1 |
| Weiser, MR | 1 |
| Nash, GM | 1 |
| Guillem, JG | 1 |
| Wei, IH | 1 |
| Kolesnick, RN | 1 |
| Veeraraghavan, H | 1 |
| Ortiz, EJ | 1 |
| Petkovska, I | 1 |
| Cercek, A | 1 |
| Manova-Todorova, KO | 1 |
| Saltz, LB | 2 |
| Lavery, JA | 1 |
| DeMatteo, RP | 1 |
| Massagué, J | 1 |
| Paty, PB | 1 |
| Yaeger, R | 1 |
| Patil, S | 2 |
| Clevers, H | 1 |
| Berger, MF | 1 |
| Lowe, SW | 1 |
| Shia, J | 1 |
| Romesser, PB | 1 |
| Dow, LE | 1 |
| Garcia-Aguilar, J | 1 |
| Sawyers, CL | 1 |
| Smith, JJ | 1 |
| Yoshimatsu, K | 3 |
| Sano, M | 1 |
| Satake, M | 1 |
| Imaizumi, R | 1 |
| Ito, Y | 5 |
| Koike, T | 2 |
| Maeda, H | 5 |
| Ida, A | 1 |
| Yamada, Y | 6 |
| Katsube, T | 1 |
| Duman, FD | 1 |
| Akkoc, Y | 1 |
| Demirci, G | 1 |
| Bavili, N | 1 |
| Kiraz, A | 1 |
| Gozuacik, D | 1 |
| Acar, HY | 1 |
| Wattenberg, MM | 1 |
| Asch, D | 1 |
| Yu, S | 1 |
| O'Dwyer, PJ | 5 |
| Domchek, SM | 1 |
| Nathanson, KL | 1 |
| Rosen, MA | 1 |
| Beatty, GL | 1 |
| Siegelman, ES | 1 |
| Reiss, KA | 1 |
| Yue, GGL | 1 |
| Fung, KP | 1 |
| Yu, J | 2 |
| Lau, CBS | 1 |
| Chiu, PWY | 1 |
| Ren, Y | 1 |
| Li, T | 1 |
| Du, LY | 1 |
| Qiu, Y | 1 |
| Wang, SB | 1 |
| Lei, KJ | 1 |
| Jia, YM | 1 |
| Hori, A | 2 |
| Ohira, R | 1 |
| Nakamura, T | 5 |
| Kimura, Y | 4 |
| Ueda, S | 2 |
| Torii, M | 1 |
| Kennoki, N | 2 |
| Hori, S | 2 |
| Sastre, J | 3 |
| Orden, V | 1 |
| Martínez, A | 1 |
| Bando, I | 1 |
| Balbín, M | 1 |
| Bellosillo, B | 1 |
| Palanca, S | 1 |
| Peligros Gomez, MI | 1 |
| Mediero, B | 1 |
| Llovet, P | 1 |
| Moral, VM | 1 |
| Viéitez, JM | 1 |
| García-Alfonso, P | 2 |
| Calle, SG | 1 |
| Ortiz-Morales, MJ | 1 |
| Salud, A | 1 |
| Quintero, G | 1 |
| Lopez, C | 1 |
| Díaz-Rubio, E | 2 |
| Aranda, E | 4 |
| Kitagawa, Y | 3 |
| Ota, Y | 2 |
| Suenaga, M | 1 |
| Kim, SA | 1 |
| Kim, JW | 2 |
| Suh, KJ | 1 |
| Chang, W | 1 |
| Oh, HK | 1 |
| Cho, JY | 3 |
| Kim, DW | 1 |
| Cho, S | 1 |
| Kim, JH | 2 |
| Kim, K | 3 |
| Kang, SB | 1 |
| Jheon, S | 1 |
| Lee, KW | 1 |
| Suker, M | 1 |
| Groot Koerkamp, B | 1 |
| Nuyttens, JJ | 2 |
| Dwarkasing, RS | 2 |
| Homs, MYV | 1 |
| Eskens, FALM | 1 |
| van Eijck, CHJ | 1 |
| Bockorny, B | 1 |
| Semenisty, V | 1 |
| Macarulla, T | 1 |
| Borazanci, E | 1 |
| Wolpin, BM | 1 |
| Stemmer, SM | 1 |
| Golan, T | 1 |
| Geva, R | 1 |
| Borad, MJ | 1 |
| Pedersen, KS | 1 |
| Park, JO | 4 |
| Ramirez, RA | 1 |
| Abad, DG | 1 |
| Feliu, J | 2 |
| Muñoz, A | 1 |
| Ponz-Sarvise, M | 1 |
| Peled, A | 1 |
| Lustig, TM | 1 |
| Bohana-Kashtan, O | 1 |
| Shaw, SM | 1 |
| Sorani, E | 1 |
| Chaney, M | 1 |
| Kadosh, S | 1 |
| Vainstein Haras, A | 1 |
| Von Hoff, DD | 3 |
| Hidalgo, M | 1 |
| Wang, Z | 2 |
| Zhou, X | 1 |
| Chen, Y | 7 |
| Lin, Y | 2 |
| Kong, F | 1 |
| Fu, J | 2 |
| Yue, Q | 1 |
| Mercier, F | 1 |
| Kerioui, M | 1 |
| Desmée, S | 1 |
| Guedj, J | 1 |
| Krieter, O | 1 |
| Bruno, R | 1 |
| Wan, J | 1 |
| Ling, XA | 1 |
| Ding, GG | 1 |
| Wang, M | 2 |
| Du, N | 1 |
| Liang, T | 1 |
| Xiao, GD | 1 |
| Li, K | 1 |
| Wang, JC | 1 |
| Xu, CW | 2 |
| Peng, ZY | 1 |
| Tang, SC | 1 |
| Sun, X | 1 |
| Oliveira, CC | 1 |
| Marques, AR | 1 |
| Apolinário, I | 1 |
| Brandão, I | 1 |
| Dang, N | 1 |
| Waer, M | 1 |
| Sprangers, B | 1 |
| González Astorga, B | 1 |
| Salvà Ballabrera, F | 1 |
| Aranda Aguilar, E | 1 |
| Élez Fernández, E | 1 |
| González Flores, E | 1 |
| Vera García, R | 1 |
| Fernández Montes, A | 1 |
| López Muñoz, AM | 1 |
| Salud Salvia, A | 1 |
| Abe, K | 1 |
| Kanehira, M | 1 |
| Ohkouchi, S | 1 |
| Kumata, S | 1 |
| Suzuki, Y | 3 |
| Oishi, H | 1 |
| Noda, M | 1 |
| Sakurada, A | 1 |
| Miyauchi, E | 1 |
| Fujiwara, T | 1 |
| Harigae, H | 1 |
| Okada, Y | 6 |
| Tanabe, R | 1 |
| Ehata, S | 1 |
| Kubota, SI | 1 |
| Morishita, Y | 3 |
| Ueda, HR | 1 |
| Miyazono, K | 1 |
| Liu, K | 1 |
| Li, J | 7 |
| Liao, J | 1 |
| Ma, L | 1 |
| Liu, L | 2 |
| Erickson, NT | 1 |
| Ricard, I | 1 |
| von Weikersthal, LF | 1 |
| Lerch, MM | 1 |
| Decker, T | 1 |
| Kiani, A | 1 |
| Kaiser, F | 1 |
| Heintges, T | 1 |
| Kahl, C | 1 |
| Kullmann, F | 1 |
| Scheithauer, W | 4 |
| Link, H | 1 |
| Höffkes, HG | 2 |
| Moehler, M | 2 |
| Gesenhues, AB | 1 |
| Theurich, S | 1 |
| Michl, M | 1 |
| Modest, DP | 1 |
| Algül, H | 1 |
| Stintzing, S | 1 |
| Heinemann, V | 2 |
| Holch, JW | 1 |
| Al-Batran, SE | 1 |
| Homann, N | 1 |
| Pauligk, C | 1 |
| Illerhaus, G | 1 |
| Martens, UM | 1 |
| Stoehlmacher, J | 1 |
| Schmalenberg, H | 1 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 1 |
| Messmann, H | 1 |
| Fischbach, W | 1 |
| Hartmann, JT | 2 |
| Mayer, F | 1 |
| Koenigsmann, M | 1 |
| Arnold, D | 1 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 1 |
| Jäger, E | 2 |
| Bechstein, W | 1 |
| Ronellenfitsch, U | 1 |
| Mönig, S | 1 |
| Hofheinz, RD | 2 |
| Dore-Savard, L | 1 |
| Chen, Z | 3 |
| Winnard, PT | 1 |
| Krishnamachary, B | 1 |
| Raman, V | 1 |
| Black, ME | 1 |
| Bhujwalla, ZM | 1 |
| Baggio, R | 1 |
| Chavel, P | 1 |
| Tisseau, L | 1 |
| Darrieux, L | 1 |
| Safa, G | 1 |
| Evesque, L | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Tuan Falk, A | 1 |
| Doyen, J | 1 |
| Reure, J | 1 |
| Cavaglione, G | 1 |
| François, E | 1 |
| Yuki, T | 1 |
| Guo, N | 1 |
| Yin, R | 1 |
| Song, L | 1 |
| Wang, D | 1 |
| O'Neill, AF | 1 |
| Towbin, AJ | 1 |
| Krailo, MD | 1 |
| Xia, C | 1 |
| Gao, Y | 2 |
| McCarville, MB | 1 |
| Meyers, RL | 1 |
| McGahren, ED | 1 |
| Tiao, GM | 1 |
| Dunn, SP | 1 |
| Langham, MR | 1 |
| Weldon, CB | 1 |
| Finegold, MJ | 1 |
| Ranganathan, S | 1 |
| Furman, WL | 1 |
| Malogolowkin, M | 1 |
| Rodriguez-Galindo, C | 1 |
| Katzenstein, HM | 1 |
| Monfort, JB | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Francès, C | 1 |
| Barbaud, A | 1 |
| Senet, P | 1 |
| Tessitore, A | 1 |
| Bruera, G | 2 |
| Mastroiaco, V | 1 |
| Cannita, K | 3 |
| Cortellini, A | 1 |
| Cocciolone, V | 1 |
| Dal Mas, A | 1 |
| Calvisi, G | 1 |
| Zazzeroni, F | 1 |
| Ficorella, C | 3 |
| Ricevuto, E | 4 |
| Alesse, E | 1 |
| Zykova, T | 1 |
| Zhu, F | 2 |
| Wang, L | 3 |
| Lim, DY | 1 |
| Yao, K | 1 |
| Roh, E | 1 |
| Yoon, SP | 1 |
| Kim, HG | 2 |
| Bae, KB | 1 |
| Wen, W | 2 |
| Shin, SH | 1 |
| Nadas, J | 1 |
| Li, Y | 2 |
| Ma, W | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Sasaki, S | 1 |
| Baba, T | 1 |
| Muranaka, H | 1 |
| Tanabe, Y | 1 |
| Takahashi, C | 1 |
| Matsugo, S | 1 |
| Mukaida, N | 1 |
| Tokoro, T | 1 |
| Nakamura, K | 3 |
| Hirose, A | 1 |
| Nakanuma, S | 2 |
| Okamoto, K | 2 |
| Kinoshita, J | 1 |
| Makino, I | 1 |
| Hayashi, H | 3 |
| Oyama, K | 4 |
| Miyashita, T | 1 |
| Tajima, H | 1 |
| Takamura, H | 1 |
| Ninomiya, I | 2 |
| Fushida, S | 3 |
| Ohta, T | 3 |
| Peng, Y | 1 |
| Cao, D | 2 |
| Bi, F | 2 |
| Li, Z | 1 |
| Gou, H | 1 |
| Wu, GJ | 1 |
| Pen, J | 1 |
| An, S | 1 |
| Liu, Y | 2 |
| Hao, Q | 1 |
| Guo, XX | 2 |
| Xu, TR | 1 |
| Yin, Y | 1 |
| Wu, B | 1 |
| Huang, Z | 1 |
| Zhuang, W | 1 |
| Xu, Z | 1 |
| Huang, C | 2 |
| Zhang, J | 5 |
| Akin, S | 1 |
| Kas Guner, C | 1 |
| Urushiyama, H | 1 |
| Jo, T | 1 |
| Yasunaga, H | 1 |
| Michihata, N | 1 |
| Matsui, H | 2 |
| Hasegawa, W | 1 |
| Takeshima, H | 1 |
| Sakamoto, Y | 2 |
| Hiraishi, Y | 1 |
| Mitani, A | 1 |
| Fushimi, K | 1 |
| Nagase, T | 1 |
| Yamauchi, Y | 1 |
| Shinohara, S | 1 |
| Hyodo, M | 1 |
| Ota, G | 1 |
| Inoue, Y | 6 |
| Sato, H | 2 |
| Tsukahara, M | 1 |
| Okada, M | 1 |
| Lefor, AK | 1 |
| Yasuda, Y | 1 |
| Sangi, S | 1 |
| SreeHarsha, N | 1 |
| Bawadekji, A | 1 |
| Al Ali, M | 1 |
| Bachet, JB | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 1 |
| Raoul, JL | 2 |
| Lecomte, T | 3 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Pernot, S | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 1 |
| Etienne, PL | 1 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Lepage, C | 1 |
| Taieb, J | 3 |
| Takemoto, K | 1 |
| Miyahara, N | 1 |
| Chikuie, N | 1 |
| Hamamoto, T | 2 |
| Ishino, T | 1 |
| Ueda, T | 1 |
| Takeno, S | 1 |
| Çömlekçi, E | 1 |
| Kutlu, HM | 1 |
| Vejselova Sezer, C | 1 |
| Saint-Jean, A | 1 |
| Reguart, N | 1 |
| Eixarch, A | 1 |
| Adán, A | 1 |
| Castellà, C | 1 |
| Sánchez-Dalmau, B | 1 |
| Sainz-de-la-Maza, M | 1 |
| Senda, N | 1 |
| Miyagaki, T | 2 |
| Oka, T | 2 |
| Nonogaki, A | 1 |
| Yoshizaki, A | 1 |
| Shibata, S | 2 |
| Sato, S | 5 |
| Bang, YJ | 2 |
| Kang, YK | 1 |
| Ng, M | 1 |
| Chung, HC | 3 |
| Wainberg, ZA | 1 |
| Gendreau, S | 1 |
| Chan, WY | 2 |
| Xu, N | 1 |
| Maslyar, D | 1 |
| Meng, R | 1 |
| Chau, I | 2 |
| Ajani, JA | 4 |
| Wang-Gillam, A | 1 |
| Hubner, RA | 1 |
| Siveke, JT | 1 |
| Belanger, B | 1 |
| de Jong, FA | 1 |
| Mirakhur, B | 1 |
| Chen, LT | 2 |
| Zhao, C | 1 |
| Shen, G | 2 |
| Shi, M | 2 |
| Zhang, N | 1 |
| Hu, G | 1 |
| Hu, X | 1 |
| Chen, J | 2 |
| Shao, X | 1 |
| Han, F | 1 |
| Mai, H | 1 |
| Chua, MLK | 1 |
| Xie, C | 1 |
| Lyu, N | 1 |
| Kong, Y | 1 |
| Pan, T | 1 |
| Mu, L | 1 |
| Li, S | 3 |
| Deng, H | 1 |
| Xu, L | 1 |
| Guo, R | 1 |
| Chen, M | 1 |
| Wu, P | 1 |
| Zhao, M | 1 |
| Lin, H | 1 |
| Lu, X | 1 |
| Chi, P | 1 |
| Exposito, F | 1 |
| Villalba, M | 1 |
| Redrado, M | 1 |
| de Aberasturi, AL | 1 |
| Cirauqui, C | 1 |
| Redin, E | 1 |
| Guruceaga, E | 1 |
| de Andrea, C | 1 |
| Vicent, S | 1 |
| Ajona, D | 1 |
| Montuenga, LM | 1 |
| Pio, R | 1 |
| Calvo, A | 1 |
| Callebout, E | 1 |
| Ribeiro, SM | 1 |
| Laurent, S | 1 |
| De Man, M | 1 |
| Ferdinande, L | 1 |
| Claes, KBM | 1 |
| Van der Meulen, J | 1 |
| Geboes, KP | 1 |
| Komatsu, H | 1 |
| Izumi, N | 1 |
| Tsukioka, T | 1 |
| Inoue, H | 2 |
| Miyamoto, H | 2 |
| Nishiyama, N | 1 |
| Pintova, S | 1 |
| Dharmupari, S | 1 |
| Moshier, E | 1 |
| Zubizarreta, N | 1 |
| Ang, C | 1 |
| Holcombe, RF | 1 |
| Benitez, JC | 1 |
| Mezquita, L | 1 |
| Colle, R | 1 |
| Tselikas, L | 1 |
| Botticella, A | 1 |
| Caramella, C | 1 |
| Besse, B | 1 |
| Pan, X | 1 |
| Sun, H | 2 |
| Yan, M | 1 |
| Zhang, H | 3 |
| Miyazaki, T | 6 |
| Hasegawa, Y | 2 |
| Hanai, N | 1 |
| Ozawa, T | 1 |
| Hirakawa, H | 2 |
| Suzuki, A | 2 |
| Okamoto, H | 1 |
| Harata, I | 1 |
| Arredondo, J | 1 |
| Baixauli, J | 1 |
| Beorlegui, C | 1 |
| Arbea, L | 1 |
| Rodríguez, J | 1 |
| Sola, JJ | 1 |
| Chopitea, A | 1 |
| Hernández-Lizoáin, JL | 1 |
| Darwiche, K | 1 |
| Zarogoulidis, P | 2 |
| Karamanos, NK | 1 |
| Domvri, K | 1 |
| Chatzaki, E | 2 |
| Constantinidis, TC | 1 |
| Kakolyris, S | 1 |
| Zarogoulidis, K | 2 |
| Schaller, G | 1 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| Skrzypek, K | 1 |
| Tertil, M | 1 |
| Golda, S | 1 |
| Ciesla, M | 1 |
| Weglarczyk, K | 1 |
| Collet, G | 1 |
| Guichard, A | 1 |
| Kozakowska, M | 1 |
| Boczkowski, J | 1 |
| Was, H | 1 |
| Gil, T | 1 |
| Kuzdzal, J | 1 |
| Muchova, L | 1 |
| Vitek, L | 1 |
| Loboda, A | 1 |
| Jozkowicz, A | 1 |
| Kieda, C | 1 |
| Dulak, J | 1 |
| Chi, YH | 1 |
| Jiang, WC | 1 |
| Du, F | 1 |
| Sun, YK | 1 |
| Song, Y | 1 |
| Yang, L | 2 |
| Zhou, AP | 1 |
| Wang, JW | 1 |
| Shen, HJ | 1 |
| Wang, YH | 1 |
| Uygun, K | 1 |
| Bilici, A | 2 |
| Kaya, S | 1 |
| Oven Ustaalioglu, BB | 1 |
| Yildiz, R | 1 |
| Temiz, S | 1 |
| Seker, M | 2 |
| Aksu, G | 1 |
| Cabuk, D | 1 |
| Gumus, M | 2 |
| Bian, L | 1 |
| Wang, T | 2 |
| Jiang, Z | 1 |
| Brandi, G | 1 |
| Derenzini, E | 1 |
| Falcone, A | 3 |
| Masi, G | 3 |
| Loupakis, F | 3 |
| Pietrabissa, A | 2 |
| Pinna, AD | 1 |
| Ercolani, G | 1 |
| Pantaleo, MA | 1 |
| Di Girolamo, S | 1 |
| Grazi, GL | 1 |
| de Rosa, F | 1 |
| Biasco, G | 1 |
| Tezuka, T | 1 |
| Hamada, C | 1 |
| Ishida, H | 3 |
| Ooshiro, M | 1 |
| Matsuoka, H | 1 |
| Kawasaki, S | 1 |
| Mishima, H | 3 |
| Maeda, K | 1 |
| Sakamoto, J | 3 |
| Koda, K | 1 |
| Koike, N | 1 |
| Ohshima, Y | 1 |
| Takeuchi, T | 1 |
| Arita, S | 1 |
| Liang, J | 2 |
| Qian, Y | 2 |
| Xu, D | 1 |
| Yin, Q | 1 |
| Pan, HJ | 1 |
| Zhang, SH | 2 |
| He, HW | 1 |
| Li, XQ | 1 |
| Zhang, YP | 3 |
| Shao, RG | 1 |
| Yang, TY | 1 |
| Chang, GC | 1 |
| Hsu, SL | 1 |
| Huang, YR | 1 |
| Chiu, LY | 1 |
| Sheu, GT | 1 |
| Cunningham, D | 3 |
| Lang, I | 2 |
| Marcuello, E | 3 |
| Lorusso, V | 1 |
| Ocvirk, J | 2 |
| Shin, DB | 1 |
| Jonker, D | 1 |
| Osborne, S | 1 |
| Andre, N | 2 |
| Waterkamp, D | 1 |
| Saunders, MP | 1 |
| Alishekevitz, D | 1 |
| Bril, R | 1 |
| Loven, D | 1 |
| Miller, V | 1 |
| Voloshin, T | 1 |
| Gingis-Velistki, S | 1 |
| Fremder, E | 1 |
| Scherer, SJ | 1 |
| Shaked, Y | 1 |
| Ahn, JY | 2 |
| Min, HY | 2 |
| Jeong, JH | 1 |
| Byun, Y | 1 |
| Lee, HY | 2 |
| Hiraki, M | 1 |
| Nishimura, J | 1 |
| Ohtsuka, M | 2 |
| Shiomi, H | 1 |
| Uemura, M | 1 |
| Haraguchi, N | 2 |
| Hata, T | 1 |
| Hayashi, T | 6 |
| Takemasa, I | 1 |
| Mizushima, T | 1 |
| Isohashi, F | 1 |
| Yoshioka, Y | 2 |
| Ogawa, K | 3 |
| Doki, Y | 2 |
| Mori, M | 2 |
| Yamamoto, H | 1 |
| Paradisi, A | 1 |
| Creveaux, M | 1 |
| Gibert, B | 1 |
| Devailly, G | 1 |
| Redoulez, E | 1 |
| Neves, D | 1 |
| Cleyssac, E | 1 |
| Treilleux, I | 1 |
| Klein, C | 1 |
| Niederfellner, G | 1 |
| Cassier, PA | 2 |
| Bernet, A | 1 |
| Mehlen, P | 1 |
| Guo, X | 2 |
| Liu, TS | 2 |
| Yu, YY | 1 |
| Zhou, YH | 1 |
| Zhuang, RY | 1 |
| Cui, YH | 1 |
| Kajiura, S | 2 |
| Hosokawa, A | 1 |
| Yoshita, H | 1 |
| Ueda, Y | 4 |
| Ueda, A | 2 |
| Mihara, H | 1 |
| Ando, T | 2 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 2 |
| Sugiyama, T | 2 |
| Yasui, T | 2 |
| Mukubo, H | 1 |
| Sato, N | 4 |
| Kita, I | 1 |
| Yabe, N | 1 |
| Murai, S | 1 |
| Shimizu, H | 1 |
| Kitasato, K | 1 |
| Yoshikawa, T | 1 |
| Oto, I | 1 |
| Nakadai, J | 1 |
| Hasegawa, H | 4 |
| Deguchi, K | 2 |
| Nishikawa, K | 1 |
| Iwase, K | 2 |
| Kawada, J | 1 |
| Aono, T | 2 |
| Yoshida, H | 1 |
| Nomura, M | 3 |
| Tamagawa, H | 1 |
| Matsuda, C | 1 |
| Deguchi, T | 1 |
| Higashi, S | 1 |
| Okumura, Y | 1 |
| Noguchi, Y | 1 |
| Takagi, M | 1 |
| Fukui, A | 1 |
| Tanaka, Y | 5 |
| Tomoda, M | 1 |
| Kawahara, H | 1 |
| Watanabe, K | 2 |
| Enomoto, H | 1 |
| Akiba, T | 1 |
| Yanaga, K | 1 |
| Hirata, K | 6 |
| Nagata, N | 1 |
| Kato, T | 8 |
| Okuyama, Y | 1 |
| Andoh, H | 1 |
| Oba, K | 1 |
| Hazama, S | 1 |
| Mochinaga, K | 2 |
| Tsuchiya, T | 3 |
| Nagasaki, T | 3 |
| Arai, J | 2 |
| Tominaga, T | 3 |
| Yamasaki, N | 3 |
| Matsumoto, K | 2 |
| Nanashima, A | 2 |
| Tsukamoto, K | 2 |
| Nagayasu, T | 3 |
| Jung, M | 1 |
| Holmqvist, A | 1 |
| Sun, XF | 1 |
| Albertsson, M | 1 |
| Barrueco, N | 1 |
| Such Díaz, A | 1 |
| Sáez de la Fuente, J | 1 |
| Escobar, I | 1 |
| Liu, XH | 1 |
| Man, YN | 1 |
| Cao, R | 1 |
| Liu, C | 2 |
| Wu, XZ | 1 |
| Li, B | 1 |
| Tsao, SW | 1 |
| Chan, KW | 1 |
| Ludwig, DL | 1 |
| Novosyadlyy, R | 1 |
| Li, YY | 1 |
| He, QY | 1 |
| Cheung, AL | 1 |
| Qiu, M | 1 |
| Iwata, H | 1 |
| Hatanaka, M | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Ha, SW | 1 |
| Wei, L | 1 |
| Liang, X | 1 |
| Liu, J | 4 |
| Wang, WJ | 1 |
| Zhang, JN | 1 |
| Zhang, XY | 1 |
| Yanagihara, Y | 1 |
| Tanji, N | 1 |
| Miura, N | 1 |
| Shirato, A | 1 |
| Nishimura, K | 2 |
| Fukumoto, T | 1 |
| Azuma, K | 1 |
| Miyauchi, Y | 1 |
| Kikugawa, T | 1 |
| Yokoyama, M | 1 |
| Koca, D | 2 |
| Ünal, OÜ | 1 |
| Öztop, I | 2 |
| Yılmaz, U | 2 |
| Zhu, X | 2 |
| Peng, W | 1 |
| Sun, S | 3 |
| Cao, J | 1 |
| Ji, D | 1 |
| Liu, X | 3 |
| Wang, C | 2 |
| Huang, M | 1 |
| Yu, H | 2 |
| Guo, W | 1 |
| Yin, J | 1 |
| Rudloff, U | 1 |
| Langan, RC | 1 |
| Mullinax, JE | 1 |
| Beane, JD | 1 |
| Steinberg, SM | 1 |
| Beresnev, T | 1 |
| Webb, CC | 1 |
| Walker, M | 1 |
| Toomey, MA | 1 |
| Schrump, D | 1 |
| Pandalai, P | 1 |
| Stojadinovic, A | 1 |
| Avital, I | 1 |
| Subbiah, IM | 1 |
| Blackmon, SH | 1 |
| Correa, AM | 1 |
| Kee, B | 1 |
| Vaporciyan, AA | 1 |
| Swisher, SG | 1 |
| Eng, C | 1 |
| Lu, W | 1 |
| Zuo, Y | 1 |
| Feng, Y | 1 |
| Ding, M | 1 |
| Huang, W | 1 |
| Ye, J | 1 |
| Xiao, J | 1 |
| Zha, X | 1 |
| Xu, H | 1 |
| Aoe, K | 1 |
| Takigawa, N | 3 |
| Hotta, K | 3 |
| Maeda, T | 2 |
| Kishino, D | 1 |
| Nogami, N | 1 |
| Tabata, M | 4 |
| Harita, S | 1 |
| Okada, T | 1 |
| Kubo, T | 1 |
| Hosokawa, S | 1 |
| Fujiwara, K | 2 |
| Gemba, K | 2 |
| Yasugi, M | 1 |
| Kozuki, T | 1 |
| Kato, Y | 1 |
| Katsui, K | 1 |
| Kanazawa, S | 2 |
| Ueoka, H | 3 |
| Tanimoto, M | 3 |
| Kiura, K | 7 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Cheng, AL | 2 |
| Vaid, AK | 1 |
| Ma, BB | 1 |
| Teh, C | 1 |
| Ahn, JB | 1 |
| Bello, M | 1 |
| Charoentum, C | 1 |
| de Lima Lopes, G | 1 |
| Ho, GF | 1 |
| Kong, HL | 1 |
| Lam, KO | 1 |
| Park, YS | 4 |
| Sriuranpong, V | 1 |
| Sudoyo, AW | 1 |
| Wang, JY | 2 |
| Zhang, SZ | 1 |
| Ciardiello, F | 1 |
| Köhne, CH | 2 |
| Shaw, M | 1 |
| Kim, TW | 1 |
| Michael, M | 2 |
| Chander, S | 1 |
| McKendrick, J | 2 |
| MacKay, JR | 1 |
| Steel, M | 1 |
| Hicks, R | 1 |
| Heriot, A | 1 |
| Leong, T | 1 |
| Cooray, P | 2 |
| Jefford, M | 1 |
| Zalcberg, J | 1 |
| Bressel, M | 1 |
| McClure, B | 1 |
| Ngan, SY | 2 |
| Cui, DX | 1 |
| Wang, XJ | 1 |
| Zhang, XR | 1 |
| Zhao, TK | 1 |
| Liu, SM | 1 |
| Ma, WQ | 1 |
| Gao, ZQ | 1 |
| Magata, H | 1 |
| Kondo, K | 2 |
| Otani, K | 2 |
| Yano, K | 1 |
| Yonei, A | 1 |
| Akasu, I | 1 |
| Sato, Y | 6 |
| Marutsuka, H | 1 |
| Fukushima, G | 1 |
| Kataoka, H | 1 |
| Zhao, JG | 1 |
| Ren, KM | 1 |
| Tang, J | 2 |
| Yan, D | 2 |
| Zheng, X | 2 |
| Tu, L | 1 |
| Jia, J | 1 |
| Cheng, L | 1 |
| Cinar, P | 1 |
| Calkins, SM | 1 |
| Venook, AP | 2 |
| Kelley, RK | 1 |
| Duran, AO | 1 |
| Karaca, H | 1 |
| Besiroglu, M | 1 |
| Bayoglu, IV | 1 |
| Menekse, S | 1 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Bahceci, A | 1 |
| Uysal, M | 1 |
| Sevinc, A | 1 |
| Hacibekiroglu, I | 2 |
| Aksoy, A | 1 |
| Tanriverdi, O | 1 |
| Arpaci, E | 1 |
| Inanc, M | 1 |
| Dane, F | 1 |
| Ozkan, M | 1 |
| Izumi, H | 2 |
| Touge, H | 2 |
| Igishi, T | 3 |
| Makino, H | 2 |
| Nishii-Ito, S | 1 |
| Takata, M | 2 |
| Nakazaki, H | 1 |
| Matsumoto, S | 4 |
| Kodani, M | 2 |
| Kurai, J | 2 |
| Takeda, K | 3 |
| Sakamoto, T | 2 |
| Yanai, M | 1 |
| Tanaka, N | 3 |
| Nirodi, CS | 1 |
| Shimizu, E | 3 |
| Zhao, HY | 1 |
| Chen, GY | 2 |
| Li, XL | 3 |
| Feng, JF | 1 |
| Shi, MQ | 1 |
| Cheng, Y | 2 |
| Ma, LX | 1 |
| Gu, CP | 1 |
| Song, XQ | 1 |
| Zhou, D | 1 |
| Ji, YL | 1 |
| Li, RZ | 1 |
| Xue, LF | 1 |
| Li, P | 1 |
| Liang, XH | 1 |
| Dong, L | 1 |
| Cui, WC | 1 |
| Pang, MX | 1 |
| Ojima, H | 1 |
| Fukuchi, M | 1 |
| Sakai, M | 1 |
| Sohda, M | 1 |
| Suzuki, S | 4 |
| Ieta, K | 1 |
| Saito, K | 2 |
| Sano, A | 1 |
| Yokobori, T | 1 |
| Inose, T | 1 |
| Nakajima, M | 1 |
| Kato, H | 4 |
| Kuwano, H | 2 |
| Marks, E | 1 |
| Rizvi, SM | 1 |
| Sarwani, N | 1 |
| Yang, Z | 1 |
| El-Deiry, WS | 1 |
| Cho, H | 1 |
| Nishiike, S | 1 |
| Yamamoto, Y | 4 |
| Takenaka, Y | 1 |
| Nakahara, S | 1 |
| Hanamoto, A | 1 |
| Inohara, H | 1 |
| Hishida, T | 1 |
| Tsuboi, M | 1 |
| Shukuya, T | 1 |
| Takamochi, K | 1 |
| Sakurai, H | 1 |
| Yoh, K | 1 |
| Ohashi, Y | 1 |
| Kunitoh, H | 1 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Cayir, K | 1 |
| Simsek, M | 1 |
| Bilici, M | 1 |
| Tekin, SB | 1 |
| Yildirim, N | 1 |
| Bilen, N | 1 |
| Makas, I | 1 |
| Morodomi, Y | 1 |
| Okamoto, T | 1 |
| Kohno, M | 1 |
| Katsura, M | 1 |
| Takada, K | 1 |
| Fujishita, T | 1 |
| Kitahara, H | 1 |
| Shimamatsu, S | 1 |
| Yoshida, T | 6 |
| Tagawa, T | 2 |
| Okano, S | 1 |
| Maehara, Y | 5 |
| Lescut, N | 1 |
| Lepinoy, A | 1 |
| Schipman, B | 1 |
| Cerda, T | 1 |
| Guimas, V | 1 |
| Bednarek, C | 1 |
| Bosset, JF | 1 |
| Yoshioka, M | 1 |
| Uchinami, H | 1 |
| Watanabe, G | 1 |
| Miyazawa, H | 1 |
| Iida, M | 1 |
| Yoshida, M | 3 |
| Yoshioka, T | 2 |
| Nanjo, H | 1 |
| Bencsikova, B | 1 |
| Bortlicek, Z | 1 |
| Halamkova, J | 1 |
| Ostrizkova, L | 1 |
| Kiss, I | 1 |
| Melichar, B | 1 |
| Pavlik, T | 1 |
| Dusek, L | 1 |
| Valik, D | 1 |
| Vyzula, R | 1 |
| Zdrazilova-Dubska, L | 1 |
| Matlapudi, MS | 1 |
| Moin, A | 1 |
| Medishetti, R | 1 |
| Rajendra, K | 1 |
| Raichur, AM | 1 |
| Kumar, BR | 1 |
| Ma, J | 2 |
| Deng, G | 1 |
| He, J | 1 |
| Pei, H | 1 |
| Zeng, S | 1 |
| Tseng, CL | 1 |
| Wu, YC | 1 |
| Fang, HW | 1 |
| Lin, FH | 1 |
| Tang, TP | 1 |
| Wang, H | 2 |
| Yang, T | 1 |
| Otsubo, D | 1 |
| Yamashita, K | 2 |
| Fujita, M | 4 |
| Nishi, M | 1 |
| Kakeji, Y | 1 |
| Tsutsumi, S | 1 |
| Fujii, T | 2 |
| Yamaguchi, S | 1 |
| Suto, T | 1 |
| Yajima, R | 1 |
| Morita, H | 1 |
| Asao, T | 1 |
| Park, MI | 1 |
| Liang, Y | 1 |
| Bu, JG | 1 |
| Cheng, JL | 1 |
| Gao, WW | 1 |
| Xu, YC | 1 |
| Feng, J | 2 |
| Chen, BY | 1 |
| Liang, WC | 1 |
| Chen, KQ | 1 |
| Stamou, K | 1 |
| Tsamis, D | 1 |
| Pallas, N | 1 |
| Samanta, E | 1 |
| Courcoutsakis, N | 1 |
| Prassopoulos, P | 1 |
| Tentes, AA | 1 |
| Lee, JS | 10 |
| Yamashita, S | 1 |
| Shimizu, Y | 1 |
| Tominaga, H | 1 |
| Odagiri, K | 1 |
| Kurokawa, T | 4 |
| Yamaguchi, M | 2 |
| Takahashi, G | 1 |
| Sawada, G | 1 |
| Moon, J | 1 |
| Inoue, M | 3 |
| Irei, T | 1 |
| Nakahira, S | 1 |
| Hatanaka, N | 1 |
| Hoffman, RM | 2 |
| Vargas, A | 1 |
| Pagés, M | 1 |
| Buxó, E | 1 |
| Jeannin, G | 1 |
| Merle, P | 1 |
| Janicot, H | 1 |
| Thibonnier, L | 1 |
| Kwiatkowski, F | 1 |
| Naame, A | 1 |
| Chadeyras, JB | 1 |
| Galvaing, G | 1 |
| Belliere, A | 1 |
| Filaire, M | 1 |
| Verrelle, P | 2 |
| Giampieri, R | 1 |
| Maccaroni, E | 1 |
| Mandolesi, A | 1 |
| Del Prete, M | 1 |
| Andrikou, K | 1 |
| Faloppi, L | 1 |
| Bittoni, A | 1 |
| Bianconi, M | 1 |
| Scarpelli, M | 1 |
| Bracci, R | 1 |
| Scartozzi, M | 1 |
| Cascinu, S | 2 |
| Noura, S | 2 |
| Ohue, M | 2 |
| Miyoshi, N | 1 |
| Yasui, M | 1 |
| Sugimoto, N | 1 |
| Okami, J | 1 |
| Higashiyama, M | 2 |
| Fujiwara, Y | 4 |
| Yano, M | 3 |
| Sakon, M | 2 |
| Masuda, T | 2 |
| Nagai, K | 1 |
| Sanada, K | 1 |
| Takahashi, S | 7 |
| Hanaka, J | 1 |
| Takahashi, M | 5 |
| Kanamura, S | 1 |
| Wakamatsu, T | 1 |
| Nakayama, H | 1 |
| Goya, T | 1 |
| Sachdev, A | 1 |
| Matai, I | 1 |
| Gopinath, P | 1 |
| Tebbutt, NC | 2 |
| Price, TJ | 2 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 2 |
| Gebski, V | 1 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Tozkir, H | 1 |
| Albayrak, D | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Ozdemir, O | 1 |
| Demir, D | 1 |
| Akdeniz, H | 1 |
| Kurt, M | 1 |
| Dai, Y | 1 |
| Cao, P | 1 |
| Luo, Z | 1 |
| Sun, J | 1 |
| Kiflu, A | 1 |
| Sai, B | 1 |
| Wang, F | 2 |
| Li, G | 1 |
| Xiang, J | 1 |
| Stein, SM | 1 |
| James, ES | 1 |
| Cong, X | 1 |
| Kortmansky, JS | 1 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 1 |
| Salem, RR | 1 |
| Chang, B | 1 |
| Hochster, HS | 1 |
| Lacy, J | 1 |
| Walter, T | 2 |
| Planchard, D | 1 |
| Bouledrak, K | 1 |
| Scoazec, JY | 2 |
| Souquet, PJ | 1 |
| Dussol, AS | 1 |
| Guigay, J | 1 |
| Hervieu, V | 2 |
| Berdelou, A | 1 |
| Ducreux, M | 4 |
| Arpin, D | 1 |
| Lombard-Bohas, C | 2 |
| Baudin, E | 2 |
| Komatsu, Y | 2 |
| Uchida, T | 2 |
| Abe, N | 2 |
| Ito, K | 4 |
| Matsuda, K | 3 |
| Fujinaga, A | 1 |
| Díez de Corcuera, I | 1 |
| Manzano, JL | 2 |
| Valladares-Ayerbes, M | 2 |
| Alcaide, J | 1 |
| García García, T | 1 |
| Vera, R | 1 |
| Yun, Q | 1 |
| Wang, SS | 1 |
| Yang, JP | 1 |
| Fan, J | 1 |
| Yang, LL | 1 |
| Fu, SZ | 1 |
| Wu, JB | 1 |
| Zhang, XF | 2 |
| Guo, ZQ | 1 |
| Zhao, CC | 1 |
| Xu, CY | 1 |
| Han, M | 1 |
| Li, C | 2 |
| Fattouh, K | 1 |
| Collet-Benzaquen, D | 1 |
| Provensal, AM | 1 |
| Desseigne, F | 1 |
| Castillo, C | 1 |
| Combemale, P | 1 |
| de la Fouchardière, A | 1 |
| Russo, A | 3 |
| Saide, A | 1 |
| Cagliani, R | 1 |
| Cantile, M | 1 |
| Botti, G | 1 |
| Russo, G | 1 |
| Kang, JH | 3 |
| Lee, SH | 2 |
| Hong, D | 1 |
| Son, J | 1 |
| Hong, KM | 1 |
| Song, J | 1 |
| Kim, SY | 1 |
| Xu, Q | 1 |
| Bertocchi, P | 1 |
| Aroldi, F | 1 |
| Prochilo, T | 1 |
| Meriggi, F | 1 |
| Beretta, GD | 2 |
| Zaniboni, A | 2 |
| Nozawa, H | 3 |
| Ishihara, S | 1 |
| Kawai, K | 2 |
| Hata, K | 2 |
| Kiyomatsu, T | 1 |
| Tanaka, T | 3 |
| Nishikawa, T | 2 |
| Yasuda, K | 4 |
| Sasaki, K | 4 |
| Murono, K | 1 |
| Nakajima, J | 1 |
| Watanabe, T | 3 |
| Seim, NB | 1 |
| Kang, SY | 1 |
| Bhandari, M | 1 |
| Jones, RG | 1 |
| Teknos, TN | 1 |
| Nazim, UM | 1 |
| Rasheduzzaman, M | 1 |
| Lee, YJ | 1 |
| Seol, DW | 1 |
| Park, SY | 1 |
| Yang, QL | 1 |
| Ling, Y | 1 |
| Becerra, CR | 1 |
| Verma, UN | 1 |
| Tran, HT | 1 |
| Tavana, D | 1 |
| Williams, NS | 1 |
| Frenkel, EP | 2 |
| Rachakatla, RS | 1 |
| Pyle, MM | 1 |
| Ayuzawa, R | 1 |
| Edwards, SM | 1 |
| Marini, FC | 1 |
| Weiss, ML | 1 |
| Tamura, M | 3 |
| Troyer, D | 1 |
| Leong, SS | 1 |
| Wee, J | 1 |
| Rajan, S | 1 |
| Toh, CK | 1 |
| Lim, WT | 1 |
| Hee, SW | 1 |
| Tay, MH | 1 |
| Poon, D | 1 |
| Tan, EH | 1 |
| Kubo, H | 2 |
| Kitahara, M | 1 |
| Kanekiyo, S | 1 |
| Tada, K | 2 |
| Katayama, S | 1 |
| Osako, T | 1 |
| Ushijima, M | 1 |
| Tokudome, N | 2 |
| Sugihara, T | 2 |
| Iwase, T | 2 |
| Matsuura, M | 2 |
| Hatake, K | 3 |
| Mitry, E | 4 |
| Fields, AL | 1 |
| Bleiberg, H | 1 |
| Labianca, R | 4 |
| Portier, G | 1 |
| Tu, D | 2 |
| Nitti, D | 1 |
| Torri, V | 1 |
| Elias, D | 3 |
| O'Callaghan, C | 1 |
| Langer, B | 1 |
| Martignoni, G | 1 |
| Bouché, O | 1 |
| Lazorthes, F | 1 |
| Van Cutsem, E | 1 |
| Bedenne, L | 1 |
| Moore, MJ | 1 |
| Rougier, P | 5 |
| Osaki, Y | 1 |
| Harshman, LC | 1 |
| Srinivas, S | 1 |
| Fornaro, L | 2 |
| Bursi, S | 1 |
| Vasile, E | 2 |
| Antonuzzo, A | 1 |
| Chiara, S | 1 |
| Pfanner, E | 1 |
| Di Paolo, A | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Bratta, M | 1 |
| Bisegna, R | 1 |
| Rea, S | 1 |
| Wang, ZH | 1 |
| Guo, J | 1 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Liu, B | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Chen, JX | 1 |
| Tang, Q | 1 |
| Zhu, HN | 1 |
| Zheng, YD | 1 |
| Hoshikawa, K | 1 |
| Aoki, K | 2 |
| Noda, H | 2 |
| Nitta, H | 1 |
| Wakabayashi, G | 1 |
| Plumridge, NM | 1 |
| Millward, MJ | 1 |
| Rischin, D | 1 |
| Macmanus, MP | 1 |
| Wirth, A | 1 |
| Yuen, K | 1 |
| Ball, DL | 2 |
| Arévalo Lobera, S | 1 |
| Sagastibeltza Mariñelarena, N | 1 |
| Elejoste Echeberría, I | 1 |
| Melé Olivé, M | 1 |
| Egaña Otaño, L | 1 |
| Basterretxea Badiola, L | 1 |
| La Casta Muñoa, A | 1 |
| Azkue Gabilondo, M | 1 |
| Ishihama, H | 1 |
| Chida, M | 1 |
| Araki, O | 1 |
| Karube, Y | 1 |
| Seki, N | 1 |
| Umezu, H | 2 |
| Honma, K | 1 |
| Masawa, N | 1 |
| Miyoshi, S | 3 |
| Ota, K | 3 |
| Kurita, S | 1 |
| Nishimura, M | 3 |
| Ogawa, M | 3 |
| Kamei, Y | 1 |
| Imai, K | 1 |
| Ariyoshi, Y | 1 |
| Kataoka, K | 2 |
| Murakami, M | 2 |
| Oyama, A | 1 |
| Hoshino, A | 1 |
| Amo, H | 1 |
| Kawahara, A | 1 |
| Akagi, Y | 2 |
| Hattori, S | 3 |
| Mizobe, T | 1 |
| Shirouzu, K | 3 |
| Ono, M | 1 |
| Yanagawa, T | 1 |
| Kuwano, M | 1 |
| Kage, M | 1 |
| Baki, M | 1 |
| Feng, FZ | 1 |
| Xiang, Y | 5 |
| Wan, XR | 3 |
| Yang, XY | 6 |
| Xavier, MH | 1 |
| Vergueiro, Tde R | 1 |
| Vilar, EG | 1 |
| Pinto, JM | 1 |
| Issa, MC | 1 |
| Pereira, GB | 1 |
| Carocha, AP | 1 |
| Yoshida, N | 1 |
| Kochi, M | 3 |
| Funada, T | 1 |
| Mamiya, T | 1 |
| Ohkubo, R | 1 |
| Kaiga, T | 1 |
| Takayama, T | 4 |
| Zhao, J | 1 |
| Aguilar, G | 1 |
| Palencia, S | 1 |
| Newton, E | 1 |
| Abo, A | 1 |
| Zhang, JD | 1 |
| Shao, ZY | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Bai, YX | 1 |
| Shen, L | 1 |
| Zhang, HG | 1 |
| Wan, DS | 2 |
| Chen, S | 1 |
| Jia, TZ | 1 |
| Jin, ML | 1 |
| Li, SF | 1 |
| He, LH | 1 |
| Shi, YH | 1 |
| Hao, CF | 1 |
| Dong, GL | 1 |
| Tong, ZS | 1 |
| Okabe, T | 2 |
| Okamoto, I | 3 |
| Tsukioka, S | 2 |
| Uchida, J | 2 |
| Hatashita, E | 2 |
| Nishio, K | 4 |
| Fukuoka, M | 5 |
| Jänne, PA | 1 |
| Nakagawa, K | 7 |
| Kim, SH | 3 |
| Kwon, HC | 1 |
| Oh, SY | 1 |
| Lee, DM | 1 |
| Lee, S | 1 |
| Lee, JH | 1 |
| Roh, MS | 1 |
| Kim, DC | 1 |
| Park, KJ | 1 |
| Choi, HJ | 1 |
| Kim, HJ | 3 |
| Novarino, A | 2 |
| Satolli, MA | 2 |
| Chiappino, I | 2 |
| Giacobino, A | 3 |
| Bellone, G | 2 |
| Rahimi, F | 1 |
| Milanesi, E | 1 |
| Bertetto, O | 2 |
| Ciuffreda, L | 3 |
| Chayahara, N | 1 |
| Tamura, T | 3 |
| Yamamori, M | 1 |
| Kadowaki, Y | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Tsuda, M | 1 |
| Nishisaki, H | 1 |
| Okumura, K | 1 |
| Azuma, T | 2 |
| Kasuga, M | 1 |
| Sakaeda, T | 1 |
| Hirai, M | 1 |
| Yata, Y | 1 |
| Nakayama, Y | 3 |
| Hirano, K | 1 |
| Tokimitsu, Y | 1 |
| Kudo, H | 1 |
| Yasumura, S | 1 |
| Takahara, T | 1 |
| Paydas, S | 1 |
| Bicakci, K | 1 |
| Yavuz, S | 1 |
| Pollina, L | 1 |
| Cupini, S | 1 |
| Ricci, S | 1 |
| Brunetti, IM | 1 |
| Ferraldeschi, R | 1 |
| Naso, G | 1 |
| Filipponi, F | 1 |
| Goletti, O | 1 |
| Baldi, G | 1 |
| Andreuccetti, M | 1 |
| Tsuchida, M | 1 |
| Yamato, Y | 1 |
| Hashimoto, T | 1 |
| Shinohara, H | 1 |
| Yoshiya, K | 1 |
| Hayashi, J | 2 |
| Martinez-Balibrea, E | 1 |
| Martínez-Cardús, A | 1 |
| Musulén, E | 1 |
| Ginés, A | 1 |
| Plasencia, C | 1 |
| Neamati, N | 1 |
| Abad, A | 2 |
| Daliani, DD | 1 |
| Tannir, NM | 1 |
| Papandreou, CN | 1 |
| Swisher, S | 1 |
| Wood, CG | 1 |
| Swanson, DA | 1 |
| Logothetis, CJ | 4 |
| Jonasch, E | 1 |
| Homma, S | 1 |
| Ishii, Y | 3 |
| Morishima, Y | 1 |
| Yamadori, T | 1 |
| Matsuno, Y | 1 |
| Kikuchi, N | 2 |
| Satoh, H | 3 |
| Hizawa, N | 1 |
| Itoh, K | 1 |
| Yamamoto, M | 2 |
| Vizio, B | 1 |
| Brondino, G | 1 |
| Addeo, A | 1 |
| Prati, A | 1 |
| Campra, D | 1 |
| Fronda, GR | 1 |
| Waters, SH | 1 |
| Gillibrand, A | 1 |
| Berry, H | 1 |
| Kumar, S | 1 |
| Velikova, G | 1 |
| Dodwell, DJ | 1 |
| Perren, TJ | 1 |
| Shi, D | 1 |
| Shi, G | 1 |
| Huang, G | 1 |
| Lartigau, E | 1 |
| Javle, M | 1 |
| Garrett, C | 1 |
| Pande, A | 1 |
| Kuvshinoff, B | 1 |
| Litwin, A | 1 |
| Phelan, J | 1 |
| Gibbs, J | 1 |
| Iyer, R | 1 |
| Feng, F | 4 |
| Wan, X | 1 |
| Yang, X | 2 |
| Valentini, V | 1 |
| Massaccesi, M | 1 |
| Balducci, M | 1 |
| Mantini, G | 1 |
| Micciché, F | 1 |
| Mattiucci, GC | 1 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Nagano, H | 4 |
| Yoshifuku, K | 1 |
| Kurono, Y | 1 |
| Mohan, P | 1 |
| Sukumar, R | 1 |
| Surendran, R | 1 |
| Sathyabhama, C | 1 |
| Jayanthi, V | 1 |
| Mendiola, C | 1 |
| Vaz, MA | 1 |
| Wang, CZ | 1 |
| Xie, JT | 1 |
| Aung, HH | 1 |
| Tong, R | 1 |
| McEntee, E | 1 |
| Yuan, CS | 1 |
| Schmidt, C | 1 |
| Pivot, XB | 1 |
| Li, RK | 1 |
| Thomas, ES | 1 |
| Fein, LE | 1 |
| Chan, VF | 1 |
| Jassem, J | 1 |
| de Mendoza, FH | 1 |
| Mukhopadyay, P | 1 |
| Roché, HH | 1 |
| Koide, T | 1 |
| Katayama, T | 1 |
| Matsuda, H | 2 |
| Yamagishi, Y | 2 |
| Okuda, M | 1 |
| Kataoka, Y | 1 |
| Milman, S | 1 |
| Kim, AW | 1 |
| Warren, WH | 1 |
| Liptay, MJ | 1 |
| Miller, C | 1 |
| Basu, S | 1 |
| Faber, LP | 8 |
| Ho, JC | 2 |
| Lam, DC | 1 |
| Wong, MK | 1 |
| Lam, B | 2 |
| Ip, MS | 1 |
| Lam, WK | 4 |
| Wang, FH | 3 |
| Zhang, DS | 2 |
| Wang, ZQ | 3 |
| Xu, RH | 3 |
| Jiang, WQ | 3 |
| He, YJ | 3 |
| An, X | 2 |
| Xiang, XJ | 2 |
| Power, DG | 1 |
| Kemeny, NE | 1 |
| Matsuo, K | 4 |
| Chi, DS | 1 |
| Eno, ML | 1 |
| Im, DD | 1 |
| Rosenshein, NB | 1 |
| Amari, M | 1 |
| Ishida, T | 3 |
| Takeda, M | 1 |
| Ohuchi, N | 1 |
| Takahashi, H | 2 |
| Arimura, Y | 1 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 1 |
| Shinomura, Y | 1 |
| Hosokawa, M | 2 |
| Kim, ST | 2 |
| Lee, J | 4 |
| Lee, KT | 1 |
| Lee, JK | 1 |
| Heo, JS | 1 |
| Choi, DW | 1 |
| Park, SH | 2 |
| Lim, HY | 2 |
| Kang, WK | 3 |
| Muto, Y | 1 |
| Endo, J | 1 |
| Asakage, M | 1 |
| Furukawa, Y | 1 |
| Arai, M | 1 |
| Uchida, N | 1 |
| Ishiguro, K | 2 |
| Suda, T | 2 |
| Tamura, J | 1 |
| Nakauchi, M | 1 |
| Kitaguchi, K | 1 |
| Sakikubo, M | 1 |
| Ura, K | 1 |
| Taira, K | 1 |
| Ohe, H | 1 |
| Yoshikawa, A | 1 |
| Ishigami, S | 2 |
| Baba, N | 1 |
| Dubey, PK | 1 |
| Singodia, D | 1 |
| Vyas, SP | 1 |
| Koshiishi, H | 1 |
| Park, S | 1 |
| Matsuyama, T | 3 |
| Goto, H | 2 |
| Kakimoto, Y | 1 |
| Sakamoto, K | 1 |
| Nishida, K | 1 |
| Okamura, T | 3 |
| Minami, T | 1 |
| Maruyama, M | 2 |
| Takahashi, E | 1 |
| Koshiishi, Y | 1 |
| Matsushita, D | 1 |
| Kitazono, M | 1 |
| Baba, K | 1 |
| Shinchi, H | 1 |
| Ueno, S | 1 |
| Ogawa, H | 1 |
| Natsugoe, S | 1 |
| Seo, YR | 1 |
| Kim, CK | 1 |
| Park, SK | 1 |
| Koh, ES | 1 |
| Hong, DS | 1 |
| Zhou, J | 1 |
| Zhang, WM | 1 |
| Chen, H | 1 |
| Xie, B | 1 |
| Zheng, JH | 1 |
| Xu, ZY | 1 |
| Lin, JR | 1 |
| Vrdoljak, E | 1 |
| Mise, BP | 1 |
| Lukić, B | 1 |
| Curić, Z | 1 |
| Bosković, L | 1 |
| Tica, I | 1 |
| Tokalov, SV | 1 |
| Abolmaali, ND | 1 |
| Ding, J | 1 |
| Sun, W | 1 |
| Wu, K | 1 |
| Ning, B | 1 |
| Gong, W | 1 |
| He, G | 1 |
| Huang, S | 1 |
| Ding, X | 1 |
| Yin, P | 1 |
| Liu, Q | 1 |
| Xie, W | 1 |
| Hongoh, S | 1 |
| Nomoto, T | 1 |
| Kawakami, M | 1 |
| Hanai, K | 1 |
| Inatsuchi, H | 1 |
| Terachi, T | 1 |
| Guo, JF | 1 |
| Zhang, B | 2 |
| Wu, F | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Peng, J | 1 |
| Zaanan, A | 1 |
| Costes, L | 1 |
| Gauthier, M | 1 |
| Malka, D | 2 |
| Locher, C | 1 |
| Tougeron, D | 1 |
| Gornet, JM | 1 |
| Sobhani, I | 1 |
| Moulin, V | 1 |
| Afchain, P | 1 |
| Bonnetain, F | 1 |
| Aparicio, T | 1 |
| Sogabe, S | 1 |
| Yuki, S | 1 |
| Takagi, T | 1 |
| Takano, H | 1 |
| Kawamoto, Y | 1 |
| Nakatsumi, H | 1 |
| Sasaki, T | 3 |
| Iwanaga, I | 1 |
| Uehata, Y | 1 |
| Asaka, M | 1 |
| Takada, M | 2 |
| Terunuma, H | 1 |
| Deng, X | 1 |
| Dewan, MZ | 1 |
| Saji, S | 2 |
| Kuroi, K | 1 |
| Yamamoto, N | 3 |
| Toi, M | 2 |
| Rousseau, F | 1 |
| Retornaz, F | 1 |
| Joly, F | 1 |
| Esterni, B | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Fargeot, P | 1 |
| Luporsi, E | 1 |
| Servent, V | 1 |
| Laguerre, B | 1 |
| Brain, E | 1 |
| Geneve, J | 1 |
| Taura, M | 1 |
| Fukuda, R | 1 |
| Suico, MA | 1 |
| Eguma, A | 1 |
| Koga, T | 2 |
| Shuto, T | 1 |
| Sato, T | 4 |
| Morino-Koga, S | 1 |
| Kai, H | 1 |
| Noro, R | 2 |
| Miyanaga, A | 1 |
| Minegishi, Y | 2 |
| Okano, T | 1 |
| Seike, M | 1 |
| Soeno, C | 1 |
| Yoshimura, A | 1 |
| Gemma, A | 2 |
| Tran, B | 1 |
| Morelli, MF | 2 |
| Santomaggio, A | 1 |
| De Galitiis, F | 2 |
| Tudini, M | 1 |
| Mancini, M | 2 |
| Pelliccione, M | 1 |
| Calista, F | 1 |
| Guglielmi, F | 1 |
| Martella, F | 1 |
| Lanfiuti Baldi, P | 1 |
| Porzio, G | 2 |
| Gebbia, N | 1 |
| Iacobelli, S | 2 |
| Marchetti, P | 2 |
| Yi, H | 2 |
| Cho, HJ | 2 |
| Cho, SM | 2 |
| Lee, DG | 1 |
| Abd El-Aty, AM | 1 |
| Yoon, SJ | 3 |
| Bae, GW | 1 |
| Nho, K | 1 |
| Kim, B | 1 |
| Lee, CH | 2 |
| Kim, JS | 3 |
| Bartlett, MG | 1 |
| Shin, HC | 2 |
| Ogata, S | 1 |
| Ozeki, Y | 1 |
| Nakanishi, K | 1 |
| Fujita, Y | 1 |
| Tanaka, F | 1 |
| Hasegawa, S | 2 |
| Mio, T | 1 |
| Wada, H | 5 |
| Hiroi, S | 1 |
| Tominaga, S | 1 |
| Aida, S | 1 |
| Takeuchi, K | 1 |
| Kawai, T | 1 |
| Kefeli, U | 1 |
| Ustaalioglu, BB | 1 |
| Kefeli, AU | 1 |
| Yildirim, ME | 1 |
| Chua, TC | 1 |
| Liauw, W | 1 |
| Koong, HN | 1 |
| Esquivel, J | 1 |
| Takezawa, K | 1 |
| Tanizaki, J | 1 |
| Kuwata, K | 1 |
| Yamaguchi, H | 1 |
| Honda, M | 1 |
| Miura, A | 2 |
| Izumi, Y | 1 |
| Ryotokuji, T | 1 |
| Monma, K | 1 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 1 |
| Tanaka, K | 4 |
| Toyokawa, A | 1 |
| Kanemitsu, K | 1 |
| Okuda, T | 1 |
| Iwasaki, T | 1 |
| Ryan, DP | 2 |
| Engelman, JA | 1 |
| Ferrone, CR | 1 |
| Sahani, DV | 1 |
| Lisovsky, M | 1 |
| Li, HM | 1 |
| Chen, XF | 1 |
| Xie, KC | 1 |
| Huang, Q | 2 |
| Wan, YW | 1 |
| Rathnagiriswaran, S | 1 |
| Castranova, V | 1 |
| Guo, NL | 1 |
| Son, JY | 1 |
| Shin, JW | 1 |
| Wang, JH | 1 |
| Park, HJ | 1 |
| Raghavendran, HR | 1 |
| Son, CG | 1 |
| Konings, IR | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 1 |
| de Bruijn, P | 1 |
| Ghobadi Moghaddam-Helmantel, IM | 1 |
| van Dam, LM | 1 |
| Wiemer, EA | 1 |
| Verweij, J | 1 |
| Loos, WJ | 1 |
| Mac Manus, MP | 1 |
| Ding, Z | 1 |
| Hogg, A | 1 |
| Herschtal, A | 1 |
| Binns, D | 1 |
| Hicks, RJ | 1 |
| Shoji, H | 1 |
| Kuroki, M | 2 |
| Hiramoto, K | 1 |
| Matsumura, Y | 1 |
| Kikuchi, Y | 2 |
| Mladkova, J | 1 |
| Sanda, M | 1 |
| Matouskova, E | 1 |
| Selicharova, I | 1 |
| Hill, A | 1 |
| Bergin, P | 1 |
| Hanning, F | 1 |
| Thompson, P | 1 |
| Findlay, M | 1 |
| Damianovich, D | 1 |
| McKeage, MJ | 1 |
| Jung, A | 1 |
| Jaitner, S | 1 |
| Schäffauer, AJ | 1 |
| Kirchner, T | 1 |
| Grimminger, PP | 1 |
| Schneider, PM | 1 |
| Metzger, R | 2 |
| Vallböhmer, D | 1 |
| Hölscher, AH | 1 |
| Danenberg, PV | 2 |
| Brabender, J | 1 |
| Kume, S | 1 |
| Kubota, T | 3 |
| Hirata, T | 1 |
| Torigoe, Y | 1 |
| Ikeda, O | 1 |
| Goto, Y | 1 |
| Spigel, DR | 1 |
| Greco, FA | 2 |
| Waterhouse, D | 1 |
| Shipley, D | 1 |
| Lane, CM | 1 |
| Vazquez, ER | 1 |
| Clark, BL | 1 |
| Infante, JR | 1 |
| Bendell, JC | 2 |
| Burris, HA | 1 |
| Hainsworth, JD | 2 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 1 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Bruneton, D | 1 |
| Pilleul, F | 1 |
| Chayvialle, JA | 1 |
| Cui, Y | 1 |
| Wu, Q | 1 |
| Kong, D | 1 |
| Song, T | 1 |
| Ru, T | 1 |
| Chen, P | 2 |
| Kalantarian, P | 1 |
| Najafabadi, AR | 1 |
| Haririan, I | 1 |
| Vatanara, A | 1 |
| Yamini, Y | 1 |
| Darabi, M | 1 |
| Gilani, K | 1 |
| Honda, S | 1 |
| Hidaka, S | 1 |
| Nakamura, Y | 2 |
| Xia, LP | 1 |
| Wu, PH | 1 |
| Xia, JC | 1 |
| Guan, ZZ | 1 |
| Guo, GF | 1 |
| Zeng, YX | 1 |
| Mori, Y | 1 |
| Nishimura, T | 2 |
| Kitano, T | 1 |
| Yoshimura, K | 2 |
| Kanai, M | 1 |
| Hazama, M | 1 |
| Ishiguro, H | 1 |
| Nagayama, S | 2 |
| Yanagihara, K | 1 |
| Teramukai, S | 1 |
| Chiba, T | 1 |
| Sakai, Y | 1 |
| Fukushima, M | 13 |
| Ando, M | 4 |
| Nagahama, T | 4 |
| Fukuda, A | 3 |
| Ami, K | 3 |
| Hataji, K | 1 |
| Ganno, H | 3 |
| Kawasaki, N | 1 |
| Arai, K | 3 |
| Tei, S | 2 |
| Osawa, G | 1 |
| Otani, T | 1 |
| Yano, Y | 1 |
| Itagaki, H | 1 |
| Matsumoto, A | 3 |
| Fujimoto, T | 1 |
| Umehara, A | 1 |
| Kikuchi, A | 2 |
| Ishikawa, T | 4 |
| Uetake, H | 4 |
| Tanaka, S | 4 |
| Arii, S | 2 |
| Sugihara, K | 4 |
| Fukuda, S | 1 |
| Kano, S | 1 |
| Shingai, T | 1 |
| Motoori, M | 2 |
| Kishi, K | 1 |
| Miyashiro, I | 1 |
| Gotoh, K | 1 |
| Yamada, T | 4 |
| Ohigashi, H | 1 |
| Ishikawa, O | 1 |
| Fridlyand, J | 1 |
| Kaiser, LD | 1 |
| Fyfe, G | 1 |
| Freyer, G | 1 |
| Duret, A | 1 |
| Milano, G | 3 |
| Chatelut, E | 1 |
| Rebischung, C | 1 |
| Delord, JP | 1 |
| Merrouche, Y | 1 |
| Lledo, G | 1 |
| Etienne, MC | 1 |
| Falandry, C | 1 |
| Wang, LP | 1 |
| Zhang, QL | 1 |
| Jia, Z | 1 |
| Hu, XC | 1 |
| Wang, BY | 1 |
| Choi, YJ | 1 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Sobočanec, S | 1 |
| Balog, T | 1 |
| Šariċ, A | 1 |
| Mačak-Šafranko, Ž | 1 |
| Štroser, M | 1 |
| Žarković, K | 1 |
| Žarković, N | 1 |
| Stojković, R | 1 |
| Ivanković, S | 1 |
| Marotti, T | 1 |
| Nakagawa, M | 2 |
| Hamada, A | 1 |
| Yoshihara, Y | 1 |
| Ishizaka, T | 1 |
| Takahashi, N | 2 |
| Sawada, R | 1 |
| Mukai, J | 1 |
| Iwamoto, H | 1 |
| Torimura, T | 1 |
| Hashimoto, O | 1 |
| Inoue, K | 3 |
| Kurogi, J | 1 |
| Niizeki, T | 1 |
| Kuwahara, R | 1 |
| Abe, M | 1 |
| Koga, H | 1 |
| Yano, H | 1 |
| Kerbel, RS | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Shien, K | 1 |
| Yamashita, M | 1 |
| Okazaki, M | 1 |
| Suehisa, H | 2 |
| Sawada, S | 1 |
| Colucci, G | 1 |
| Giuliani, F | 1 |
| Garufi, C | 2 |
| Mattioli, R | 1 |
| Manzione, L | 2 |
| Lopez, M | 1 |
| Parrella, P | 1 |
| Tommasi, S | 1 |
| Copetti, M | 1 |
| Daniele, B | 1 |
| Pisconti, S | 1 |
| Tuveri, G | 1 |
| Silvestris, N | 1 |
| Maiello, E | 1 |
| Ferreira, A | 1 |
| Vieira, C | 1 |
| Rodrigues, A | 1 |
| Pereira, D | 1 |
| Rodrigues, H | 1 |
| Dávila, C | 1 |
| Bento, S | 1 |
| Xie, T | 1 |
| Li, DR | 1 |
| Mao, NQ | 1 |
| Liu, DS | 1 |
| Zuo, CT | 1 |
| Zhang, W | 3 |
| Huang, DM | 1 |
| Delpeuch, A | 1 |
| Leveque, D | 1 |
| Rob, L | 1 |
| Bergerat, JP | 1 |
| Rebersek, M | 1 |
| Boc, M | 1 |
| Rouquette, I | 1 |
| Mazieres, J | 1 |
| Zhang, D | 1 |
| Ochi, N | 1 |
| Tanimoto, Y | 1 |
| Ichihara, E | 1 |
| Chen, SZ | 2 |
| Chen, XM | 1 |
| Ding, Y | 1 |
| Wang, XC | 1 |
| Zhang, F | 1 |
| Mo, KL | 1 |
| Afonso, S | 2 |
| Viani, G | 1 |
| Afonso, V | 1 |
| Stefano, E | 1 |
| de Melo, JV | 1 |
| Vieira de Melo, MS | 1 |
| Abad, MH | 1 |
| Yi, BR | 2 |
| O, SN | 1 |
| Kang, NH | 1 |
| Hwang, KA | 1 |
| Kim, SU | 2 |
| Jeung, EB | 1 |
| Kim, YB | 2 |
| Heo, GJ | 1 |
| Choi, KC | 2 |
| Yamasaki, M | 1 |
| Miyata, H | 1 |
| Shiraishi, O | 1 |
| Peng, YF | 1 |
| Yasuda, T | 1 |
| Shiozaki, H | 1 |
| Polysalov, VN | 1 |
| Rutkin, IO | 1 |
| Krotova, OA | 1 |
| Tlostanova, MS | 1 |
| Suzuki, C | 2 |
| Blomqvist, L | 1 |
| Sundin, A | 1 |
| Jacobsson, H | 1 |
| Byström, P | 1 |
| Berglund, Å | 1 |
| Nygren, P | 1 |
| Glimelius, B | 1 |
| Rai, K | 1 |
| Tsushima, M | 1 |
| Kudo, K | 1 |
| Mizuta, M | 1 |
| Yonei, T | 2 |
| Yamadori, I | 1 |
| Nitzkorski, JR | 1 |
| Farma, JM | 1 |
| Watson, JC | 1 |
| Siripurapu, V | 1 |
| Matteotti, RS | 1 |
| Sigurdson, ER | 2 |
| Kaira, K | 1 |
| Okumura, T | 1 |
| Ohde, Y | 1 |
| Takahashi, T | 1 |
| Murakami, H | 1 |
| Kondo, H | 2 |
| Nakajima, T | 2 |
| Tsuboi, K | 1 |
| Kawase, Y | 1 |
| Okochi, O | 1 |
| Hattori, M | 1 |
| Takami, Y | 1 |
| Takeda, S | 2 |
| Mizuno, A | 1 |
| Uno, Y | 1 |
| Sasada, Y | 1 |
| Takamura, S | 2 |
| Kozaki, K | 1 |
| Muratore, A | 1 |
| Zimmitti, G | 1 |
| Ribero, D | 1 |
| Mellano, A | 1 |
| Viganò, L | 1 |
| Capussotti, L | 1 |
| Chen, LC | 1 |
| Wu, YH | 1 |
| Liu, IH | 1 |
| Ho, CL | 1 |
| Lee, WC | 1 |
| Chang, CH | 1 |
| Lan, KL | 1 |
| Ting, G | 1 |
| Lee, TW | 1 |
| Shien, JH | 1 |
| Huang, MY | 1 |
| Chen, MJ | 1 |
| Tsai, HL | 1 |
| Kuo, CH | 1 |
| Ma, CJ | 1 |
| Hou, MF | 1 |
| Chuang, SC | 1 |
| Lin, SR | 1 |
| Zannino, D | 1 |
| Wilson, K | 1 |
| Simes, RJ | 1 |
| Cassidy, J | 1 |
| Van Hazel, GA | 1 |
| Robinson, BA | 1 |
| Broad, A | 1 |
| Ackland, SP | 1 |
| Chang, YR | 1 |
| Han, DS | 1 |
| Kong, SH | 1 |
| Lee, HJ | 2 |
| Kim, WH | 1 |
| Yang, HK | 1 |
| Tani, S | 1 |
| Murata, S | 1 |
| Fukunaga, K | 1 |
| Morita, M | 2 |
| Hirata, Y | 2 |
| Iida, H | 3 |
| Kakuno, A | 1 |
| Nishigami, T | 1 |
| Yamanaka, N | 2 |
| Donzelli, S | 1 |
| Fontemaggi, G | 1 |
| Fazi, F | 1 |
| Di Agostino, S | 1 |
| Padula, F | 1 |
| Biagioni, F | 1 |
| Muti, P | 1 |
| Strano, S | 1 |
| Blandino, G | 1 |
| Shintani, Y | 2 |
| Funakoshi, Y | 1 |
| Matsumura, A | 2 |
| Ohta, M | 3 |
| Okumura, M | 1 |
| Kobayashi, H | 7 |
| Higuchi, T | 2 |
| Enomoto, M | 1 |
| Iida, S | 3 |
| Ishiguro, M | 3 |
| Kato, S | 3 |
| Ono, H | 1 |
| Yamauchi, S | 2 |
| Masuda, D | 1 |
| Nakamura, M | 6 |
| Watayo, Y | 1 |
| Amagasa, H | 2 |
| Markova, B | 1 |
| Hähnel, PS | 1 |
| Kasper, S | 1 |
| Herbertz, S | 1 |
| Schuler, M | 1 |
| Breitenbuecher, F | 1 |
| Shang, BY | 1 |
| Shang, Y | 1 |
| Zhen, YS | 2 |
| Gaya, A | 1 |
| Tse, V | 1 |
| Hirano, G | 1 |
| Sakurai, K | 1 |
| Sohda, T | 2 |
| Kunimoto, H | 1 |
| Yotsumoto, K | 1 |
| Fukunaga, A | 1 |
| Iwashita, H | 1 |
| Yokoyama, K | 1 |
| Morihara, D | 1 |
| Takeyama, Y | 1 |
| Sakamoto, M | 1 |
| Irie, M | 1 |
| Iwata, K | 1 |
| Shakado, S | 1 |
| Sakisaka, S | 1 |
| Benavides, M | 1 |
| Pericay, C | 1 |
| Gil-Calle, S | 2 |
| Massutí, B | 1 |
| Aparicio, J | 1 |
| Dueñas, R | 1 |
| González-Flores, E | 1 |
| Carrato, A | 2 |
| Gómez, A | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Cho, MH | 1 |
| Yi, JH | 1 |
| Yim, DS | 1 |
| Jo, K | 1 |
| Park, JA | 1 |
| Kim, NH | 1 |
| Amidon, GL | 1 |
| Treska, V | 1 |
| Safranek, J | 1 |
| Lysak, D | 1 |
| Mirka, H | 1 |
| Skalicky, T | 1 |
| Slauf, F | 1 |
| Hes, O | 1 |
| Michaelson, JS | 1 |
| Kelly, R | 1 |
| Wortham, K | 1 |
| Joseph, IB | 2 |
| Yamazaki, H | 1 |
| Aoki, T | 3 |
| Kaneko, A | 1 |
| Nishiyama, M | 1 |
| Miyahara, M | 1 |
| Yamashita, Y | 1 |
| Hoshino, H | 1 |
| Endo, T | 1 |
| Ochiai, H | 2 |
| Hoshino, Y | 2 |
| Matsunaga, A | 1 |
| Shigeta, K | 1 |
| Seo, Y | 1 |
| Hoshino, G | 1 |
| Hohenforst-Schmidt, W | 1 |
| Goldberg, EP | 1 |
| Galaktidou, G | 1 |
| Kontakiotis, T | 1 |
| Karamanos, N | 1 |
| Iitaka, D | 1 |
| Shiozaki, A | 1 |
| Fujiwara, H | 1 |
| Ichikawa, D | 1 |
| Komatsu, S | 1 |
| Murayama, Y | 1 |
| Ikoma, H | 1 |
| Kuriu, Y | 1 |
| Nakanishi, M | 1 |
| Ochiai, T | 2 |
| Kokuba, Y | 1 |
| Sonoyama, T | 1 |
| Otsuji, E | 1 |
| Novarino, AM | 1 |
| Napoletano, R | 1 |
| Ceccarelli, M | 1 |
| Ciccone, G | 1 |
| Schena, M | 1 |
| Han, JY | 8 |
| Nam, BH | 1 |
| Kim, HY | 6 |
| Kim, HT | 2 |
| Yan, S | 1 |
| Jiang, X | 1 |
| Yang, J | 1 |
| Wang, YX | 1 |
| Ayez, N | 1 |
| Alberda, WJ | 1 |
| Burger, JW | 1 |
| Eggermont, AM | 1 |
| Willemssen, FE | 1 |
| Verhoef, C | 1 |
| Shiroyama, T | 1 |
| Kijima, T | 1 |
| Komuta, K | 2 |
| Yamamoto, S | 3 |
| Minami, S | 1 |
| Ogata, Y | 2 |
| Okafuji, K | 1 |
| Imamura, F | 1 |
| Hirashima, T | 1 |
| Tachibana, I | 1 |
| Kawase, I | 1 |
| Kumanogoh, A | 1 |
| Uguen, T | 1 |
| Leconte, B | 1 |
| Desgrippes, R | 1 |
| Tchoundeu, B | 1 |
| Bretagne, JF | 1 |
| Manfredi, S | 1 |
| Tenti, S | 1 |
| Correale, P | 1 |
| Conca, R | 1 |
| Pastina, P | 1 |
| Fioravanti, A | 1 |
| Bertino, EM | 1 |
| Bekaii-Saab, T | 1 |
| Fernandez, S | 1 |
| Diasio, RB | 2 |
| Karim, NA | 1 |
| Otterson, GA | 2 |
| Villalona-Calero, MA | 2 |
| Inal, A | 1 |
| Kaplan, MA | 1 |
| Kuçukoner, M | 1 |
| Urakci, Z | 1 |
| Guven, M | 1 |
| Nas, N | 1 |
| Yunce, M | 1 |
| Işikdogan, A | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Jin, Y | 1 |
| Ye, X | 1 |
| Shao, L | 1 |
| Lin, BC | 1 |
| He, CX | 1 |
| Zhang, BB | 1 |
| Ohta, K | 1 |
| Matsui, S | 1 |
| Murao, S | 1 |
| Seki, R | 1 |
| Takasaki, J | 1 |
| Kamikozuru, H | 1 |
| Kodaka, F | 1 |
| Okazaki, S | 1 |
| Suzuki, N | 1 |
| Tominaga, K | 1 |
| Hoshino, M | 2 |
| Naruse, H | 1 |
| Shi, MM | 1 |
| Xiong, YL | 1 |
| Jia, XS | 1 |
| Wang, EH | 1 |
| Kumamoto, K | 1 |
| Ishibashi, K | 1 |
| Hatano, S | 3 |
| Matsuzawa, T | 1 |
| Okada, N | 2 |
| Kumagai, Y | 1 |
| Baba, H | 4 |
| Haga, N | 1 |
| Sugimura, T | 1 |
| Sharma, S | 1 |
| Kemeny, N | 3 |
| Kelsen, DP | 1 |
| Ilson, D | 1 |
| O'Reilly, E | 1 |
| Zaknoen, S | 1 |
| Baum, C | 1 |
| Statkevich, P | 1 |
| Hollywood, E | 1 |
| Zhu, Y | 1 |
| Boige, V | 2 |
| Artru, P | 3 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 1 |
| Vaillant, JN | 1 |
| Algar Algar, FJ | 1 |
| Alvarez Kindelán, A | 1 |
| Fuentes Vaamonde, E | 1 |
| Salvatierra Velázquez, A | 1 |
| Baamonde Laborda, C | 1 |
| López Pujol, FJ | 1 |
| Osterlund, P | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Ishio, T | 1 |
| Kohnoe, S | 3 |
| Endo, K | 1 |
| Ikeda, Y | 2 |
| Toh, Y | 1 |
| Kawamoto, K | 1 |
| Koyama, M | 1 |
| Inaba, Y | 2 |
| Watabe, S | 1 |
| Hayashi, K | 3 |
| Ohe, S | 1 |
| Chiba, M | 1 |
| Goel, S | 1 |
| Jhawer, M | 1 |
| Rajdev, L | 1 |
| Hopkins, U | 1 |
| Fehn, K | 1 |
| Baker, C | 1 |
| Chun, HG | 1 |
| Makower, D | 1 |
| Landau, L | 1 |
| Hoffman, A | 1 |
| Wadler, S | 1 |
| Mani, S | 1 |
| Brickelmaier, M | 1 |
| Carmillo, A | 1 |
| Goelz, S | 1 |
| Barsoum, J | 1 |
| Qin, XQ | 1 |
| Ojima, E | 1 |
| Miki, C | 1 |
| Hatada, T | 1 |
| Mohri, T | 1 |
| Kusunoki, M | 1 |
| Heidemann, E | 1 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 2 |
| Yamada, H | 1 |
| Ichikawa, W | 2 |
| Shirota, Y | 1 |
| Nihei, Z | 1 |
| Hirayama, R | 1 |
| Marsh, JC | 1 |
| Catalano, P | 1 |
| Huang, J | 2 |
| Graham, DL | 1 |
| Cornfeld, MJ | 2 |
| Benson, AB | 3 |
| Sadahiro, S | 3 |
| Ishikawa, K | 2 |
| Maeda, Y | 5 |
| Saguchi, T | 1 |
| Yasuda, S | 2 |
| Makuuchi, H | 4 |
| Murayama, C | 2 |
| Yamamoto, T | 3 |
| Fuwa, N | 3 |
| Kodaira, T | 1 |
| Kamata, M | 1 |
| Furutani, K | 1 |
| Tachibana, H | 1 |
| Goseki, N | 1 |
| Takamatsu, S | 1 |
| Nosaka, T | 1 |
| Teramoto, K | 1 |
| Kumagai, J | 1 |
| Nakajima, N | 2 |
| Hata, Y | 2 |
| Matsuoka, S | 1 |
| Itoh, T | 2 |
| Osada, T | 1 |
| Sano, F | 1 |
| Schüll, B | 2 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Depisch, D | 2 |
| Schneeweiss, B | 1 |
| Lang, F | 2 |
| Kornek, GV | 3 |
| Yano, T | 3 |
| Ninomiya, S | 1 |
| Takeo, S | 1 |
| Schneider, T | 2 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Cai, GR | 1 |
| Li, PW | 1 |
| Jiao, LP | 1 |
| Yu, RC | 3 |
| Rao, XQ | 2 |
| Tang, WJ | 1 |
| Duan, P | 1 |
| Wang, ZM | 1 |
| Fukuyama, Y | 1 |
| Ichinose, Y | 1 |
| Sawada, M | 1 |
| Ono, Y | 1 |
| Hattori, K | 1 |
| Kohchi, Y | 1 |
| Oikawa, N | 1 |
| Suda, H | 1 |
| Ura, M | 1 |
| Miwa, M | 3 |
| Endoh, M | 1 |
| Eda, H | 2 |
| Tanimura, H | 1 |
| Kawashima, A | 1 |
| Horii, I | 1 |
| Ishitsuka, H | 2 |
| Shimma, N | 1 |
| de Bruin, M | 2 |
| van Capel, T | 1 |
| Van der Born, K | 1 |
| Kruyt, FA | 1 |
| Hoekman, K | 1 |
| Pinedo, HM | 3 |
| Peters, GJ | 4 |
| Magnin, V | 1 |
| Moutardier, V | 1 |
| Giovannini, MH | 1 |
| Lelong, B | 1 |
| Giovannini, M | 1 |
| Viret, F | 1 |
| Monges, G | 1 |
| Bardou, VJ | 1 |
| Alzieu, C | 1 |
| Delpero, JR | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Rudi, J | 1 |
| Sagawa, T | 3 |
| Tsuji, Y | 2 |
| Takayanagi, N | 1 |
| Hirayama, Y | 1 |
| Sakamaki, S | 1 |
| Chiba, H | 2 |
| Iyama, S | 2 |
| Oku, T | 1 |
| Niitsu, Y | 2 |
| Burmeister, BH | 2 |
| Schache, D | 1 |
| Burmeister, EA | 1 |
| Bell, A | 1 |
| Poulsen, MG | 1 |
| Walpole, ET | 1 |
| Mackintosh, J | 2 |
| Fusai, G | 1 |
| Davidson, BR | 1 |
| Grundmann, JU | 1 |
| Weisshaar, E | 1 |
| Franke, I | 1 |
| Bonnekoh, B | 1 |
| Gollnick, H | 1 |
| Mabro, M | 3 |
| Louvet, C | 3 |
| André, T | 3 |
| Carola, E | 2 |
| Gilles-Amar, V | 1 |
| Krulik, M | 2 |
| de Gramont, A | 3 |
| Li, PP | 1 |
| Chen, YZ | 1 |
| Jiao, SC | 1 |
| Lu, SX | 1 |
| Kawabata, H | 3 |
| Takase, I | 1 |
| Murata, A | 1 |
| Nakajima, H | 1 |
| Focan, C | 3 |
| Kreutz, F | 3 |
| Moeneclaye, N | 1 |
| Focan-Henrard, D | 3 |
| Motoyama, H | 1 |
| Funakoshi, K | 1 |
| Akiyama, N | 1 |
| Inayoshi, J | 1 |
| Kozakai, I | 1 |
| Arai, F | 1 |
| Takii, Y | 1 |
| Saito, Y | 2 |
| Yoshizawa, H | 1 |
| Tanaka, J | 1 |
| Kagamu, H | 1 |
| Maruyama, Y | 1 |
| Miyao, H | 1 |
| Iwashima, A | 1 |
| Suzuki, E | 1 |
| Gejyo, F | 1 |
| FOYE, LV | 2 |
| WILLETT, FM | 2 |
| HALL, B | 1 |
| ROTH, M | 2 |
| HALL, BE | 1 |
| HELSPER, JT | 1 |
| SHARP, GS | 1 |
| ANSFIELD, FJ | 2 |
| CURRERI, AR | 2 |
| LANGDON, EA | 1 |
| OTTOMAN, RE | 1 |
| ROCHLIN, DB | 1 |
| SMART, CR | 1 |
| KENIS, Y | 2 |
| KARNOFSKY, DA | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| SULLIVAN, RD | 1 |
| ZUREK, WZ | 1 |
| HOLSTI, LR | 2 |
| BRULE, G | 1 |
| SCHLUMBERGER, JR | 1 |
| GRISCELLI, C | 1 |
| WILSON, WL | 2 |
| DELAGARZA, JG | 1 |
| BLOKHINA, NG | 1 |
| BYCHKOV, MB | 3 |
| STARICHKOV, MS | 5 |
| Nabeshima, S | 1 |
| Kishihara, Y | 1 |
| Nabeshima, A | 1 |
| Yamaga, S | 1 |
| Kinjo, M | 1 |
| Kashiwagi, S | 1 |
| Tajima, T | 2 |
| Akazawa, S | 2 |
| Yamashina, T | 1 |
| Murakami, T | 2 |
| Nakazima, T | 1 |
| Sakurai, T | 4 |
| Matsui, T | 1 |
| Kotake, K | 1 |
| Koyama, Y | 3 |
| Lee, DH | 6 |
| Hong, EK | 3 |
| Yoon, SM | 4 |
| Chun, JH | 2 |
| Lee, HG | 4 |
| Lee, SY | 4 |
| Shin, EH | 2 |
| Nakayama, K | 1 |
| Itou, T | 1 |
| Celikoğlu, F | 1 |
| Celikoğlu, SI | 1 |
| Hasegawa, K | 2 |
| Takashima, I | 1 |
| Shinoura, H | 1 |
| Kato, K | 1 |
| Ebuchi, M | 1 |
| Lou, E | 1 |
| Kellman, RM | 1 |
| Hutchison, R | 1 |
| Shillitoe, EJ | 1 |
| Jiang, K | 1 |
| Delarue, FL | 1 |
| Sebti, SM | 1 |
| Galetta, D | 1 |
| Cesario, A | 1 |
| Margaritora, S | 1 |
| Porziella, V | 1 |
| Macis, G | 1 |
| D'Angelillo, RM | 1 |
| Trodella, L | 1 |
| Sterzi, S | 1 |
| Granone, P | 1 |
| Antón, A | 1 |
| Massutti, B | 1 |
| Cervantes, A | 1 |
| Fenández-Martos, C | 1 |
| Gallén, M | 1 |
| Huarte, L | 1 |
| Balcells, M | 1 |
| Kim, EA | 1 |
| Lee, JJ | 4 |
| Ju, SY | 1 |
| Kitai, T | 1 |
| Nomura, A | 1 |
| Miki, A | 1 |
| Ukikusa, M | 1 |
| Kojima, N | 1 |
| Nishikawa, S | 1 |
| Ishigaki, T | 1 |
| Todo, G | 1 |
| Jenkins, DE | 1 |
| Oei, Y | 1 |
| Hornig, YS | 1 |
| Yu, SF | 1 |
| Dusich, J | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Watanabe, A | 3 |
| Taniguchi, M | 1 |
| Fukuda, Y | 1 |
| Fujio, N | 1 |
| Takatori, H | 1 |
| Tsukazaki, T | 1 |
| Terakura, M | 1 |
| Mayumi, K | 1 |
| Koyama, I | 1 |
| Tsukazaki, Y | 1 |
| Osugi, H | 1 |
| Schuell, B | 1 |
| Laengle, F | 1 |
| Gruenberger, T | 1 |
| Penz, M | 1 |
| Karall, K | 1 |
| Südhoff, T | 1 |
| Enderle, MD | 1 |
| Pahlke, M | 1 |
| Petz, C | 1 |
| Teschendorf, C | 1 |
| Graeven, U | 1 |
| Schmiegel, W | 1 |
| Kasakura, Y | 1 |
| Fujii, M | 4 |
| Sato, K | 3 |
| Kobayashi, M | 4 |
| Wattenberg, LW | 2 |
| Wiedmann, TS | 2 |
| Estensen, RD | 1 |
| Kondo, Y | 1 |
| Terashima, M | 3 |
| Sato, A | 1 |
| Taguchi, T | 7 |
| Wei, J | 1 |
| Blum, S | 1 |
| Unger, M | 1 |
| Jarmy, G | 1 |
| Lamparter, M | 1 |
| Geishauser, A | 1 |
| Vlastos, GA | 1 |
| Chan, G | 1 |
| Fischer, KD | 1 |
| Rattat, D | 1 |
| Debatin, KM | 1 |
| Hatzopoulos, AK | 1 |
| Beltinger, C | 1 |
| Oechsle, K | 1 |
| Reis, HE | 1 |
| Haag, C | 1 |
| Niederle, N | 1 |
| Wilke, HJ | 1 |
| Pflüger, KH | 1 |
| Batran, SA | 1 |
| Büchele, T | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Matsukura, S | 1 |
| Samejima, R | 1 |
| Tanaka, M | 2 |
| Hidaka, K | 1 |
| Yamagishi, H | 1 |
| Yamashita, T | 1 |
| Itoh, N | 1 |
| Itoi, H | 1 |
| Shirasaka, T | 6 |
| Hirabayashi, H | 1 |
| Tanaka, H | 2 |
| Iuchi, K | 1 |
| Kido, T | 1 |
| Kershaw, MH | 1 |
| Jackson, JT | 1 |
| Haynes, NM | 1 |
| Teng, MW | 1 |
| Moeller, M | 1 |
| Hayakawa, Y | 1 |
| Street, SE | 1 |
| Cameron, R | 1 |
| Tanner, JE | 1 |
| Trapani, JA | 1 |
| Smyth, MJ | 1 |
| Darcy, PK | 1 |
| Terada, I | 1 |
| Yoshizumi, T | 1 |
| Takino, T | 2 |
| Nagai, N | 1 |
| Morita, A | 1 |
| Nishimura, G | 3 |
| Fujimura, T | 2 |
| Miwa, K | 2 |
| Jiang, ZF | 1 |
| Song, ST | 1 |
| Yu, JX | 1 |
| Hong, YS | 1 |
| Song, SY | 2 |
| Lee, SI | 1 |
| Noh, SH | 1 |
| Park, JN | 1 |
| Lee, KS | 1 |
| Norman, AR | 2 |
| Waters, JS | 1 |
| Topham, C | 1 |
| Middleton, G | 1 |
| Hill, M | 1 |
| Ross, PJ | 2 |
| Katopodis, R | 1 |
| Stewart, G | 1 |
| Oates, JR | 1 |
| Guglielmi, A | 2 |
| Barni, S | 1 |
| Pella, N | 1 |
| Belvedere, O | 1 |
| Grossi, F | 2 |
| Frontini, L | 1 |
| Puglisi, F | 1 |
| Sobrero, A | 2 |
| Morio, A | 1 |
| Futagawa, T | 1 |
| Oh, T | 1 |
| Yamazaki, A | 1 |
| Konno, H | 1 |
| Hashimoto, K | 2 |
| Shigeoka, Y | 2 |
| Nakanishi, H | 2 |
| Hitsuda, Y | 1 |
| Goel, R | 1 |
| Chouinard, E | 1 |
| Stewart, DJ | 3 |
| Huan, S | 1 |
| Hirte, H | 1 |
| Stafford, S | 1 |
| Waterfield, B | 1 |
| Roach, J | 1 |
| Lathia, C | 1 |
| Agarwal, V | 1 |
| Humphrey, R | 1 |
| Walsh, W | 1 |
| Matthews, S | 1 |
| Seymour, L | 1 |
| Doi, K | 1 |
| Ohchi, T | 1 |
| Ogata, K | 1 |
| Ishimoto, T | 1 |
| Hashimoto, D | 1 |
| Muranaka, T | 1 |
| Kondo, M | 2 |
| Ota, H | 1 |
| Damdinsuren, B | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Nakamori, S | 1 |
| Monden, M | 1 |
| Dosik, M | 1 |
| Kaufman, R | 1 |
| Blumenthal, RD | 2 |
| Osorio, L | 1 |
| Hayes, MK | 1 |
| Horak, ID | 1 |
| Hansen, HJ | 1 |
| Goldenberg, DM | 2 |
| Presicci, PF | 1 |
| Veronesi, G | 1 |
| D'Aiuto, M | 1 |
| Spaggiari, L | 1 |
| Hitre, E | 1 |
| Delaunoit, T | 1 |
| Alberts, SR | 2 |
| Sargent, DJ | 1 |
| Green, E | 1 |
| Goldberg, RM | 1 |
| Krook, J | 1 |
| Fuchs, C | 3 |
| Ramanathan, RK | 1 |
| Williamson, SK | 1 |
| Morton, RF | 1 |
| Findlay, BP | 1 |
| Ishizu, K | 1 |
| Temmink, OH | 1 |
| Comijn, EM | 1 |
| Muneoka, K | 4 |
| Shirai, Y | 4 |
| Yokoyama, N | 5 |
| Wakai, T | 4 |
| Hatakeyama, K | 4 |
| Horino, K | 1 |
| Kimura, M | 1 |
| Arima, T | 1 |
| Kuhara, H | 1 |
| Uemura, K | 1 |
| Yamada, K | 2 |
| Takeyama, O | 1 |
| Usui, Y | 1 |
| Kindwall-Keller, T | 1 |
| Young, D | 2 |
| Neki, A | 1 |
| Criswell, T | 1 |
| Nuovo, G | 1 |
| Soong, R | 1 |
| Diasio, R | 1 |
| Seium, Y | 1 |
| Stupp, R | 1 |
| Ruhstaller, T | 1 |
| Gervaz, P | 1 |
| Mentha, G | 1 |
| Philippe, M | 1 |
| Allal, A | 1 |
| Trembleau, C | 1 |
| Bauer, J | 1 |
| Morant, R | 1 |
| Roth, AD | 1 |
| Yuan, JB | 1 |
| Liu, ZX | 1 |
| Ji, SH | 1 |
| Lim, DH | 1 |
| Park, BB | 1 |
| Park, KW | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Byrne, MJ | 1 |
| Phillips, M | 1 |
| Powell, A | 1 |
| Cameron, F | 1 |
| Joseph, D | 1 |
| Spry, N | 2 |
| Dewar, J | 1 |
| Van Hazel, G | 1 |
| Buck, M | 1 |
| Lund, H | 1 |
| De Melker, Y | 1 |
| Newman, M | 1 |
| Comella, P | 1 |
| Massidda, B | 1 |
| Palmeri, S | 1 |
| Farris, A | 2 |
| Lucia, LD | 1 |
| Natale, D | 1 |
| Maiorino, L | 1 |
| Tafuto, S | 1 |
| Cataldis, GD | 1 |
| Casaretti, R | 1 |
| Lin, RX | 1 |
| Tuo, CW | 1 |
| Lü, QJ | 1 |
| Wang, SQ | 1 |
| Yu, BM | 1 |
| Wu, WQ | 1 |
| Takechi, T | 1 |
| Okabe, H | 1 |
| Ikeda, K | 2 |
| Fujioka, A | 1 |
| Nakagawa, F | 1 |
| Ohshimo, H | 1 |
| Kitazato, K | 1 |
| Takao, M | 1 |
| Watanabe, F | 1 |
| Tarukawa, T | 1 |
| Shimamoto, A | 1 |
| Kaneda, M | 1 |
| Sakai, T | 1 |
| Shimpo, H | 1 |
| Yada, I | 1 |
| Okumura, S | 1 |
| Oguri, T | 2 |
| Achiwa, H | 2 |
| Bessho, Y | 2 |
| Muramatsu, H | 1 |
| Niimi, T | 1 |
| Ueda, R | 2 |
| Engstrom, PF | 2 |
| Chen, YJ | 1 |
| Choti, MA | 1 |
| Dilawari, RA | 1 |
| Enke, CA | 1 |
| Fakih, MG | 1 |
| Kiel, K | 1 |
| Knol, JA | 2 |
| Leong, LA | 1 |
| Ludwig, KA | 1 |
| Martin, EW | 1 |
| Rao, S | 1 |
| Saif, MW | 1 |
| Saltz, L | 1 |
| Skibber, JM | 1 |
| Yeatman, TJ | 1 |
| Chiba, N | 1 |
| Shibata, H | 1 |
| Sakayori, M | 1 |
| Otsuka, K | 1 |
| Kakudo, Y | 1 |
| Ohori, H | 1 |
| Yamaura, G | 1 |
| Ishioka, C | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Suzuki, M | 2 |
| Hanyu, F | 1 |
| Tanaka, R | 1 |
| Ueki, T | 1 |
| Mitsugi, K | 4 |
| Umeno, M | 1 |
| Nakano, S | 8 |
| Maciá-Escalante, S | 1 |
| Guillén-Ponce, C | 1 |
| Molina-Garrido, MJ | 1 |
| Carrato-Mena, A | 1 |
| Matsuoka, T | 1 |
| Morikage, N | 1 |
| Kobayashi, T | 2 |
| Kuga, T | 1 |
| Nakayama, T | 1 |
| Fujii, Y | 1 |
| Nishimoto, T | 1 |
| Kiriyama, K | 1 |
| Yabu, M | 1 |
| Himeno, S | 1 |
| Anami, Y | 1 |
| Oguma, S | 1 |
| Matsuda, Y | 2 |
| Yamaki, T | 2 |
| Sazawa, Y | 1 |
| Komiya, H | 1 |
| Izai, J | 1 |
| Ota, T | 1 |
| Park, CG | 1 |
| Paik, YH | 1 |
| Chang, YS | 2 |
| Lee, SJ | 1 |
| Lee, DK | 1 |
| Chung, JB | 1 |
| Park, MS | 1 |
| Yu, JS | 1 |
| Yoon, DS | 1 |
| Poh, SB | 1 |
| Bai, LY | 1 |
| Chen, PM | 4 |
| Honda, K | 2 |
| Sumiyoshi, T | 1 |
| Yoshizaki, N | 1 |
| Kuroiwa, G | 1 |
| Huang, SL | 1 |
| Wu, Y | 1 |
| Zhang, XQ | 1 |
| Ying, L | 1 |
| Zhao, HF | 1 |
| Kojima, H | 2 |
| Yamamura, Y | 1 |
| Tsujinaka, T | 1 |
| Hyodo, I | 2 |
| Koizumi, W | 1 |
| Lin, CC | 1 |
| Hsu, CH | 1 |
| Huang, CY | 1 |
| Vogelzang, NJ | 2 |
| Pu, YS | 1 |
| Saeki, T | 2 |
| Kimura, T | 1 |
| Mukai, M | 1 |
| Ninomiya, H | 1 |
| Wakui, K | 1 |
| Komatsu, N | 1 |
| Tsuchiya, K | 1 |
| Nakasaki, H | 1 |
| Yoshino, H | 1 |
| Kinoshita, S | 1 |
| Emori, N | 1 |
| Kadoya, S | 1 |
| Hiranuma, C | 1 |
| Koizumi, H | 1 |
| Morita, K | 2 |
| Bando, H | 1 |
| Murakami, N | 1 |
| Morese, R | 1 |
| Cianci, G | 1 |
| Di Rocco, ZC | 1 |
| De Tursi, M | 1 |
| Tinari, N | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Hitzman, CJ | 1 |
| Ducreux, MP | 1 |
| Leboulleux, S | 1 |
| Kergoat, P | 1 |
| Dromain, C | 1 |
| de Baere, T | 1 |
| Sabourin, JC | 1 |
| Duvillard, P | 1 |
| Lasser, P | 2 |
| Schlumberger, M | 2 |
| Cobo-Dols, M | 1 |
| Alés-Díaz, I | 1 |
| Villar-Chamorro, E | 1 |
| Alcaide-García, J | 1 |
| Montesa-Pino, A | 1 |
| Gutiérrez-Calderón, V | 1 |
| Benavides-Orgaz, M | 1 |
| Cho, CD | 1 |
| Fisher, GA | 1 |
| Halsey, J | 1 |
| Sikic, BI | 1 |
| Lauwers, GY | 1 |
| Willett, C | 1 |
| Clark, JW | 2 |
| Warshaw, AL | 1 |
| Wain, JC | 2 |
| Melloni, G | 1 |
| Doglioni, C | 1 |
| Bandiera, A | 1 |
| Carretta, A | 1 |
| Ciriaco, P | 1 |
| Arrigoni, G | 1 |
| Zannini, P | 1 |
| Taira, N | 1 |
| Aogi, K | 1 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Nishimura, R | 1 |
| Doihara, H | 1 |
| Khrichkova, TY | 1 |
| Gol'dberg, VE | 1 |
| Matyash, MG | 1 |
| Vysotskaya, VV | 1 |
| Matsuda, T | 1 |
| Ogino, K | 1 |
| Hiroyoshi, M | 1 |
| Fujita, H | 5 |
| Toyama, H | 1 |
| Kawai, Y | 1 |
| Makita, D | 1 |
| Tsunemi, K | 1 |
| Moritomo, H | 1 |
| Sakata, J | 1 |
| Yoon, S | 1 |
| Schmassmann-Suhijar, D | 1 |
| Zuber, M | 1 |
| Konietzny, P | 1 |
| Schmassmann, A | 1 |
| Lu, JI | 1 |
| Carhart, RL | 1 |
| Graziano, SL | 1 |
| Gajra, A | 1 |
| Shirao, K | 1 |
| Doi, T | 1 |
| Arai, Y | 1 |
| Takemiya, S | 1 |
| Takiuchi, H | 1 |
| Jiang, GM | 1 |
| Zhao, JW | 1 |
| Chen, YX | 1 |
| Tian, F | 1 |
| Alacacioglu, A | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Somali, I | 1 |
| Zhou, ZH | 1 |
| Liu, LM | 1 |
| Cheng, WW | 1 |
| Meng, ZQ | 1 |
| Lin, JH | 1 |
| Zhang, XJ | 1 |
| Jiang, GL | 1 |
| Feng, FY | 2 |
| Wu, LY | 1 |
| Hu, Y | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Nakano, J | 1 |
| Liu, D | 1 |
| Masuya, D | 1 |
| Nakashima, T | 1 |
| Yokomise, H | 3 |
| Ueno, M | 1 |
| Pierard, S | 1 |
| Gregoire, V | 1 |
| Weynand, B | 1 |
| Machiels, JP | 1 |
| Atzpodien, J | 2 |
| Kirchner, H | 1 |
| Rebmann, U | 1 |
| Soder, M | 1 |
| Gertenbach, U | 1 |
| Siebels, M | 1 |
| Roigas, J | 1 |
| Raschke, R | 1 |
| Salm, S | 1 |
| Schwindl, B | 1 |
| Müller, SC | 1 |
| Hauser, S | 1 |
| Leiber, C | 1 |
| Huland, E | 1 |
| Heinzer, H | 1 |
| Siemer, S | 1 |
| Metzner, B | 1 |
| Heynemann, H | 1 |
| Fornara, P | 1 |
| Reitz, M | 1 |
| Seike, J | 2 |
| Honda, J | 2 |
| Miyoshi, T | 2 |
| Umemoto, A | 2 |
| Tangoku, A | 4 |
| Jorgensen, TJ | 1 |
| Tian, H | 1 |
| Menon, K | 2 |
| Frost, D | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Deguchi, Y | 1 |
| Sonoda, K | 1 |
| Chujo, M | 1 |
| Miura, T | 4 |
| Kawano, Y | 1 |
| Miyawaki, M | 1 |
| Imakiire, T | 1 |
| Hayashita, Y | 1 |
| Kawahara, K | 1 |
| Tournigand, C | 1 |
| Mineur, L | 1 |
| Fellague-Chebra, R | 1 |
| Flesch, M | 1 |
| Hebbar, M | 1 |
| Postel Vinay, S | 1 |
| Bidard, FC | 1 |
| Segawa, Y | 2 |
| Watanabe, Y | 2 |
| Kamei, H | 2 |
| Moritaka, T | 1 |
| Shibayama, T | 1 |
| Shinkai, T | 2 |
| Hiraki, S | 2 |
| Takemoto, M | 1 |
| Mai, HQ | 1 |
| Zeng, ZY | 1 |
| Feng, KT | 1 |
| Ye, YL | 1 |
| Zhang, CQ | 1 |
| Liang, WJ | 1 |
| Mo, HY | 1 |
| Hong, MH | 1 |
| Shiiki, S | 1 |
| Sonoo, H | 1 |
| Seki, M | 1 |
| Nomura, T | 1 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Nakashima, K | 2 |
| Ikeda, M | 2 |
| Kurebayashi, J | 1 |
| Yoshidome, K | 1 |
| Imabun, S | 1 |
| Nakahara, M | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Tsujimoto, M | 2 |
| Nakao, K | 1 |
| Souglakos, J | 2 |
| Kalykaki, A | 2 |
| Vamvakas, L | 2 |
| Androulakis, N | 2 |
| Kalbakis, K | 2 |
| Agelaki, S | 2 |
| Vardakis, N | 1 |
| Tzardi, M | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Tsetis, D | 1 |
| Sfakiotaki, G | 2 |
| Chatzidaki, D | 1 |
| Mavroudis, D | 2 |
| Georgoulias, V | 2 |
| Karakuzu, A | 1 |
| Koc, M | 1 |
| Ozdemir, S | 1 |
| Fukada, T | 1 |
| Yasuno, K | 1 |
| Koyama, T | 2 |
| Seike, K | 1 |
| Kametaka, H | 1 |
| Hashimoto, R | 1 |
| Kawano, H | 1 |
| Hasegawa, A | 1 |
| Takenobu, T | 1 |
| Kokubo, M | 1 |
| Taniike, N | 1 |
| Nagano, M | 1 |
| Furutani, M | 1 |
| Ohnishi, M | 1 |
| Shitara, K | 2 |
| Munakata, M | 2 |
| Kudo, T | 1 |
| Muto, O | 2 |
| Okada, R | 2 |
| Mitobe, S | 2 |
| Sakata, Y | 3 |
| Ishii, E | 1 |
| Yabu, K | 1 |
| Yang, JJ | 2 |
| Chen, D | 1 |
| Fu, X | 1 |
| Zu, Y | 1 |
| Ozasa, H | 1 |
| Maeno, K | 1 |
| Yoshimasu, T | 2 |
| Oura, S | 3 |
| Hirai, I | 2 |
| Tamaki, T | 2 |
| Kokawa, Y | 1 |
| Ohta, F | 1 |
| Nakamura, R | 1 |
| Kawago, M | 1 |
| Tanino, H | 2 |
| Okamura, Y | 1 |
| Furukawa, T | 2 |
| Wang, CT | 1 |
| Cao, KJ | 1 |
| Xie, GF | 1 |
| Huang, PY | 1 |
| Enoki, T | 1 |
| Kitada, K | 1 |
| Harada, E | 1 |
| Noshima, S | 1 |
| Hamano, K | 1 |
| Gutova, M | 1 |
| Najbauer, J | 1 |
| Gevorgyan, A | 1 |
| Metz, MZ | 1 |
| Weng, Y | 1 |
| Shih, CC | 1 |
| Aboody, KS | 1 |
| Li, JG | 1 |
| Kamoshita, N | 1 |
| Makita, F | 1 |
| Matsuzaki, Y | 1 |
| Kabeya, K | 1 |
| Neri, B | 1 |
| Pantaleo, P | 1 |
| Giommoni, E | 1 |
| Grifoni, R | 1 |
| Paoletti, C | 1 |
| Rotella, V | 1 |
| Pantalone, D | 1 |
| Taddei, A | 1 |
| Mercatelli, A | 1 |
| Tonelli, P | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Shi, YX | 1 |
| Tsukamoto, G | 1 |
| Ibaragi, S | 1 |
| Shimo, T | 1 |
| Kishimoto, K | 1 |
| Mese, H | 1 |
| Aoe, M | 1 |
| Sasaki, A | 1 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 1 |
| Noso, Y | 1 |
| Fine, RL | 1 |
| Fogelman, DR | 1 |
| Schreibman, SM | 1 |
| Desai, M | 1 |
| Sherman, W | 1 |
| Strauss, J | 1 |
| Guba, S | 1 |
| Andrade, R | 1 |
| Chabot, J | 1 |
| Giantonio, BJ | 1 |
| Catalano, PJ | 1 |
| Meropol, NJ | 2 |
| Mitchell, EP | 1 |
| Schwartz, MA | 1 |
| Marshall, JL | 1 |
| Gotoh, M | 1 |
| Emmanouilides, C | 1 |
| Christophylakis, C | 1 |
| Kotsakis, A | 1 |
| Diamandidou, E | 1 |
| Touroutoglou, N | 1 |
| Chatzidakis, A | 1 |
| Ishizaki, T | 1 |
| Abe, T | 2 |
| Koyanagi, Y | 3 |
| Katsumata, K | 1 |
| Wada, T | 2 |
| Tsuchida, A | 1 |
| Rosati, G | 1 |
| Bilancia, D | 1 |
| Germano, D | 1 |
| Dinota, A | 1 |
| Romano, R | 1 |
| Reggiardo, G | 1 |
| Schneider, BJ | 1 |
| El-Rayes, B | 1 |
| Muler, JH | 1 |
| Philip, PA | 2 |
| Kalemkerian, GP | 1 |
| Griffith, KA | 2 |
| Zalupski, MM | 2 |
| Seike, Y | 1 |
| Shionoya, A | 1 |
| Kawakami, A | 1 |
| Ogawa, N | 1 |
| Kudoh, S | 2 |
| Kasai, M | 1 |
| Murakami, S | 1 |
| Yang, ZY | 1 |
| Hong, X | 1 |
| Lu, L | 1 |
| Zhang, CH | 1 |
| Yamazaki, K | 1 |
| Yoshino, T | 1 |
| Boku, N | 1 |
| Lévi, F | 4 |
| Karaboué, A | 1 |
| de la Valette, V | 1 |
| Baron, B | 1 |
| Giacchetti, S | 1 |
| Toyooka, S | 1 |
| Uchida, A | 1 |
| Soh, J | 1 |
| Ouchida, M | 1 |
| Date, H | 1 |
| Desai, SP | 1 |
| El-Rayes, BF | 1 |
| Ben-Josef, E | 1 |
| Greenson, JK | 1 |
| Huang, EH | 1 |
| McGinn, CJ | 1 |
| Nikaido, T | 1 |
| Wada, Y | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Araki, H | 2 |
| Kato, J | 1 |
| Ray-Coquard, I | 1 |
| Bachelot, T | 1 |
| Saba, C | 1 |
| Confavreux, C | 1 |
| Brantus, JF | 1 |
| Rustam, F | 1 |
| Ghesquière, H | 1 |
| Sebban, C | 1 |
| Biron, P | 1 |
| Guastalla, JP | 1 |
| Blay, JY | 1 |
| Sueyoshi, S | 1 |
| Sasahara, H | 1 |
| Mori, N | 3 |
| Nagano, T | 1 |
| Yamana, H | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Crump, M | 2 |
| Gluck, S | 1 |
| Stewart, D | 1 |
| Levine, M | 1 |
| Kirkbride, P | 1 |
| Dancey, J | 1 |
| O'Reilly, S | 1 |
| Shore, T | 1 |
| Couban, S | 1 |
| Girouard, C | 2 |
| Marlin, S | 1 |
| Shepherd, L | 1 |
| Pritchard, KI | 1 |
| Fujisawa, M | 1 |
| Ono, S | 1 |
| Nitta, S | 1 |
| Ishiyama, S | 1 |
| Shinjou, K | 1 |
| Machida, M | 1 |
| Kitabatake, T | 1 |
| Ishibiki, Y | 1 |
| Urao, M | 1 |
| Kojima, K | 2 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Kajimoto, S | 1 |
| Horie, M | 2 |
| Manabe, H | 1 |
| Masuda, Y | 1 |
| Shibayama-Imazu, T | 1 |
| Nakajo, S | 1 |
| Gong, XF | 1 |
| Obama, T | 1 |
| Itabe, H | 1 |
| Nakaya, K | 1 |
| Motoyama, S | 1 |
| Hosono, Y | 1 |
| Maruyama, K | 1 |
| Okuyama, M | 1 |
| Saito, R | 1 |
| Hentrich, M | 1 |
| Schiel, X | 1 |
| Scheidt, B | 1 |
| Reitmeier, M | 1 |
| Hoffmann, U | 1 |
| Lutz, L | 1 |
| Hidaka, A | 1 |
| Hamaji, Y | 1 |
| Taniguchi, S | 1 |
| Fujimori, M | 1 |
| Harvey, J | 2 |
| Macleod, C | 1 |
| Borg, M | 1 |
| Millar, JL | 1 |
| Graham, P | 1 |
| Zissiadis, Y | 1 |
| Kneebone, A | 1 |
| Carroll, S | 1 |
| Davies, T | 1 |
| Reece, WH | 1 |
| Iacopetta, B | 1 |
| Goldstein, D | 1 |
| Beg, MS | 1 |
| Komrokji, RS | 1 |
| Ahmed, K | 1 |
| Safa, MM | 1 |
| Kaida, Y | 1 |
| Inui, N | 1 |
| Nakamura, H | 2 |
| Watanabe, H | 1 |
| Chida, K | 1 |
| Kelner, MJ | 1 |
| McMorris, TC | 1 |
| Rojas, RJ | 1 |
| Estes, LA | 1 |
| Suthipinijtham, P | 1 |
| Ceppi, P | 1 |
| Volante, M | 1 |
| Ferrero, A | 1 |
| Righi, L | 1 |
| Rapa, I | 1 |
| Rosas, R | 1 |
| Berruti, A | 1 |
| Dogliotti, L | 1 |
| Scagliotti, GV | 1 |
| Papotti, M | 1 |
| Giusti, RM | 1 |
| Shastri, K | 1 |
| Pilaro, AM | 1 |
| Cordoba-Rodriguez, R | 1 |
| Koti, K | 1 |
| Rothmann, M | 1 |
| Men, AY | 1 |
| Zhao, H | 1 |
| Hughes, M | 1 |
| Keegan, P | 1 |
| Weiss, KD | 1 |
| Pazdur, R | 2 |
| Lieuw-a-Fa, M | 1 |
| Peringa, J | 1 |
| Leeksma, O | 1 |
| Terpstra, W | 1 |
| Zuckerman, DS | 1 |
| Iwasa, T | 1 |
| Satoh, T | 1 |
| Tamura, K | 1 |
| Pant, S | 1 |
| Landon, MB | 1 |
| Blumenfeld, M | 1 |
| Farrar, W | 1 |
| Shapiro, CL | 1 |
| Suyama, H | 1 |
| Yamasaki, A | 1 |
| Sumikawa, T | 1 |
| Viel, E | 1 |
| Demarchi, MF | 1 |
| Chaigneau, L | 1 |
| Nguyen, T | 1 |
| Legat, C | 1 |
| Stein, U | 1 |
| Thiery-Vuillemin, A | 1 |
| Limat, S | 1 |
| Pivot, X | 1 |
| Borg, C | 1 |
| Fujita, K | 1 |
| Sasaki, Y | 2 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Norton, L | 1 |
| Hudis, C | 1 |
| Nemkova, EV | 1 |
| Mus, VF | 1 |
| Boeck, S | 1 |
| Wilkowski, R | 1 |
| Bruns, CJ | 1 |
| Issels, RD | 1 |
| Schulz, C | 1 |
| Moosmann, N | 1 |
| Laessig, D | 1 |
| Haas, M | 1 |
| Golf, A | 1 |
| Hess, D | 1 |
| Koberle, D | 1 |
| Thurlimann, B | 1 |
| Pagani, O | 1 |
| Schonenberger, A | 1 |
| Mattmann, S | 1 |
| Rochlitz, C | 1 |
| Rauch, D | 1 |
| Schuller, JC | 1 |
| Ballabeni, P | 1 |
| Ribi, K | 1 |
| Chan, SY | 1 |
| Ho, PC | 1 |
| Furuta, R | 1 |
| Ina, K | 1 |
| Kataoka, T | 1 |
| Nagao, S | 1 |
| Kayukawa, S | 1 |
| Mori, F | 1 |
| Masaki, A | 1 |
| Kiribuchi, M | 1 |
| Gault, MH | 1 |
| Cohen, MW | 1 |
| Kahana, LM | 1 |
| Leelin, FT | 1 |
| Meakins, JF | 1 |
| Aronovitch, M | 1 |
| Hall, TC | 3 |
| Dederick, MM | 1 |
| Chalmers, TC | 1 |
| Krant, MJ | 2 |
| Shnider, BI | 3 |
| Lynch, JJ | 1 |
| Holland, JF | 1 |
| Ross, C | 1 |
| Koons, CR | 1 |
| Owens, AH | 1 |
| Frei, E | 4 |
| Brindley, C | 1 |
| Miller, SP | 1 |
| Brenner, S | 1 |
| Hosley, HF | 1 |
| Olson, KB | 1 |
| Brocard, H | 2 |
| Akoun, G | 2 |
| Turpin, G | 1 |
| Gendre, JP | 1 |
| Zhang, ZY | 1 |
| Wang, SZ | 1 |
| Gustavsson, B | 1 |
| Hafström, L | 1 |
| Okazaki, H | 1 |
| Fujii, S | 1 |
| Gunstream, SR | 1 |
| Seidenfeld, JJ | 1 |
| Sobonya, RE | 1 |
| McMahon, LJ | 2 |
| Dimitriadis, K | 1 |
| Boutis, L | 1 |
| Tavantzis, J | 1 |
| Mouratidou, D | 1 |
| Bouchoris, N | 1 |
| Koukourikos, S | 1 |
| Hatzigogos, K | 1 |
| Safarini, S | 1 |
| Cohen, MH | 2 |
| Johnston-Early, A | 1 |
| Citron, ML | 2 |
| Krasnow, SH | 1 |
| Fossieck, BE | 2 |
| Hayashida, S | 1 |
| Sugimoto, K | 1 |
| Evans, RG | 1 |
| Burgert, EO | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Pritchard, DJ | 1 |
| Bruckman, JE | 1 |
| Barone, RM | 1 |
| Byfield, JE | 3 |
| Goldfarb, PB | 1 |
| Frankel, S | 1 |
| Ginn, C | 1 |
| Greer, S | 2 |
| Weltz, MD | 1 |
| Perry, DJ | 2 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Hara, Y | 3 |
| Tannock, IF | 2 |
| Sutherland, DJ | 1 |
| Taylor, RE | 1 |
| Smith, IE | 3 |
| Ford, HT | 1 |
| Bryant, BM | 1 |
| Casey, AJ | 1 |
| Smyth, JF | 1 |
| Horai, T | 3 |
| Sone, H | 1 |
| Takenaga, A | 2 |
| Ikegami, H | 4 |
| Matsuda, M | 4 |
| Miller, TP | 4 |
| Livingston, RB | 5 |
| Nixon, DW | 1 |
| Shlaer, SM | 1 |
| Weick, JK | 3 |
| Grozea, PN | 1 |
| Carlin, DA | 1 |
| McCracken, JD | 1 |
| Chen, T | 3 |
| White, J | 1 |
| Samson, M | 1 |
| Stephens, R | 1 |
| Coltman, CA | 4 |
| Saiki, J | 1 |
| Lane, M | 3 |
| Bonnet, J | 1 |
| McGavran, M | 1 |
| Vine, E | 1 |
| Ghanbarpour, A | 1 |
| Shani, J | 1 |
| Siemsen, JK | 1 |
| Wolf, W | 1 |
| Shorthouse, AJ | 1 |
| Jones, JM | 1 |
| Steel, GG | 1 |
| Peckham, MJ | 1 |
| White, JE | 1 |
| McCracken, J | 1 |
| Kennedy, P | 1 |
| Seydel, HG | 1 |
| Hartman, G | 1 |
| Mira, J | 1 |
| Khan, M | 1 |
| Durrance, FY | 1 |
| Skinner, O | 1 |
| Iigo, M | 5 |
| Nakajima, Y | 2 |
| Kuretani, K | 3 |
| Hoshi, A | 4 |
| Komatubara, S | 1 |
| Sato, G | 1 |
| Teramoto, S | 1 |
| Nakamura, S | 2 |
| Flicker, M | 1 |
| Neumann, M | 1 |
| Fujisawa, T | 1 |
| Yamaguchi, Y | 2 |
| Chorba, T | 1 |
| Orenstein, JM | 1 |
| Harisiadis, L | 1 |
| Moody, T | 1 |
| Burton, T | 1 |
| Schulof, RS | 1 |
| Herrmann, R | 3 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 1 |
| Spencer, HJ | 1 |
| Tormey, D | 1 |
| Gelman, R | 1 |
| Falkson, G | 3 |
| Vogel, CL | 1 |
| Smalley, RV | 1 |
| Raney, M | 1 |
| Krauss, S | 1 |
| Carpenter, J | 1 |
| Velez-Garcia, E | 1 |
| Fishkin, E | 1 |
| Raab, S | 1 |
| Moore, MR | 1 |
| Stagg, M | 1 |
| Kiseleva, ES | 2 |
| Pitskhelauri, VG | 1 |
| Trakhtenberg, AKh | 4 |
| Bidiak, IP | 1 |
| Zholkiver, KI | 1 |
| Basu, TK | 1 |
| Wakui, A | 1 |
| Samuels, ML | 4 |
| von Eschenbach, AC | 2 |
| Trindade, A | 2 |
| Ogden, S | 1 |
| Grant, C | 1 |
| Johnson, DE | 3 |
| Ninomiya, K | 1 |
| Sekido, S | 1 |
| Araki, T | 1 |
| Pedersen, JE | 1 |
| Barron, G | 1 |
| Mizuno, H | 2 |
| Inomata, T | 2 |
| Umezawa, T | 1 |
| Shimizu, F | 2 |
| Arakawa, M | 2 |
| Tsuruo, T | 4 |
| Naganuma, K | 3 |
| Yamori, T | 2 |
| Oh-Hara, T | 1 |
| Tsukagoshi, S | 5 |
| Sakurai, Y | 3 |
| Voznyĭ, EK | 2 |
| Besova, NS | 1 |
| Kurkina, TV | 1 |
| Al'tshtuller, IuB | 1 |
| Kozlov, AM | 1 |
| Novikov, AM | 1 |
| Bassalyk, LS | 1 |
| Sof'ina, ZP | 1 |
| Braunschweiger, PG | 2 |
| Ting, HL | 2 |
| Schiffer, LM | 2 |
| Carey, RW | 2 |
| Cadman, EC | 1 |
| Glick, JH | 1 |
| Cross, J | 1 |
| Horton, J | 3 |
| Taylor, SG | 6 |
| Dymarskiĭ, LIu | 3 |
| Sanchakova, AV | 1 |
| Aleksandrova, GI | 1 |
| Trishkina, EA | 1 |
| Ohno, K | 2 |
| Stanton, W | 1 |
| Sharp, TR | 1 |
| Frankel, SS | 2 |
| Koziol, J | 1 |
| Vaage, J | 2 |
| Costanza, ME | 3 |
| Israel, L | 5 |
| Breau, JL | 1 |
| Aguilera, J | 1 |
| Queisser, W | 2 |
| Schnitzler, G | 1 |
| Heim, ME | 2 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, F | 1 |
| Hori, K | 1 |
| Stevens, AN | 1 |
| Morris, PG | 1 |
| Iles, RA | 1 |
| Sheldon, PW | 1 |
| Griffiths, JR | 1 |
| Sasagawa, K | 1 |
| Shinkai, K | 1 |
| Kono, A | 2 |
| Matsushima, Y | 1 |
| Carter, WH | 1 |
| Wampler, GL | 6 |
| Stablein, DM | 2 |
| Campbell, ED | 1 |
| Furue, H | 5 |
| Machida, T | 2 |
| Masuda, F | 1 |
| Nivinskaia, MM | 3 |
| Abramova, NA | 1 |
| Klykova, ID | 1 |
| Furusawa, E | 2 |
| Sokugawa, L | 1 |
| Satomi, Y | 1 |
| Leibovici, J | 1 |
| Stark, Y | 1 |
| Wolman, M | 1 |
| Mulder, JH | 3 |
| Smink, T | 3 |
| Ossewaarde, T | 1 |
| van Putten, LM | 3 |
| Woods, RL | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Levi, JA | 1 |
| Brodie, GN | 1 |
| Solan, A | 1 |
| Vogl, SE | 1 |
| Kaplan, BH | 1 |
| Berenzweig, M | 1 |
| Richard, J | 1 |
| Lanham, R | 1 |
| Helmkamp, BF | 1 |
| Beecham, JB | 1 |
| Wandtke, JC | 1 |
| Keys, H | 1 |
| Abisatov, KhA | 4 |
| Floyd, RA | 1 |
| Hornbeck, CL | 1 |
| Griffiths, JC | 1 |
| Finck, SJ | 1 |
| Gupta, RK | 1 |
| Giuliano, AE | 1 |
| Morton, DL | 1 |
| Jurga, L | 2 |
| Mrinák, J | 1 |
| Ponist, J | 1 |
| Sefara, P | 1 |
| Berc, A | 1 |
| McDermott, BJ | 1 |
| van den Berg, HW | 1 |
| Murphy, RF | 1 |
| Takimoto, M | 1 |
| Kodama, K | 2 |
| Yokoi, H | 1 |
| Enomoto, K | 1 |
| Ohki, S | 1 |
| Komita, T | 1 |
| Iketa, T | 1 |
| Ikenaga, M | 1 |
| Arimori, S | 1 |
| Nagao, T | 1 |
| Drago, JR | 1 |
| Worgul, TJ | 1 |
| Gallagher, C | 1 |
| Takita, H | 2 |
| Edgerton, F | 1 |
| Marabella, P | 1 |
| Conway, D | 1 |
| Harguindey, S | 1 |
| Tokuzen, R | 1 |
| Rosi, DR | 1 |
| Nogeire, C | 1 |
| Brown, B | 1 |
| Ali, M | 1 |
| Ewer, M | 1 |
| Samuels, M | 1 |
| Inomata, M | 1 |
| Ando, N | 1 |
| Anderson, G | 3 |
| Deeley, TJ | 1 |
| Smith, C | 1 |
| Jani, J | 1 |
| Düker, D | 1 |
| Zimm, S | 1 |
| Hartmann, HR | 2 |
| Bollag, W | 2 |
| Jones, MA | 1 |
| Williams, G | 1 |
| Greco, C | 1 |
| Calabresi, F | 1 |
| Corsi, A | 1 |
| Pericoli, N | 1 |
| Caputo, M | 1 |
| Neubauer, BL | 1 |
| Best, KL | 1 |
| Counts, DF | 1 |
| Goode, RL | 1 |
| Hoover, DM | 1 |
| Jones, CD | 1 |
| Sarosdy, MF | 1 |
| Shaar, CJ | 1 |
| Tanzer, LR | 1 |
| Merriman, RL | 1 |
| Mah, K | 1 |
| Keane, TJ | 1 |
| Van Dyk, J | 1 |
| Braban, LE | 1 |
| Poon, PY | 1 |
| Hao, Y | 1 |
| Dreicer, R | 1 |
| Forest, PK | 1 |
| Williams, RD | 1 |
| Kakinuma, H | 1 |
| Vokes, EE | 8 |
| Haraf, DJ | 5 |
| Drinkard, LC | 2 |
| Hoffman, PC | 4 |
| Ferguson, MK | 3 |
| Watson, S | 2 |
| Lane, NJ | 1 |
| Golomb, HM | 4 |
| Hyogo, H | 1 |
| Kido, S | 1 |
| Yamamoto, K | 3 |
| Kida, M | 1 |
| Akiyama, J | 1 |
| Nakao, A | 1 |
| Nakajima, A | 1 |
| Nabeyama, A | 1 |
| Sakagami, K | 1 |
| Van den Hout, BM | 1 |
| Taal, BG | 1 |
| Gortzak, E | 1 |
| Zoetmulder, FA | 1 |
| Boot, H | 1 |
| Niho, Y | 7 |
| Pisch, J | 1 |
| Berson, AM | 1 |
| Malamud, S | 1 |
| Beattie, EJ | 3 |
| Vikram, B | 1 |
| van Triest, B | 1 |
| Telleman, F | 1 |
| van der Wilt, CL | 2 |
| Noguchi, S | 2 |
| Shuin, T | 1 |
| Kubota, Y | 1 |
| Masuda, M | 1 |
| Yao, M | 1 |
| Hosaka, M | 1 |
| Rice, TW | 1 |
| Adelstein, DJ | 1 |
| Koka, A | 1 |
| Tefft, M | 1 |
| Kirby, TJ | 1 |
| Van Kirk, MA | 1 |
| Taylor, ME | 1 |
| Olencki, TE | 1 |
| Peereboom, D | 1 |
| Budd, GT | 1 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Wang, GM | 1 |
| Chen, CH | 2 |
| Sun, GZ | 1 |
| Klastersky, J | 2 |
| Sculier, JP | 2 |
| Ries, F | 2 |
| Dabouis, G | 3 |
| Libert, P | 2 |
| Schmerber, J | 2 |
| Thiriaux, J | 2 |
| Berchier, MC | 2 |
| Bureau, G | 2 |
| Van Cutsem, O | 2 |
| Khansur, T | 1 |
| Allred, C | 1 |
| Little, D | 1 |
| Anand, V | 1 |
| Kattan, J | 2 |
| Culine, S | 2 |
| Theodore, C | 2 |
| Droz, JP | 4 |
| Ellis, PA | 1 |
| Talbot, DC | 1 |
| Nicolson, MC | 1 |
| Priest, K | 1 |
| Ashley, S | 1 |
| Sakuyama, T | 1 |
| Shimono, S | 1 |
| Inomata, Y | 1 |
| Isshi, K | 1 |
| Chibai, M | 1 |
| Tadaoka, N | 1 |
| Morere, JF | 1 |
| Duran, A | 1 |
| Tcherakian, F | 1 |
| Boaziz, C | 1 |
| Valeyre, D | 1 |
| Battesti, JP | 1 |
| Breu, JL | 1 |
| Dahrouge, S | 1 |
| Soltys, KM | 1 |
| Evans, WK | 3 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Asakawa, M | 2 |
| Yoshida, K | 1 |
| Niitani, H | 4 |
| Igarashi, W | 1 |
| Ohtake, T | 1 |
| Ono, T | 1 |
| Hatakeyama, Y | 2 |
| Abe, R | 1 |
| Farhat, F | 1 |
| Bekradda, M | 1 |
| Peng, XM | 1 |
| Moinpour, CM | 1 |
| Samuels, BL | 1 |
| Bitran, JD | 3 |
| Ferguson, MF | 1 |
| Thiberville, L | 1 |
| Compagnon, P | 1 |
| Moore, N | 1 |
| Bastian, G | 1 |
| Richard, MO | 1 |
| Hellot, MF | 1 |
| Vincent, C | 1 |
| Kannass, MM | 1 |
| Dominique, S | 1 |
| Thuillez, C | 1 |
| Weiden, PL | 3 |
| Piantadosi, S | 2 |
| Gao, Z | 1 |
| Meng, FH | 1 |
| Motoyama, M | 1 |
| Imaoka, T | 2 |
| Ichihara, N | 1 |
| Miyauchi, S | 3 |
| Quan, WD | 2 |
| Madajewicz, S | 1 |
| Smith, MR | 1 |
| Skeel, RT | 1 |
| Lee, M | 1 |
| Pierce, A | 1 |
| Mahaffey, W | 1 |
| Specht, S | 1 |
| Stemmler, N | 1 |
| Katoh, A | 2 |
| Nardini, S | 1 |
| Salamoun, WI | 1 |
| Utsunomiya, T | 1 |
| Kubo, M | 1 |
| Kawaguchi, T | 1 |
| Matsui, Y | 1 |
| Taylor, DD | 1 |
| Gerçel-Taylor, C | 1 |
| Fowler, WC | 2 |
| Weese, JL | 1 |
| Okayasu, T | 2 |
| Sugiyama, K | 2 |
| Lamar, RE | 1 |
| Johnson, DH | 1 |
| Murphy, PB | 1 |
| Lee, DY | 1 |
| Kim, HK | 1 |
| Paik, HC | 1 |
| Kim, SJ | 1 |
| Macchiarini, P | 1 |
| Chapelier, AR | 1 |
| Monnet, I | 3 |
| Vannetzel, JM | 2 |
| Rebischung, JL | 2 |
| Cerrina, J | 1 |
| Parquin, F | 1 |
| Ladurie, FL | 1 |
| Lenot, B | 1 |
| Dartevelle, PG | 1 |
| Saijo, N | 4 |
| Sugirnoto, Y | 1 |
| Murren, JR | 2 |
| Durivage, HJ | 1 |
| Rosenberg, AH | 1 |
| Del Prete, SA | 1 |
| Murphy, GJ | 1 |
| Buzaid, AC | 2 |
| Hait, WN | 2 |
| Ichiki, Y | 1 |
| Kanaya, S | 1 |
| Yasutake, T | 1 |
| Etoh, T | 1 |
| Ishimaru, T | 1 |
| Riggi, M | 1 |
| Cvitkovic, E | 2 |
| de Cremoux, H | 2 |
| Ruffie, P | 3 |
| Voisin, S | 2 |
| Villalobos, W | 1 |
| Azli, N | 2 |
| Saltiel, JC | 2 |
| Tatsumura, T | 2 |
| Koyama, S | 2 |
| Kitagawa, M | 1 |
| Kagamimori, S | 1 |
| Hamblin, TJ | 1 |
| Sadullah, S | 1 |
| Williamson, P | 1 |
| Stevenson, J | 1 |
| Oskam, R | 1 |
| Palmer, P | 1 |
| Franks, CR | 1 |
| Zhou, JC | 2 |
| Balaban, EP | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Ross, M | 1 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Shida, H | 1 |
| Ban, K | 1 |
| Matsumoto, M | 1 |
| Takei, Y | 1 |
| Noda, Y | 1 |
| Masuda, K | 1 |
| Imanari, T | 1 |
| Lynch, TJ | 4 |
| Kalish, LA | 3 |
| Kass, F | 2 |
| Strauss, G | 2 |
| Elias, A | 1 |
| Skarin, A | 3 |
| Shulman, L | 1 |
| Sugarbaker, D | 1 |
| Yamamitsu, S | 3 |
| Tanemura, H | 2 |
| Ito, T | 1 |
| Oshita, H | 2 |
| Asano, M | 1 |
| Kaneda, N | 1 |
| Kumazawa, I | 1 |
| Kuno, T | 1 |
| Fujita, F | 2 |
| Tsai, CM | 5 |
| Hsiao, SH | 1 |
| Frey, CM | 1 |
| Chang, KT | 1 |
| Perng, RP | 5 |
| Gazdar, AF | 4 |
| Kramer, BS | 3 |
| Nakagawaji, K | 1 |
| Tokumaru, T | 1 |
| Imaizumi, M | 1 |
| Arbaje, YM | 1 |
| Bittner, G | 1 |
| Yingling, JM | 1 |
| Storer, B | 1 |
| Schiller, JH | 2 |
| Langer, CJ | 3 |
| Curran, WJ | 2 |
| Keller, SM | 2 |
| Elias, AD | 2 |
| Shulman, LN | 2 |
| Sugarbaker, DJ | 1 |
| Roussakis, C | 1 |
| Pouchus, YF | 1 |
| Gratas, C | 1 |
| Riou, D | 1 |
| Dimou, P | 1 |
| Merle, S | 1 |
| Verbist, JF | 1 |
| Catalano, R | 1 |
| Fowler, W | 1 |
| Blankstein, K | 1 |
| Litwin, S | 2 |
| Bagchi, P | 1 |
| Nash, S | 1 |
| Comis, R | 1 |
| Ganpule, S | 1 |
| Papac, R | 1 |
| Son, YH | 1 |
| Peschel, RE | 1 |
| Durivage, H | 1 |
| Lamb, L | 1 |
| Makuch, R | 1 |
| Yang, JC | 1 |
| Shlasko, E | 1 |
| Ritchey, JL | 1 |
| Landry, JG | 1 |
| White, DE | 1 |
| Rosenberg, SA | 1 |
| Inaba, H | 1 |
| Xing, FY | 1 |
| Liu, WH | 1 |
| Dong, W | 1 |
| Zhang, SL | 1 |
| Gu, BW | 1 |
| Okazaki, K | 1 |
| Naito, H | 1 |
| Inoue, T | 2 |
| Wu, JT | 1 |
| Tamura, S | 1 |
| Sugimori, H | 1 |
| Chifu, Y | 1 |
| Kudo, J | 1 |
| Patt, YZ | 1 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Levin, B | 1 |
| Fujita, J | 3 |
| Kubo, A | 1 |
| Takigawa, K | 1 |
| Yamaji, Y | 2 |
| Takahara, J | 1 |
| Takeuchi, H | 1 |
| Inutsuka, S | 1 |
| Sugimachi, K | 4 |
| Kusama, M | 2 |
| Kimura, K | 2 |
| Kaise, H | 2 |
| Arima, M | 1 |
| Satoh, Y | 1 |
| Murata, J | 1 |
| Matsunaga, T | 1 |
| Mohiuddin, M | 1 |
| Zeitzer, KL | 1 |
| Moylan, DJ | 1 |
| Yelovich, RM | 1 |
| Rose, L | 1 |
| Denis, B | 1 |
| Chen, YM | 2 |
| Whang-Peng, J | 2 |
| Liu, JM | 3 |
| Kuo, BI | 1 |
| Wang, SY | 1 |
| Mathisen, DJ | 5 |
| Wright, C | 1 |
| Choi, N | 1 |
| Carey, R | 1 |
| Hilgenberg, A | 1 |
| Grossbard, M | 1 |
| Lynch, T | 1 |
| Grillo, H | 1 |
| Massard, G | 1 |
| Sohier, B | 1 |
| Jung, GM | 1 |
| Dietemann, A | 1 |
| Kessler, R | 1 |
| Dumont, P | 4 |
| Fraisse, P | 1 |
| Charloux, A | 1 |
| Bohner, C | 1 |
| Wihlm, JM | 1 |
| Goss, PE | 1 |
| Prince, M | 1 |
| Bedini, AV | 1 |
| Tavecchio, L | 1 |
| Lequaglie, C | 1 |
| Ravasi, G | 1 |
| Cheng, LC | 1 |
| Sham, JS | 1 |
| Chiu, CS | 1 |
| Fu, KH | 1 |
| Lee, JW | 1 |
| Mok, CK | 1 |
| Nakano, T | 2 |
| Kawase, T | 1 |
| Nishikawa, H | 1 |
| Yokota, S | 1 |
| Tachibana, T | 1 |
| Igarashi, T | 1 |
| Higashino, K | 1 |
| Maurer, U | 1 |
| Härle, M | 1 |
| Jungius, KP | 1 |
| Nomura, H | 1 |
| Murakami, Y | 1 |
| Aiba, K | 4 |
| Estes, NC | 2 |
| Giri, S | 1 |
| Fabian, C | 1 |
| Andreyev, HJ | 1 |
| Padhani, AR | 1 |
| Hill, AS | 1 |
| Webb, A | 1 |
| DiPaola, RS | 1 |
| Kaufman, A | 1 |
| Mikhail, MM | 1 |
| Davydov, MI | 1 |
| Normantovich, VA | 1 |
| Polotskiĭ, BE | 1 |
| Ivshina, AV | 1 |
| Mkheidze, DM | 1 |
| Fujita, A | 3 |
| Takabatake, H | 2 |
| Tagaki, S | 2 |
| Sekine, K | 3 |
| Kumegawa, H | 1 |
| Mori, S | 1 |
| Kanazawa, M | 1 |
| Morinaga, K | 1 |
| Kurimoto, H | 1 |
| Ono, K | 2 |
| Fuku, A | 1 |
| Togashi, M | 1 |
| Tabata, T | 1 |
| Hirakawa, K | 1 |
| Ohashi, N | 1 |
| Sindoh, J | 1 |
| Hirano, T | 1 |
| Demura, T | 1 |
| Furuse, S | 1 |
| Mizushima, Y | 1 |
| Mino, T | 1 |
| Yoshida, Y | 2 |
| Nakagawa, H | 2 |
| Asou, S | 1 |
| Wakagi, K | 1 |
| Yoshimura, G | 1 |
| Umemura, T | 1 |
| Barthel, A | 1 |
| Leonhardt, U | 1 |
| Stöckmann, F | 1 |
| Ramadori, G | 1 |
| Lokich, J | 2 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Dow, E | 1 |
| Zipoli, T | 1 |
| Gonzalves, L | 1 |
| Hisano, C | 1 |
| Okuma, K | 1 |
| Masumoto, N | 1 |
| Fujishima, H | 1 |
| Yang, N | 1 |
| Song, H | 1 |
| Yeo, W | 1 |
| Leung, TW | 2 |
| Leung, SF | 1 |
| Teo, PM | 2 |
| Chan, AT | 2 |
| Lee, WY | 1 |
| Johnson, PJ | 2 |
| Ophir, R | 2 |
| Pecht, M | 2 |
| Keisari, Y | 2 |
| Rashid, G | 2 |
| Lourie, S | 2 |
| Meshorer, A | 2 |
| Ben-Efraim, S | 2 |
| Trainin, N | 2 |
| Burstein, Y | 2 |
| Port, JL | 1 |
| Ng, B | 1 |
| Ellis, JL | 1 |
| Nawata, S | 1 |
| Lenert, JT | 1 |
| Burt, ME | 1 |
| Kano, Y | 1 |
| Akutsu, M | 1 |
| Tsunoda, S | 1 |
| Ando, J | 1 |
| Matsui, J | 1 |
| Suzuki, K | 3 |
| Ikeda, T | 1 |
| Adachi, K | 1 |
| Bonnefoi, H | 1 |
| Tsuneda, Y | 1 |
| Wakabayashi, K | 1 |
| Otsuka, Y | 1 |
| Yamagata, M | 1 |
| Iwai, S | 1 |
| Aschele, C | 1 |
| Tixi, L | 1 |
| Crawford, J | 1 |
| O'Rourke, M | 1 |
| Spiridonidis, CH | 1 |
| Yanovich, S | 1 |
| Ozer, H | 1 |
| Langleben, A | 1 |
| Hutchins, L | 1 |
| Koletsky, A | 1 |
| Clamon, G | 1 |
| Burman, S | 1 |
| White, R | 1 |
| Hohneker, J | 1 |
| Spiridonitis, CH | 1 |
| Itoh, Y | 2 |
| Muramoto, H | 1 |
| Kato, E | 1 |
| Shinoda, M | 1 |
| Sugiura, T | 2 |
| Parmar, MK | 1 |
| Ungerleider, RS | 1 |
| Simon, R | 1 |
| Beuzeboc, P | 1 |
| Livartowski, A | 1 |
| Dierick, A | 1 |
| Paraiso, D | 1 |
| Pouillart, P | 1 |
| Kobayashi, K | 1 |
| Ballarino, P | 1 |
| Castello, G | 1 |
| Lerza, R | 1 |
| Cerruti, A | 1 |
| Arboscello, E | 1 |
| Mencoboni, M | 1 |
| Bogliolo, G | 1 |
| Pannacciulli, I | 1 |
| Egusa, Y | 1 |
| Oobayashi, M | 1 |
| Isobe, T | 1 |
| Yamakido, M | 1 |
| Gabra, H | 1 |
| Cameron, DA | 1 |
| Lee, LE | 1 |
| Mackay, J | 1 |
| Leonard, RC | 1 |
| Ball, D | 1 |
| Smith, J | 1 |
| Bishop, J | 1 |
| Olver, I | 1 |
| Davis, S | 1 |
| O'Brien, P | 1 |
| Bernshaw, D | 1 |
| Ryan, G | 1 |
| Millward, M | 1 |
| Yamada, M | 1 |
| Hagiwara, Y | 1 |
| Kanayama, T | 1 |
| Moriuchi, S | 1 |
| Kaba, SE | 1 |
| Kyritsis, AP | 1 |
| Hess, K | 1 |
| Yung, WK | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 1 |
| Levin, VA | 1 |
| Kitao, Y | 1 |
| Yasuoka, R | 1 |
| Strumberg, D | 1 |
| Harstrick, A | 2 |
| Klaassen, U | 1 |
| Müller, C | 1 |
| Eberhardt, W | 1 |
| Korn, MW | 1 |
| Wilke, H | 2 |
| Seeber, S | 3 |
| Rixe, O | 1 |
| Coeffic, D | 1 |
| Orcel, B | 1 |
| Maitre, B | 1 |
| Borel, C | 1 |
| Benhammouda, A | 1 |
| Petit, T | 1 |
| Khayat, D | 1 |
| Derenne, JP | 1 |
| Colleoni, M | 1 |
| Graiff, C | 1 |
| Nelli, P | 1 |
| Vicario, G | 1 |
| Sgarbossa, G | 1 |
| Pancheri, F | 1 |
| Manente, P | 1 |
| Vanhoefer, U | 1 |
| Heidemann, A | 1 |
| Druyen, H | 1 |
| Denno, R | 1 |
| Oikawa, I | 1 |
| Mukaiya, M | 1 |
| Hiraike, N | 1 |
| Yagihashi, A | 1 |
| Takasaka, H | 1 |
| Katsuramaki, T | 1 |
| Yamashiro, K | 1 |
| Raynal, S | 1 |
| Nocentini, S | 1 |
| Croisy, A | 1 |
| Lawrence, DA | 1 |
| Jullien, P | 1 |
| Bible, KC | 1 |
| Kaufmann, SH | 1 |
| Bretel, JJ | 1 |
| Arriagada, R | 1 |
| Le Chevalier, T | 3 |
| Baldeyrou, P | 1 |
| Grunenwald, D | 1 |
| Le Péchoux, C | 1 |
| Pellae-Cosset, B | 1 |
| Bajetta, E | 3 |
| Di Bartolomeo, M | 2 |
| Somma, L | 1 |
| Del Vecchio, M | 1 |
| Artale, S | 1 |
| Zunino, F | 2 |
| Bignami, P | 1 |
| Magnani, E | 1 |
| Buzzoni, R | 2 |
| Zidani, R | 1 |
| Misset, JL | 1 |
| Sowa, M | 1 |
| Chung, Y | 1 |
| Toge, T | 1 |
| Yasumoto, K | 1 |
| Liang, S | 1 |
| Zhang, Z | 2 |
| Yen, CC | 3 |
| Tung, SL | 1 |
| Hsieh, RK | 2 |
| Chiou, TJ | 3 |
| Liu, JH | 3 |
| Wang, WS | 3 |
| Chou, CW | 1 |
| Wu, MF | 2 |
| Li, AF | 1 |
| Tie, CM | 1 |
| Chi, KH | 1 |
| Neoptolemos, JP | 1 |
| Yang, CT | 2 |
| Chang, WC | 1 |
| Chen, LH | 1 |
| Leung, WM | 1 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Rolka-Stempniewicz, G | 1 |
| Streit, M | 1 |
| Jaehde, U | 1 |
| Stremetzne, S | 1 |
| Ridwelski, K | 1 |
| Kerz, H | 1 |
| Strohbach, F | 1 |
| Hohenberger, P | 1 |
| Zwiebel, FM | 1 |
| Hebart, H | 1 |
| Böthig, R | 1 |
| Kairies, M | 1 |
| Zillig, D | 1 |
| Schuchmann, S | 1 |
| Warnecke, S | 1 |
| Thiel, E | 1 |
| Kreuser, ED | 2 |
| Lin, JK | 2 |
| Chen, WS | 2 |
| Jiang, JK | 2 |
| Fan, FS | 2 |
| Ishida, K | 1 |
| Koeda, K | 1 |
| Ohtsuka, K | 1 |
| Ogasawara, S | 1 |
| Iwaya, T | 1 |
| Thuss-Patience, P | 1 |
| Friedrich, M | 1 |
| Daniel, PT | 1 |
| Kretzschmar, A | 1 |
| Benter, T | 1 |
| Bauer, B | 1 |
| Dietz, R | 1 |
| Dörken, B | 1 |
| Gorlick, R | 1 |
| Danenberg, KD | 1 |
| Salonga, D | 1 |
| Miles, JS | 1 |
| Longo, GS | 1 |
| Banerjee, D | 1 |
| Klimstra, D | 1 |
| Jhanwar, S | 1 |
| Bertino, JR | 1 |
| Yokota, T | 1 |
| Roppongi, T | 1 |
| Kanno, K | 1 |
| Ogata, T | 2 |
| Gerard, JP | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Romestaing, P | 1 |
| Coquard, R | 1 |
| Ardiet, JM | 1 |
| Mornex, F | 1 |
| Kanematsu, A | 1 |
| Segawa, T | 1 |
| Kakehi, Y | 1 |
| Hiura, M | 1 |
| Hashimura, T | 1 |
| John, WJ | 1 |
| Foon, KA | 1 |
| Siu, LL | 1 |
| Rowinsky, EK | 1 |
| Wu, HW | 1 |
| Lin, WC | 1 |
| Hamazoe, R | 2 |
| Sumi, K | 1 |
| Murata, Y | 1 |
| Kinugasa, Y | 1 |
| Shiota, S | 1 |
| Hirooka, Y | 1 |
| Katsumata, N | 1 |
| Omuro, Y | 1 |
| Narabayashi, M | 1 |
| Adachi, I | 1 |
| Lam, KC | 1 |
| Chow, JH | 1 |
| Yim, AP | 1 |
| Mok, TS | 1 |
| Kwan, WH | 1 |
| Movsas, B | 1 |
| Hanlon, AL | 1 |
| Lanciano, R | 1 |
| Scher, RM | 1 |
| Weiner, LM | 1 |
| Hoffman, JP | 1 |
| Eisenberg, BL | 1 |
| Cooper, HS | 1 |
| Provins, S | 1 |
| Coia, LR | 1 |
| Teicher, BA | 2 |
| Ara, G | 1 |
| Buxton, D | 1 |
| Leonard, J | 1 |
| Schaub, RG | 1 |
| Song, HZ | 1 |
| Omiya, H | 1 |
| Machida, H | 1 |
| Imamura, H | 1 |
| Okamura, A | 1 |
| Hennequin, C | 1 |
| Maylin, C | 1 |
| Taniguchi, K | 1 |
| Bando, E | 1 |
| Michiwa, Y | 1 |
| Yonemura, Y | 1 |
| Wang, HZ | 1 |
| Lin, ZT | 1 |
| Gebarowska, E | 1 |
| Zabel, M | 1 |
| Majewski, A | 1 |
| Kołodziej, J | 1 |
| Funahashi, Y | 1 |
| Koyanagi, N | 1 |
| Sonoda, J | 1 |
| Kitoh, K | 1 |
| Hoshino, K | 1 |
| Ikeda, H | 1 |
| Gogna, NK | 1 |
| Bryant, GP | 1 |
| Armstrong, J | 1 |
| Kelly, W | 1 |
| Walpole, E | 1 |
| Morton, K | 1 |
| Nakayama, S | 2 |
| Ohta, D | 1 |
| Howell, JD | 1 |
| Warren, HW | 1 |
| Anderson, JH | 1 |
| Kerr, DJ | 1 |
| McArdle, CS | 1 |
| Chang, WJ | 1 |
| Tsao, TC | 1 |
| Faivre, C | 1 |
| Lusinchi, A | 1 |
| Eschwege, F | 1 |
| Abe, A | 1 |
| Inada, K | 1 |
| Tsukamoto, T | 1 |
| Yasui, K | 1 |
| Tatematsu, M | 1 |
| Danikas, D | 1 |
| Theodorou, SJ | 1 |
| Arvanitis, ML | 1 |
| Zinterhofer, LM | 1 |
| Rienzo, AA | 1 |
| Ohsawa, H | 1 |
| Mizunuma, N | 1 |
| Horikoshi, N | 2 |
| Sakae, K | 1 |
| Hiraki, Y | 1 |
| Kawahara, S | 1 |
| Eguchi, K | 2 |
| Harada, M | 1 |
| Barroso, A | 1 |
| Nogueira, R | 1 |
| Lencastre, H | 1 |
| Seada, J | 1 |
| Parente, B | 1 |
| Ohtomo, M | 1 |
| Ishikawa, H | 1 |
| Kamma, H | 1 |
| Chen, V | 1 |
| Shih, C | 1 |
| Forler, PA | 1 |
| Phares, VG | 1 |
| Amsrud, T | 1 |
| Anku, V | 1 |
| Novellino, PS | 1 |
| Trejo, YG | 1 |
| Beviacqua, M | 1 |
| Bordenave, RH | 1 |
| Rumi, LS | 1 |
| Browder, T | 1 |
| Butterfield, CE | 1 |
| Kräling, BM | 1 |
| Shi, B | 1 |
| Marshall, B | 1 |
| O'Reilly, MS | 1 |
| Folkman, J | 1 |
| Osaki, S | 1 |
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Pei, XH | 1 |
| Ueno, H | 1 |
| Hara, N | 1 |
| Bini, A | 1 |
| Zompatori, M | 1 |
| Ansaloni, L | 1 |
| Grazia, M | 1 |
| Stella, F | 1 |
| Bazzocchi, R | 1 |
| Maebeya, S | 1 |
| Bessho, T | 1 |
| Arimoto, J | 1 |
| Matsuyama, K | 1 |
| Naito, Y | 1 |
| Suzuma, T | 1 |
| Casal, R | 1 |
| Rosenfeld, M | 1 |
| Walker, PR | 1 |
| Huang, CL | 1 |
| Kobayashi, S | 2 |
| Hitomi, S | 1 |
| Song, S | 1 |
| Wientjes, MG | 1 |
| Gan, Y | 1 |
| Au, JL | 1 |
| Ishii, M | 1 |
| Iwahana, M | 1 |
| Mitsui, I | 1 |
| Minami, M | 2 |
| Imagawa, S | 1 |
| Tohgo, A | 1 |
| Ejima, A | 1 |
| Dai, A | 1 |
| Kucuk, O | 1 |
| Shevrin, DH | 1 |
| Pandya, KJ | 2 |
| Bonomi, PD | 2 |
| Backus, HH | 1 |
| Wouters, D | 1 |
| Padrón, JM | 1 |
| Molders, N | 1 |
| van Groeningen, CJ | 1 |
| Jansen, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Tsukuda, M | 1 |
| Brienza, S | 1 |
| Pugliese, P | 1 |
| Aschelter, AM | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Nisticò, C | 1 |
| Giunta, S | 1 |
| Caterino, M | 1 |
| Giannarelli, D | 1 |
| Cosimelli, M | 1 |
| Terzoli, E | 1 |
| Schmidinger, M | 1 |
| Budinsky, AC | 1 |
| Wenzel, C | 1 |
| Piribauer, M | 1 |
| Brix, R | 1 |
| Kautzky, M | 1 |
| Oder, W | 1 |
| Locker, GJ | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Eifel, PJ | 1 |
| Pan, CC | 1 |
| Chiang, H | 1 |
| Chang, YH | 1 |
| Epstein, JI | 1 |
| Akaza, H | 1 |
| Isonishi, S | 1 |
| Ogawa, O | 2 |
| Shibuya, M | 2 |
| Sone, S | 1 |
| Hinotsu, S | 1 |
| Kono, S | 1 |
| Mikami, O | 1 |
| Blackledge, G | 1 |
| Vose, B | 1 |
| Stribling, D | 1 |
| Ooi, GC | 1 |
| Tsang, KW | 1 |
| Takao, T | 2 |
| Nisida, M | 1 |
| Tamesa, T | 2 |
| Oka, M | 2 |
| Nishida, M | 1 |
| Shirasawa, H | 1 |
| Lewis, NL | 1 |
| Iwamoto, M | 1 |
| Niiya, F | 1 |
| Ikeda, S | 1 |
| Nagata, S | 1 |
| Odou, E | 1 |
| Hayabuchi, N | 1 |
| Maruyama, S | 1 |
| Okumoto, T | 1 |
| Kawasaki, K | 1 |
| Ino, H | 1 |
| Kanaya, Y | 1 |
| Otani, J | 1 |
| Soda, M | 1 |
| Behr, TM | 1 |
| Memtsoudis, S | 1 |
| Sharkey, RM | 1 |
| Gratz, S | 1 |
| Becker, W | 1 |
| Doddoli, C | 1 |
| Thomas, P | 1 |
| Reynaud-Gaubert, M | 1 |
| Giudicelli, R | 1 |
| Papazian, L | 1 |
| Fuentes, P | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Scieszka, M | 1 |
| Zielinski, M | 1 |
| Machalski, M | 1 |
| Herman, ZS | 1 |
| Müller, H | 1 |
| Guadagni, S | 1 |
| Sekikawa, T | 1 |
| Tsukui, H | 1 |
| Kina, S | 1 |
| Kawahara, T | 1 |
| Kishida, Y | 1 |
| Yakumaru, K | 1 |
| Kagami, H | 1 |
| Zori Comba, A | 1 |
| Blajman, C | 1 |
| Richardet, E | 1 |
| Bella, S | 1 |
| Vilanova, M | 1 |
| Cóppola, F | 1 |
| Van Kooten, M | 1 |
| Rodger, J | 1 |
| Giglio, R | 1 |
| Balbiani, L | 1 |
| Perazzo, F | 1 |
| Montiel, M | 1 |
| Chacón, M | 1 |
| Pujol, F | 1 |
| Mickiewicz, E | 1 |
| Cazap, E | 1 |
| Recondo, G | 1 |
| Lastiri, F | 1 |
| Simon, J | 1 |
| Wasserman, E | 1 |
| Schmilovich, A | 1 |
| Maindrault-Goebel, F | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Izrael, V | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Yang, SH | 1 |
| Wang, HS | 1 |
| Nozoe, Y | 1 |
| Sasatomi, T | 1 |
| Miyagi, Y | 1 |
| Matono, K | 1 |
| Szatkowska, L | 1 |
| Mazurkiewicz, M | 1 |
| Brzozowska, A | 1 |
| Sekikawa, K | 1 |
| Anzai, K | 2 |
| Momma, T | 1 |
| Ando, Y | 1 |
| Sassa, M | 1 |
| Endo, Y | 1 |
| Inoue, N | 1 |
| Kimijima, I | 1 |
| Takenoshita, S | 1 |
| Baz, DV | 1 |
| Bofill, JS | 1 |
| Nogueira, JA | 1 |
| Sarela, AI | 1 |
| Guthrie, JA | 1 |
| Seymour, MT | 1 |
| Ride, E | 1 |
| Guillou, PJ | 1 |
| O'Riordain, DS | 1 |
| Zhan, M | 1 |
| Yokouchi, H | 1 |
| Takami, K | 1 |
| Minamigawa, K | 1 |
| Takano, T | 1 |
| Granberg, D | 1 |
| Eriksson, B | 1 |
| Wilander, E | 1 |
| Grimfjärd, P | 1 |
| Fjällskog, ML | 1 |
| Oberg, K | 1 |
| Skogseid, B | 1 |
| Franzke, A | 1 |
| Buer, J | 1 |
| Probst-Kepper, M | 1 |
| Lindig, C | 1 |
| Framzle, M | 1 |
| Schrader, AJ | 1 |
| Ganser, A | 1 |
| Qiao, T | 1 |
| Xin, L | 1 |
| Liu, H | 1 |
| Baptiste, N | 1 |
| Friedlander, P | 1 |
| Prives, C | 1 |
| Ryu, JS | 1 |
| Choi, NC | 2 |
| Fischman, AJ | 1 |
| Wein, A | 1 |
| Riedel, C | 1 |
| Köckerling, F | 1 |
| Martus, P | 1 |
| Baum, U | 1 |
| Brueckl, WM | 1 |
| Reck, T | 1 |
| Ott, R | 1 |
| Hänsler, J | 1 |
| Bernatik, T | 1 |
| Becker, D | 1 |
| Hohenberger, W | 1 |
| Hahn, EG | 1 |
| Auerbach, M | 1 |
| Elias, EG | 4 |
| Orford, J | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Corsi, DC | 1 |
| Ciaparrone, M | 1 |
| Zannoni, G | 1 |
| Cassano, A | 2 |
| Specchia, M | 1 |
| Pozzo, C | 1 |
| Martini, M | 1 |
| Barone, C | 2 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Tomlinson, SK | 1 |
| Melin, SA | 1 |
| Higgs, V | 1 |
| White, DR | 1 |
| Savage, P | 1 |
| Case, D | 1 |
| Blackstock, AW | 1 |
| Benchalal, M | 1 |
| Yahchouchy-Chouillard, E | 1 |
| Fouere, S | 1 |
| Fingerhut, A | 1 |
| Matumoto, A | 1 |
| Asano, A | 1 |
| Emoto, T | 1 |
| Yoshikawa, K | 2 |
| Fujikawa, M | 1 |
| Hamada, E | 1 |
| Naka, Y | 1 |
| Komaki, T | 1 |
| Yamazaki, S | 1 |
| Morita, T | 1 |
| Endo, H | 1 |
| Baba, M | 1 |
| Joichi, Y | 1 |
| Kaneko, S | 1 |
| Okuyama, T | 1 |
| Nishino, H | 1 |
| Tokue, A | 1 |
| Ferrari, L | 1 |
| Procopio, G | 1 |
| Catena, L | 1 |
| Ferrario, E | 1 |
| Martinetti, A | 1 |
| Celio, L | 1 |
| Vitali, M | 1 |
| Beretta, E | 1 |
| Seregni, E | 1 |
| Bombardieri, E | 1 |
| Holoye, PY | 3 |
| Umezawa, I | 1 |
| Komiyama, K | 1 |
| Kawakubo, Y | 1 |
| Nishiyama, Y | 1 |
| Lichinitser, MR | 2 |
| Chebotareva, LI | 1 |
| Lanzotti, VJ | 2 |
| Thomas, DR | 1 |
| Boyle, LE | 1 |
| Smith, TL | 1 |
| Enck, RE | 1 |
| Golbey, RB | 1 |
| Mattern, J | 2 |
| Hinderer, H | 1 |
| Wayss, K | 2 |
| Volm, M | 2 |
| Schabel, FM | 1 |
| Tsukeda, H | 1 |
| Mizuno, S | 1 |
| Nitta, K | 1 |
| Holton, CP | 1 |
| Burrington, JD | 1 |
| Hatch, EI | 1 |
| Oberfield, RA | 1 |
| Karrer, K | 3 |
| Pridun, N | 3 |
| Denck, H | 1 |
| Nüvemann, M | 1 |
| Fernholz, HJ | 1 |
| Frik, W | 1 |
| Bernath, AM | 1 |
| Ihde, DC | 1 |
| Matthews, MJ | 1 |
| Minna, JD | 1 |
| Kas'yanenko, IV | 1 |
| Seligman, M | 1 |
| Bukowski, RM | 1 |
| Groppe, CW | 1 |
| Hewlett, JS | 1 |
| Greenstreet, RL | 1 |
| Reynolds, RD | 1 |
| O'Dell, S | 1 |
| Issell, BF | 1 |
| Valdivieso, M | 4 |
| Bodey, GP | 3 |
| Hobara, N | 1 |
| Nagashima, H | 1 |
| Kennedy, PS | 1 |
| Deas, BW | 1 |
| Rozencweig, M | 1 |
| Louie, AC | 1 |
| Muggia, FM | 2 |
| Jamieson, GG | 1 |
| Angove, RC | 1 |
| Thomas, G | 2 |
| Stewart-Jones, J | 1 |
| Sawai, K | 1 |
| Sonoda, Y | 1 |
| Ohkuma, S | 1 |
| Misawa, S | 1 |
| Balmukhanov, SB | 1 |
| Brugarolas, A | 2 |
| Lacave, AJ | 1 |
| Ribas, A | 1 |
| Buesa, JM | 1 |
| Garcia Miralles, MT | 1 |
| Luporini, G | 1 |
| Mangiarotti, F | 1 |
| Fraschini, P | 1 |
| Tassi, GC | 1 |
| De Barbieri, A | 1 |
| Butler, TP | 1 |
| MacDonald, JS | 1 |
| Smith, FP | 2 |
| Smith, LF | 1 |
| Woolley, PV | 3 |
| Schein, PS | 3 |
| Chenal, C | 1 |
| Follezou, JY | 1 |
| Fauchon, F | 1 |
| Bedikian, AY | 1 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Burgess, MA | 1 |
| Abrams, DN | 1 |
| Knaus, EE | 1 |
| Wiebe, LI | 1 |
| Rohwedder, JJ | 1 |
| Sagastume, E | 1 |
| Machida, S | 1 |
| Kakuta, H | 1 |
| Takashima, K | 1 |
| Ishioka, T | 1 |
| Ishikawa, Y | 1 |
| Onadeko, BO | 1 |
| Garibjanian, BT | 1 |
| Johnson, RK | 1 |
| Kline, I | 2 |
| Vadlamudi, S | 1 |
| Gang, M | 1 |
| Venditti, JM | 1 |
| Goldin, A | 1 |
| Copeland, EM | 1 |
| MacFadyen, BV | 1 |
| Dudrick, SJ | 1 |
| Serrou, B | 1 |
| Dubois, JB | 1 |
| Zwintz, E | 2 |
| Hill, GJ | 3 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 3 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| Bearden, JD | 1 |
| Moon, TE | 1 |
| Costanzi, JJ | 1 |
| Saiki, JH | 1 |
| Balcerzak, SP | 1 |
| Rivkin, SE | 1 |
| Morrison, FS | 1 |
| Spigel, SC | 1 |
| Fugmann, RA | 1 |
| Anderson, JC | 1 |
| Stolfi, RL | 1 |
| Martin, DS | 1 |
| Matthiessen, W | 1 |
| Pochhammer, KF | 1 |
| Khan, SV | 1 |
| Lowitz, BB | 1 |
| Ruderman, AI | 2 |
| Kiseleva, VS | 1 |
| Nivinskaya, MM | 1 |
| Dar'yalova, SL | 1 |
| Cohen, P | 1 |
| Fenichel, RL | 1 |
| Gregory, FJ | 1 |
| Alburn, HE | 1 |
| Gallmeier, WM | 2 |
| Bruntsch, U | 2 |
| Schmidt, CG | 2 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Kas'ianenko, IV | 2 |
| Dar'ialova, SL | 1 |
| Slack, NH | 1 |
| Bross, ID | 2 |
| Rees, GJ | 1 |
| Bugaighis, A | 1 |
| Shukla, SK | 1 |
| Mink, IB | 1 |
| Schimmel, DH | 1 |
| Julien, PJ | 1 |
| Gamsu, G | 1 |
| Newman, HK | 1 |
| Quan, SH | 1 |
| Carchman, RA | 1 |
| Harris, LS | 1 |
| Munson, AE | 1 |
| van Dyk, JJ | 2 |
| van der Merwe, AM | 2 |
| Falkson, HC | 2 |
| Gottlieb, JA | 2 |
| Freireich, EJ | 1 |
| Chabner, BA | 2 |
| Friedman, MA | 1 |
| Chapelier, A | 1 |
| Dartevelle, P | 1 |
| Sauvaget, J | 1 |
| Rosenthal, CJ | 1 |
| Brereton, HD | 2 |
| Ahlgren, JD | 3 |
| Lokich, JJ | 4 |
| Fryer, JG | 2 |
| Alt, DE | 1 |
| Giaccone, G | 1 |
| Beck, H | 1 |
| Capranico, G | 1 |
| Modeas, C | 3 |
| Propert, K | 1 |
| Goutsou, M | 2 |
| Green, MR | 4 |
| Sugimoto, Y | 2 |
| Ohe, Y | 3 |
| Ohmori, T | 2 |
| Morikage, T | 1 |
| Strauss, GM | 1 |
| Herndon, JE | 2 |
| Sherman, DD | 1 |
| Rege, VB | 1 |
| Clark, JR | 1 |
| Fallon, BG | 1 |
| Astone, A | 1 |
| Noviello, MR | 1 |
| Fontana, T | 1 |
| Grieco, A | 1 |
| Lyss, AP | 1 |
| Cooper, B | 1 |
| Perry, MC | 1 |
| Vinciguerra, V | 1 |
| Mason-Coughlin, K | 1 |
| Bolla, M | 2 |
| Nagy-Mignotte, H | 2 |
| Moro, D | 2 |
| Brambilla, C | 2 |
| Paramelle, B | 2 |
| Vincent, F | 2 |
| Kolodié, H | 2 |
| Vrousos, C | 2 |
| Asliaev, LA | 1 |
| Bilynskiĭ, BT | 1 |
| Geshelin, SA | 1 |
| Golotiuk, IA | 1 |
| Golotiuk, SI | 1 |
| Gritsiak, ES | 1 |
| Zhero, SV | 1 |
| Koĭfman, OG | 1 |
| Sidorik, EP | 1 |
| Laidman, PJ | 1 |
| Gebauer, K | 1 |
| Trotter, J | 1 |
| Fedeli, A | 1 |
| Luzi Fedeli, S | 1 |
| Catalano, G | 1 |
| Murphy, BR | 1 |
| Rynard, SM | 1 |
| Einhorn, LH | 2 |
| Loehrer, PJ | 2 |
| Sakamoto, O | 1 |
| Mori, H | 1 |
| Kitaichi, K | 1 |
| Koda, A | 1 |
| Robinet, G | 2 |
| Richard, P | 2 |
| Rouhart, F | 2 |
| Mocquard, Y | 2 |
| Goas, JY | 2 |
| Gouva, S | 2 |
| Clavier, J | 2 |
| Broder, LE | 1 |
| Sridhar, KS | 6 |
| Selawry, OS | 2 |
| Charyulu, KN | 1 |
| Rao, RK | 2 |
| Saldana, MJ | 4 |
| Lenz, C | 1 |
| Fischel, JL | 2 |
| Formento, P | 2 |
| Berlion, M | 2 |
| Berille, J | 2 |
| Gioanni, J | 2 |
| Bizzari, JP | 2 |
| Sella, A | 1 |
| Fitz, K | 1 |
| Dexeus, FH | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Wallace, S | 1 |
| Hilgenfeld, RU | 1 |
| Matthias, M | 1 |
| Hoksch, B | 1 |
| Boewer, C | 1 |
| Oldenkott, B | 1 |
| Knauf, WU | 1 |
| Boese-Landgraf, J | 1 |
| Schalhorn, A | 1 |
| Zeitz, M | 1 |
| Knuth, A | 1 |
| Bernhard, H | 1 |
| Klein, O | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Wong, SW | 1 |
| Içli, F | 1 |
| Günel, N | 1 |
| Dinçol, D | 1 |
| Karaoğuz, H | 1 |
| Demirkazik, A | 1 |
| Richards, F | 1 |
| Muchmore, E | 1 |
| Rege, V | 1 |
| Chahinian, AP | 1 |
| Hirsh, V | 1 |
| Poiesz, B | 1 |
| Crowley, J | 2 |
| Natale, RB | 1 |
| Hom, BL | 1 |
| Rivkin, S | 1 |
| Taylor, SA | 1 |
| Ichinose, I | 1 |
| Valone, FH | 1 |
| Gandara, DR | 1 |
| Deisseroth, AB | 1 |
| Perez, EA | 1 |
| Rayner, A | 1 |
| Aronson, FR | 1 |
| Luce, J | 1 |
| Paradise, C | 1 |
| Wang, SL | 1 |
| Zhang, CS | 1 |
| Peng, HQ | 1 |
| Wu, KH | 1 |
| Flaherty, L | 1 |
| Wozniak, A | 1 |
| Redman, B | 1 |
| Kraut, M | 1 |
| Martino, S | 1 |
| Heilbrun, L | 1 |
| Gullo, JJ | 1 |
| Phillips, JA | 1 |
| Heim, W | 1 |
| Scialla, SJ | 1 |
| LaLuna, F | 1 |
| Nevin, J | 1 |
| Alt, D | 1 |
| Oliveira, J | 1 |
| Kac, J | 1 |
| Walczak, J | 1 |
| Levy, MH | 1 |
| Padavic-Shaller, K | 1 |
| Hudes, GR | 1 |
| Comis, RL | 2 |
| Chariot, P | 1 |
| Panje, WR | 1 |
| Weichselbaum, RR | 2 |
| Moormeier, JA | 1 |
| Ratain, MJ | 1 |
| Egorin, MJ | 1 |
| Mick, R | 1 |
| Romero, JA | 1 |
| Alvarez-Vijande, R | 1 |
| Gil-Vernet, JM | 1 |
| Samsón, R | 1 |
| Fernández, I | 1 |
| Gutiérrez, R | 1 |
| Carretero, P | 1 |
| Yamauchi, N | 1 |
| Shiotani, T | 1 |
| Irino, S | 1 |
| Breneman, JC | 1 |
| Mitchell, SE | 1 |
| Hawley, DK | 1 |
| Aron, BS | 1 |
| Schroder, LE | 1 |
| Sasaki, H | 1 |
| Mori, T | 2 |
| Nakajima, S | 1 |
| Honda, R | 1 |
| Wheeler, CA | 1 |
| Ervin, T | 1 |
| Come, SE | 1 |
| Schnipper, LE | 1 |
| Bonomi, P | 7 |
| Gale, M | 1 |
| Rowland, K | 4 |
| Purl, S | 1 |
| Reddy, S | 8 |
| Lee, MS | 7 |
| Phillips, A | 1 |
| Kittle, CF | 5 |
| Warren, W | 5 |
| Higano, CS | 1 |
| Goodwin, JW | 1 |
| Barlogie, B | 1 |
| Stuckey, WJ | 1 |
| Srimuninnimit, V | 1 |
| Ardalan, B | 1 |
| Benedetto, P | 3 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Ito, H | 3 |
| Amano, H | 1 |
| Zirvi, KA | 1 |
| Atabek, U | 1 |
| Hansen, LA | 1 |
| Hughes, TE | 1 |
| Inaba, M | 1 |
| Lower, EE | 1 |
| Baughman, RP | 1 |
| Matsui, K | 1 |
| Masuda, N | 1 |
| Kusunoki, Y | 1 |
| Negoro, S | 1 |
| Ryu, S | 1 |
| Sakai, N | 1 |
| Takifuji, S | 1 |
| Degner, RA | 1 |
| Kerley, SW | 1 |
| McGregor, DH | 1 |
| Dixon, AY | 1 |
| Brugieres, L | 1 |
| Gicquel, C | 1 |
| Travagli, JP | 1 |
| Parmentier, C | 1 |
| Koizumi, J | 1 |
| Uchida, K | 1 |
| Shiraishi, H | 1 |
| Hori, M | 1 |
| Bouillet, T | 1 |
| Lepage, E | 1 |
| Gisselbrecht, C | 2 |
| Boiron, M | 1 |
| Moriguchi, S | 1 |
| Emi, Y | 1 |
| Tsujitani, S | 1 |
| Vijayakumar, S | 1 |
| Krishnasamy, S | 1 |
| Jacobs, R | 1 |
| Allegra, C | 1 |
| Dunphy, FR | 1 |
| Spitzer, G | 2 |
| Recine, D | 1 |
| Taylor, S | 2 |
| Hendrickson, FR | 2 |
| Kojima, A | 1 |
| Oshita, F | 1 |
| Miya, T | 1 |
| Cavaliere, A | 1 |
| Alberti, PF | 1 |
| Vitali, R | 1 |
| Wierzbicki, R | 1 |
| Shepherd, FA | 2 |
| Rusthoven, J | 1 |
| Aitken, SE | 1 |
| Maroun, JA | 1 |
| Ezzat, A | 1 |
| Sueyama, H | 2 |
| Peter, R | 1 |
| Oleksowicz, L | 1 |
| Morris, JC | 1 |
| Phelps, RG | 1 |
| Bruckner, HW | 3 |
| Skotinkova, OI | 1 |
| Sergeeva, NS | 1 |
| Moroz, IA | 1 |
| Sviridova, IK | 1 |
| Pelevina, II | 1 |
| Meshcheriakova, NG | 1 |
| Melent'eva, EG | 1 |
| Al'tshuler, IuB | 1 |
| Takamizawa, Y | 1 |
| Inaba, N | 1 |
| Wright, JC | 1 |
| Kato, N | 1 |
| Komuro, T | 1 |
| Cao, YF | 1 |
| Liao, ML | 1 |
| Fang, MS | 1 |
| Yang, XF | 1 |
| Wu, SZ | 1 |
| Chen, YR | 1 |
| Wu, SF | 1 |
| Huang, OL | 1 |
| Wu, SC | 1 |
| Cai, SM | 1 |
| Wang, RY | 1 |
| Ding, YQ | 1 |
| Klausner, JM | 1 |
| Gutman, M | 1 |
| Rozin, RR | 1 |
| Lelcuk, S | 1 |
| Chaitchik, S | 1 |
| Inbar, M | 1 |
| Varki, J | 1 |
| Donnelly, E | 2 |
| Davila, E | 2 |
| Hilsenbeck, S | 1 |
| Thurer, RJ | 2 |
| Fountzilas, G | 2 |
| Inoue, F | 1 |
| Takeda, I | 1 |
| Miyake, M | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Birsic, W | 1 |
| D'Oro, L | 1 |
| Charoensiri, S | 1 |
| Lele, SB | 1 |
| Piver, MS | 1 |
| Kelly, SA | 1 |
| MacLeod, PM | 1 |
| Ash, DV | 1 |
| Dembo, A | 1 |
| DePetrillo, A | 1 |
| Pringle, J | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Furusawa, M | 1 |
| Nakahara, K | 1 |
| Hashimoto, J | 1 |
| Mizuta, T | 1 |
| Akashi, A | 1 |
| Kawashima, Y | 1 |
| Araki, E | 1 |
| Kanda, Y | 1 |
| Futatsugi, K | 1 |
| Fujiki, T | 1 |
| Saifuku, K | 1 |
| Suzuki, F | 1 |
| Naoi, Y | 1 |
| Muraoka, M | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Kawano, K | 1 |
| Tada, I | 1 |
| Mitarai, Y | 1 |
| Kim, YI | 1 |
| Wuyam, B | 1 |
| Blanc-Jouvan, F | 1 |
| Weir, AB | 1 |
| Niell, HB | 1 |
| Griffin, JP | 1 |
| Rivière, A | 1 |
| Abouz, D | 1 |
| Ayela, P | 1 |
| Berthaud, P | 1 |
| Frenay, M | 1 |
| Lagrange, JL | 1 |
| Pujol, JL | 1 |
| Robillard, J | 1 |
| Urata, A | 1 |
| Apple, JS | 1 |
| Paulson, DF | 1 |
| Baber, C | 1 |
| Putman, CE | 1 |
| Blaauw, AA | 1 |
| Baker, FL | 1 |
| Tomasovic, B | 1 |
| Umbach, G | 1 |
| Thielvoldt, D | 1 |
| Zander, AR | 1 |
| Dicke, KA | 1 |
| Mickey, DD | 1 |
| Carvalho, L | 1 |
| Foulkes, K | 1 |
| Wang, QL | 2 |
| Benasso, M | 1 |
| Ferro, A | 1 |
| Bacigalupo, A | 1 |
| Toma, S | 1 |
| Vitriolo, S | 1 |
| Rosso, R | 2 |
| Merlano, M | 1 |
| Katsumi, T | 1 |
| Murayama, K | 1 |
| Rak, J | 1 |
| Kuśnierczyk, H | 1 |
| Strzadała, L | 1 |
| Kłosiewicz, S | 1 |
| Radzikowski, C | 1 |
| Mukaiyama, T | 1 |
| Kuraishi, Y | 1 |
| Zakharchenkov, AV | 2 |
| Zhiglov, MA | 2 |
| Glagolev, AN | 2 |
| Korolev, BN | 1 |
| Petrelli, N | 1 |
| Douglass, HO | 1 |
| Herrera, L | 1 |
| Russell, D | 1 |
| Mayer, RJ | 1 |
| Schinella, R | 1 |
| Green, MD | 1 |
| Martoni, A | 1 |
| Cricca, A | 1 |
| Guaraldi, M | 1 |
| Pannuti, F | 1 |
| Schuster, D | 1 |
| Flechtner, H | 1 |
| Worst, P | 1 |
| Komeda, H | 1 |
| Takahashi, Y | 1 |
| Yamada, S | 1 |
| Kuriyama, M | 1 |
| Kawada, Y | 1 |
| Cao, SS | 1 |
| Saiga, T | 1 |
| Kashu, I | 1 |
| Tabuchi, K | 1 |
| Midorikawa, O | 1 |
| McElhinney, RS | 3 |
| McCormick, JE | 3 |
| Bibby, MC | 3 |
| Double, JA | 3 |
| Atassi, G | 3 |
| Pratesi, G | 3 |
| Radacic, M | 3 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Tremblay, C | 1 |
| Spielman, M | 1 |
| Rouesse, J | 1 |
| Sevin, D | 1 |
| Bohno, K | 1 |
| Ushijima, T | 1 |
| Fukushima, K | 1 |
| Zeng, WY | 1 |
| Liu, YY | 1 |
| Higashi, H | 1 |
| Takenaka, K | 1 |
| Kanematsu, T | 1 |
| Matsumata, T | 1 |
| Dhingra, HM | 1 |
| Chiuten, DF | 1 |
| Jeffries, D | 1 |
| Murphy, WK | 1 |
| Umsawasdi, T | 1 |
| Neidhart, JA | 1 |
| Murthy, AK | 1 |
| Rowland, KM | 1 |
| Pincus, M | 2 |
| Gordon, W | 1 |
| Stansberry, PK | 1 |
| Weiss, GB | 2 |
| Thurer, R | 1 |
| Kim, Y | 1 |
| Charyulu, KK | 1 |
| Thompson, T | 1 |
| Mira, JG | 1 |
| Taylor, SL | 1 |
| Stephens, RL | 2 |
| Hesketh, PJ | 1 |
| Cooley, TP | 1 |
| Finkel, HE | 1 |
| Wright, J | 1 |
| Hesketh, AM | 1 |
| Ishino, Y | 1 |
| Terashima, H | 1 |
| Nakata, H | 1 |
| Yoshimatsu, H | 1 |
| Sanefuji, H | 1 |
| Dionet, C | 1 |
| Roux, D | 1 |
| Fraysse, P | 1 |
| Achard, JL | 1 |
| Beaupain, R | 1 |
| Rozan, R | 1 |
| Cowled, PA | 1 |
| Mackenzie, L | 1 |
| Forbes, IJ | 1 |
| Boothman, DA | 1 |
| Briggle, TV | 1 |
| Fukuda, H | 1 |
| Fujimoto, K | 1 |
| Kimoto, H | 1 |
| Tsunamura, Y | 1 |
| Ichihashi, T | 1 |
| Shimizu, J | 1 |
| Hashizume, Y | 1 |
| Schreml, W | 1 |
| Lohrmann, HP | 1 |
| Anger, B | 1 |
| Kikuchi, K | 1 |
| Jin, XJ | 1 |
| Petursson, SR | 1 |
| Chen, TT | 1 |
| O'Bryan, RM | 1 |
| Vance, RB | 1 |
| Trybula, M | 1 |
| Maffey, SC | 1 |
| Jensik, RJ | 1 |
| Axelson, JA | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 1 |
| Inoue, S | 1 |
| Yamanaka, A | 1 |
| Baraniewski, HM | 1 |
| Shaw, MT | 1 |
| Shaw, MK | 1 |
| La Ciura, P | 1 |
| La Grotta, G | 1 |
| Nigra, E | 1 |
| Comandone, A | 1 |
| Grecchi, G | 1 |
| Leria, G | 1 |
| Calciati, A | 1 |
| Crown, J | 1 |
| McKenna, A | 1 |
| Hart, R | 1 |
| Tapazoglou, E | 2 |
| Polin, L | 1 |
| Corbett, TH | 1 |
| al-Sarraf, M | 4 |
| Cohen, AM | 1 |
| Schaeffer, N | 1 |
| Higgins, J | 1 |
| Chang, AY | 1 |
| Qazi, R | 1 |
| Rubins, J | 1 |
| Asbury, R | 1 |
| Oiwa, T | 1 |
| Saito, H | 1 |
| Aota, M | 1 |
| Jinno, K | 1 |
| Daitoh, N | 1 |
| Kimoto, M | 2 |
| Sano, K | 2 |
| Anai, H | 1 |
| Kusumoto, H | 1 |
| Masuda, H | 1 |
| So, SY | 2 |
| Kung, TM | 1 |
| Sham, MK | 1 |
| Ip, M | 2 |
| Kurihara, M | 1 |
| Nakao, I | 2 |
| Komatsumoto, M | 1 |
| Hamada, J | 1 |
| Takeichi, N | 1 |
| Tanabe, T | 1 |
| Ogawa, J | 1 |
| Koide, S | 1 |
| Kawada, S | 1 |
| Shohtsu, A | 1 |
| Wang, ZT | 1 |
| Aoyama, A | 1 |
| Shimabukuro, Z | 1 |
| Ootsuka, M | 1 |
| Rustum, YM | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Barreras, L | 1 |
| Manten, H | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Shimizu, N | 1 |
| Murakami, A | 1 |
| Sawata, T | 1 |
| Shimizu, T | 1 |
| Kovalev, VN | 1 |
| Amiraliev, MA | 1 |
| Barchuk, AS | 1 |
| Malay, EF | 1 |
| Vidyak, IV | 1 |
| Grigoryeva, SP | 1 |
| Cazap, EL | 1 |
| Estevez, RA | 1 |
| Alvarez, CA | 1 |
| Lagarde, C | 1 |
| Hannois, A | 1 |
| Ahmed, S | 1 |
| Satou, H | 1 |
| Kamano, T | 1 |
| Izumi, T | 1 |
| Borisov, VI | 1 |
| Vorob'ev, AN | 1 |
| Stsetsevich, NV | 1 |
| Ass, NIa | 1 |
| Kawamura, E | 1 |
| Kurihara, H | 1 |
| Ishibiki, K | 1 |
| Abe, O | 1 |
| Takao, A | 1 |
| Okamoto, M | 1 |
| Garewal, H | 1 |
| Ahmann, FR | 1 |
| Shimura, K | 1 |
| Yoshimura, N | 1 |
| Taniguchi, T | 1 |
| Nakagawa, T | 1 |
| Burkes, R | 1 |
| Paul, K | 1 |
| DeBoer, G | 1 |
| Niwayama, S | 1 |
| Masuyama, K | 1 |
| Gritsaĭ, AA | 1 |
| Vyshinskaia, GV | 1 |
| Kondrat'eva, AP | 1 |
| Aplevich, NN | 1 |
| Morrow, M | 1 |
| Wait, RB | 1 |
| Rosenthal, RA | 1 |
| Gamelli, RL | 1 |
| Gribel', NV | 1 |
| Pashinskiĭ, VG | 1 |
| Krook, JE | 1 |
| Jett, JR | 1 |
| Fleming, TR | 1 |
| Dalton, RJ | 1 |
| Marschke, RF | 1 |
| Cullinan, SA | 1 |
| Windschitl, HE | 1 |
| Everson, LK | 1 |
| Brunk, FS | 1 |
| Laurie, JA | 1 |
| Lebeau, B | 1 |
| Brechot, JM | 1 |
| Ameille, J | 1 |
| de Fenoyl, O | 1 |
| Rochemaure, J | 1 |
| Swierz, J | 1 |
| Patchell, RA | 1 |
| Posner, JB | 1 |
| Aogauchi, R | 1 |
| Tsubota, N | 1 |
| Yamashita, C | 1 |
| Ishii, N | 1 |
| Yu, DY | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Kish, J | 1 |
| Ensley, J | 1 |
| Thurm, K | 1 |
| Wood, CD | 1 |
| Slevin, ML | 1 |
| Ponder, BA | 1 |
| Wrigley, PF | 1 |
| Panasci, L | 1 |
| Ford, J | 1 |
| Margolese, R | 1 |
| Dasmahapatra, KS | 1 |
| Citrin, P | 1 |
| Yee, R | 1 |
| Mohit-Tabatabai, MA | 1 |
| Rush, BF | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Pennington, K | 1 |
| Nobile, MT | 1 |
| Sertoli, MR | 1 |
| Bruzzone, M | 1 |
| Tagarelli, G | 1 |
| Rubagotti, A | 1 |
| Gokhale, SV | 1 |
| Ganu, UK | 1 |
| Ambaye, RY | 1 |
| Einstein, AB | 1 |
| Rudolph, RH | 1 |
| Massey, WH | 1 |
| Judkins, MP | 1 |
| Dennis, DL | 1 |
| Nitter, L | 1 |
| Depierre, A | 1 |
| Le Bourgeois, J | 1 |
| Oara, H | 1 |
| Gary-Bobo, J | 1 |
| Knock, FE | 3 |
| Galt, RM | 3 |
| Oester, YT | 3 |
| Sylvester, R | 2 |
| Sievers, DB | 1 |
| Donovan, AJ | 1 |
| Bonadonna, G | 1 |
| Tancini, G | 1 |
| Sekizuka, H | 1 |
| Haki, K | 1 |
| Iwasa, H | 1 |
| Dayal, Y | 1 |
| Binder, S | 1 |
| Nathanson, L | 2 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Wüst, GP | 1 |
| Perevodchikova, NI | 1 |
| Pirogov, AI | 2 |
| Maksimov, IA | 1 |
| Os'makov, NA | 1 |
| Smith, FE | 1 |
| Hudgins, PT | 1 |
| Tashima, CK | 1 |
| Kühböck, J | 1 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Earle, E | 1 |
| Butts, D | 1 |
| Hoaglin, LL | 1 |
| Ramirez, G | 1 |
| Komatsu, K | 1 |
| Hiratsuka, H | 1 |
| Kamisasa, A | 1 |
| Sandison, AG | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Faulkner, SL | 1 |
| Adkins, RB | 1 |
| Reynolds, VH | 1 |
| Carbone, PP | 1 |
| Glenn, EH | 1 |
| Cole, D | 1 |
| Wunderlich, HO | 1 |
| Cichy, A | 1 |
| Klvana, M | 1 |
| Carr, DT | 1 |
| Childs, DS | 1 |
| Lee, RE | 1 |
| Widow, W | 1 |
| Larsen, RR | 1 |
| Humphrey, LJ | 1 |
| Jewell, WR | 1 |
| Montminy, L | 1 |
| Cerruti, FR | 1 |
| Chernomordikova, MF | 3 |
| Lapsa, RKh | 1 |
| Skarin, AT | 1 |
| Inoguchi, T | 1 |
| Sasatomi, N | 1 |
| Kumaoka, S | 1 |
| Kuwano, K | 1 |
| Takeda, H | 1 |
| Valenti, S | 2 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Kasianenko, IV | 1 |
| Ierusalimskii, EL | 1 |
| Omelchenko, AT | 1 |
| Perlia, CP | 1 |
| Dana, M | 1 |
| Ishida, M | 3 |
| Morota, N | 1 |
| Asakura, H | 1 |
| Ellert, J | 1 |
| Chauvin, HF | 1 |
| Canellos, GP | 1 |
| Devita, VT | 1 |
| Gold, GL | 1 |
| Young, RC | 1 |
| Osieka, R | 1 |
| Castor, H | 1 |
| Fritsch, H | 1 |
| Drings, P | 1 |
| Moskwa, G | 1 |
| von Kaick, G | 1 |
| Smolianskaia, AZ | 1 |
| Schilling, A | 1 |
| Miller, S | 1 |
| Moore, GE | 1 |
| Ausmans, R | 1 |
| Nadler, S | 1 |
| Jones, R | 1 |
| Slack, N | 1 |
| Rimm, AA | 1 |
| Anderson, JM | 2 |
| Hutchison, J | 2 |
| Haller, JD | 1 |
| Bron, KM | 1 |
| Wholey, MH | 1 |
| Poller, S | 1 |
| Enerson, DM | 1 |
| Olson, K | 1 |
| Mannes, P | 1 |
| Derriks, R | 1 |
| Moens, R | 1 |
| Heynen, E | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Levy, A | 1 |
| Clément, F | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| Melikidze, GN | 1 |
| Denisov, LE | 1 |
| Ahmann, DL | 1 |
| Cohen, Y | 1 |
| Lichtig, C | 1 |
| Robinson, E | 1 |
| O'Brien, PH | 1 |
| Artz, CP | 1 |
| Vaughn, CB | 1 |
| Reed, ML | 1 |
| Vaitkevicious, VK | 1 |
| Pavlov, AS | 1 |
| Volkova, MA | 1 |
| Zuev, VI | 1 |
| Wolberg, WH | 1 |
| Furukawa, K | 1 |
| Kanko, T | 1 |
| Harashima, S | 1 |
| Gordan, GS | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Tsoĭ, AI | 1 |
| Dement'eva, NI | 1 |
| Sulaeva, LS | 1 |
| Jacobs, EM | 2 |
| Reeves, WJ | 1 |
| Wood, DA | 2 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| Bateman, JR | 1 |
| Oka, S | 3 |
| Lawton, RL | 1 |
| Gulesserian, HP | 1 |
| Lahiri, SR | 1 |
| Boileau, G | 1 |
| Wilson, RE | 1 |
| Piro, AJ | 1 |
| Aliapoulios, MA | 1 |
| Moore, FD | 1 |
| Cohen, JL | 1 |
| Matias, PI | 1 |
| Baxter, D | 1 |
| Brambilla, G | 1 |
| Caraceni, CE | 1 |
| Cavanna, M | 1 |
| Parodi, S | 1 |
| Ohno, T | 1 |
| Harrison, LH | 1 |
| Cox, CE | 1 |
| Banks, KW | 1 |
| Boyce, WH | 1 |
| Neyazaki, T | 1 |
| Seki, Y | 1 |
| Egawa, N | 1 |
| Mouriquand, J | 1 |
| Brun, J | 1 |
| Perrin-Fayolle, M | 1 |
| Pison, H | 1 |
| Kofman, J | 1 |
| Rall, DP | 1 |
| Nordman, E | 1 |
| Fazio, M | 1 |
| Minetto, E | 1 |
| Cavallero, P | 1 |
| Sartoris, S | 1 |
| Mariani, R | 1 |
| Bo de Stefanis, M | 1 |
| Wong, P | 1 |
| Sardesai, S | 1 |
| Vaitkevicius, VK | 1 |
| Mansfield, CM | 1 |
| Kramer, S | 1 |
| Southard, ME | 1 |
| Deemarsky, LY | 1 |
| Mitchell, MS | 1 |
| DeConti, RC | 1 |
| Serpick, AA | 1 |
| Dorigoni, A | 1 |
| Peris, GC | 1 |
| Scarponi, F | 1 |
| Alcozer, G | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Kanno, I | 1 |
| Saito, T | 1 |
| Genevrier, R | 1 |
| Gouletquer, J | 1 |
| Lemenager, J | 1 |
| Foubert, C | 1 |
| Neel, JP | 1 |
| Reboul, AR | 1 |
| Lewest, G | 1 |
| Morere, P | 1 |
| Chauvet, MC | 1 |
| Vaudour, P | 1 |
| Maisse, P | 1 |
| Stain, JP | 1 |
| Lenail, C | 1 |
| Nadler, SH | 1 |
| Bernard, E | 1 |
| Luce, JK | 1 |
| Shima, T | 1 |
| Fleming, JW | 1 |
| Shimkin, MB | 1 |
| McDonough, M | 1 |
| Baserga, R | 1 |
| Thatcher, D | 1 |
| Wieder, R | 1 |
| Martz, G | 1 |
| Danczkay, I | 1 |
| Traldi, A | 1 |
| Morini, A | 1 |
| Freckman, HA | 1 |
| Mendez, FL | 1 |
| Maurer, ER | 1 |
| Fry, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research[NCT05290961] | 30 participants (Anticipated) | Observational [Patient Registry] | 2022-03-09 | Recruiting | |||
| Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405] | Phase 3 | 350 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444] | Phase 2 | 240 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study[NCT02826486] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment[NCT05576545] | 73 participants (Actual) | Interventional | 2020-09-18 | Completed | |||
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT01896531] | Phase 2 | 153 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma[NCT01616849] | Phase 2 | 39 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer[NCT00484939] | Phase 3 | 280 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655] | Phase 3 | 15 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
| A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)[NCT00816868] | Phase 2 | 62 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920] | Phase 3 | 244 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer[NCT00100815] | Phase 2 | 50 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992[NCT01880515] | Phase 2 | 107 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2[NCT01542437] | Phase 2 | 66 participants (Actual) | Interventional | 2012-01-31 | Active, not recruiting | ||
| A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219] | Phase 2 | 36 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial[NCT03503136] | Phase 3 | 632 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients[NCT00201825] | Phase 2 | 29 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies[NCT00003867] | Phase 1 | 30 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy[NCT00379665] | Phase 2 | 25 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy[NCT04042298] | 106 participants (Anticipated) | Observational | 2019-06-25 | Recruiting | |||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| The Effect and Safety on Unresectable CRLM From RFA in Combination With Second-line Chemotherapy and Bevacizumab Compared With the Combination of Second-line Chemotherapy and Bevacizumab: a Randomized and Controlled Clinical Trial[NCT03686254] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2018-07-16 | Recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy[NCT00003032] | Phase 3 | 224 participants (Actual) | Interventional | 1997-04-25 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902] | Phase 1/Phase 2 | 110 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage[NCT01393769] | Phase 2 | 5 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease).) | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens[NCT02829008] | Phase 2 | 120 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Ipatasertib + mFOLFOX6 | 70 |
| Placebo + mFOLFOX6 | 80 |
Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumor | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 4.63 | 4.70 | 4.70 |
| Placebo + mFOLFOX6 | 5.85 | 5.98 | 6.80 |
Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 52.1 | 50.0 | 52.2 |
| Placebo + mFOLFOX6 | 57.3 | 73.3 | 56.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 11.96 | 14.82 | 11.66 |
| Placebo + mFOLFOX6 | 15.31 | 21.78 | 17.22 |
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years
| Intervention | months (Median) | |
|---|---|---|
| All Randomized Participants | Participants With PTEN Loss Tumors | |
| Ipatasertib + mFOLFOX6 | 6.57 | 7.10 |
| Placebo + mFOLFOX6 | 7.52 | 7.39 |
(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Day 1: 1 hour post-dose | Day 1: 4 hours post-dose | Day 5: pre-dose | Day 5: 2 hours post-dose | |
| Ipatasertib + mFOLFOX6 | 506 | 389 | 90.7 | 557 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Duration of follow-up is defined as the time in days from randomization until disease progression or death, or time to censoring for overall survival. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Days (Mean) |
|---|---|
| Bevacizumab + Capecitabine | 540.5 |
| Capecitabine | 479.2 |
Duration of response was defined as the time in months from the first confirmed complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.7 |
| Capecitabine | 9.4 |
Overall survival was defined as the time in months from randomization to death from any cause. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 20.7 |
| Capecitabine | 17.0 |
Reported is the percentage of participants requiring additional treatment for malignancy in the survival follow-up period. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Bevacizumab + Capecitabine | 50.7 |
| Capecitabine | 49.3 |
Progression-free survival was defined as the time in months from the date of randomization to the date of disease progression or death from any cause, whichever occurred first. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter (SLD). All other lesions were identified as non-TLs and recorded at baseline. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.1 |
| Capecitabine | 5.1 |
Time to response was defined as the time in months from the date of first study treatment to the date of the first documentation of complete response (CR) or partial response (PR), whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. Participants who did not have a confirmed response were censored at the date of the last evaluable tumor assessment, or if that was unavailable, at the date of the first dose of study medication. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | NA |
| Capecitabine | NA |
BOR was defined as the best response (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], not evaluable [NE], or not assessed [NA]) recorded from the start of study treatment until disease progression (PD) or death. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not assessed | |
| Bevacizumab + Capecitabine | 2.9 | 17.1 | 54.3 | 10.0 | 15.7 |
| Capecitabine | 1.4 | 8.6 | 48.6 | 21.4 | 20.0 |
The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all predisease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Reported is the percentage of participants in each of the 6 ECOG performance status categories. (NCT00484939)
Timeframe: Baseline to the Safety Follow-up which occurred 28 days after the last dose of treatment (up to 5 years 8 months).
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 7 ECOG = 0 (n=117,110) | Week 7 ECOG = 1 | Week 7 ECOG = 2 | Week 7 ECOG = 3 | Week 7 ECOG = 4 | Week 7 ECOG = 5 | Week 16 ECOG = 0 (n=88,77) | Week 16 ECOG = 1 | Week 16 ECOG = 2 | Week 16 ECOG = 3 | Week 16 ECOG = 4 | Week 16 ECOG = 5 | Week 25 ECOG = 0 (n=66,42) | Week 25 ECOG = 1 | Week 25 ECOG = 2 | Week 25 ECOG = 3 | Week 25 ECOG = 4 | Week 25 ECOG = 5 | Week 34 ECOG = 0 (n=48,24) | Week 34 ECOG = 1 | Week 34 ECOG = 2 | Week 34 ECOG = 3 | Week 34 ECOG = 4 | Week 34 ECOG = 5 | Safety Follow-up ECOG = 0 (n=89,82) | Safety Follow-up ECOG = 1 | Safety Follow-up ECOG = 2 | Safety Follow-up ECOG = 3 | Safety Follow-up ECOG = 4 | Safety Follow-up ECOG = 5 | |
| Bevacizumab + Capecitabine | 50.4 | 47.0 | 1.7 | 0.9 | 0.0 | 0.0 | 50.0 | 45.5 | 3.4 | 1.1 | 0.0 | 0.0 | 43.9 | 48.5 | 6.1 | 1.5 | 0.0 | 0.0 | 39.6 | 58.3 | 0.0 | 2.1 | 0.0 | 0.0 | 33.7 | 47.2 | 12.4 | 6.7 | 0.0 | 0.0 |
| Capecitabine | 34.5 | 58.2 | 5.5 | 1.8 | 0.0 | 0.0 | 36.4 | 51.9 | 11.7 | 0.0 | 0.0 | 0.0 | 45.2 | 45.2 | 9.5 | 0.0 | 0.0 | 0.0 | 33.3 | 58.3 | 8.3 | 0.0 | 0.0 | 0.0 | 32.9 | 45.1 | 14.6 | 4.9 | 1.2 | 1.2 |
Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 2 |
| Systemic Chemotherapy Alone | 0 |
Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1
| Intervention | ml (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 650 |
Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours
| Intervention | hours (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 10.1 |
Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks
| Intervention | Days (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 17 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 8 |
| Systemic Chemotherapy Alone | 5 |
CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1
| Intervention | Scores on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1
| Intervention | Stage (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 Before Surgery | Patient 1 After Surgery | Patient 2 Before Surgery | Patient 2 After Surgery | Patient 3 Before Surgery | Patient 3 After Surgery | Patient 4 Before Surgery | Patient 4 After Surgery | Patient 5 Before Surgery | Patient 5 After Surgery | Patient 6 Before Surgery | Patient 6 After Surgery | Patient 7 Before Surgery | Patient 7 After Surgery | Patient 8 Before Surgery | Paitent 8 After Surgery | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #4 | Patient #6 | Patient #7 | Patient #9 | Patient #11 | Patient #15 | |
| Surgery + HIPEC + Systemic Chemotherapy | 19 | 11 | 11 | 4 | 14 | 5 | 12 | 0 |
Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #3 | Patient #5 | Patient #8 | Patient #10 | Patient #12 | Patient #13 | Patient #14 | |
| Systemic Chemotherapy Alone | 17 | 6 | 10 | 0 | 0 | 8 | 0 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
Response was evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; Overall Response (OR) = CR + PR. (NCT00100815)
Timeframe: Pre-treatment and every 6 weeks from treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 22.0 |
(NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 9.8 |
Grade 3, 4 or 5 toxicity rate (NCT00100815)
Timeframe: Subjects were evaluated for adverse events at each study visit for the duration of their participation in the study, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 70 |
Quality of Life was assessed using EORTC QLQ-PAN26. All measures range in score from 1 to 4 as lower scores indicate better outcomes. The improved Quality of Life is defined as a greater than 5% decrease in 2 consecutive scores compared with the baseline score. (NCT00100815)
Timeframe: assessed at baseline then weekly for 3 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 56.0 |
Progressive Disease is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 5.7 |
Sum of participants who experienced any grade rash according to the Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0, from the initiation of BIBW2992 compared to week 8. (NCT01880515)
Timeframe: Percentage of adverse events at week 8
| Intervention | Percentage of Patients w/any grade rash (Number) |
|---|---|
| Tetracycline | 44.5 |
| No Tetracycline | 75.5 |
From the start of consumption of BIBW 2992 to the date progression or last follow up (NCT01880515)
Timeframe: Participants will be followed for the duration of the treatment, an average of 8 weeks.
| Intervention | months (Median) |
|---|---|
| Tetracycline | 8.1 |
| No Tetracycline | 12.3 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 31 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 55 |
Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 25.7 |
Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 9 |
(NCT00201825)
Timeframe: one year
| Intervention | months (Median) |
|---|---|
| Docetaxel and Capecitabine | 10.5 |
(NCT00201825)
Timeframe: Every 35 days
| Intervention | months (Median) |
|---|---|
| Docetaxel and Capecitabine | 3.3 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00201825)
Timeframe: Every 35 days
| Intervention | patients (Number) | ||||
|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Stable Disease | Disease Progression | Overall response (CR + PR) | |
| Docetaxel and Capecitabine | 0 | 5 | 14 | 9 | 5 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
62 reviews available for fluorouracil and Lung Neoplasms
| Article | Year |
|---|---|
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopen | 2022 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2021 |
Postmenopausal choriocarcinoma: a rare case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin, beta Subuni | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2018 |
Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.
Topics: Administration, Inhalation; Adsorption; Aerosols; Antibodies, Monoclonal, Humanized; Antineoplastic | 2013 |
[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2014 |
[A Case of Drug-Induced Thrombocytopenia Resulting from Sensitivity to Oxaliplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colon, Tran | 2015 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2011 |
[A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Lung Disease | 2011 |
[A brief overview of a lung cancer biomarker: thymidylate synthase].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 2011 |
A preclinical and clinical review of aflibercept for the management of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2012 |
[FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Topics: Adenoviridae; Aged; Anemia; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Carcinoma, N | 2012 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; F | 2002 |
[Current status of the neo-adjuvant and adjuvant therapy for the resectable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2003 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2003 |
Management of colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Balloon Occlusion; Catheter Ablation; Colorectal Neoplasms; Combine | 2003 |
[Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Liver Neoplasms; Lun | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluor | 2003 |
[Treatment for recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine | 2004 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
[Clinical trials of vnorelbine in breast cancer--its scientific usefulness and development history until regulatory approval].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2006 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circadi | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
The promise of biochemical modulation in combined modality therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1994 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
[Optimal administration of 5-FU and cisplatin based on biochemical modulation in the treatment of non-resectable non-small cell lung carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 1994 |
[Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; Dose-Re | 1994 |
Measuring quality of life: an emerging science.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1994 |
Non small cell lung cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophos | 1994 |
Malignant cystosarcoma phyllodes: an unusual presentation and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fat | 1993 |
Concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chicago; Cisplatin; | 1994 |
Surgical treatment of stage III lung cancer after chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Small Cell; Carcinom | 1994 |
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin | 1996 |
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1997 |
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1997 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Interferon use in solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
[Theoretical basis for low-dose CDDP/5-FU therapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1999 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2001 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Concurrent radiotherapy and chemotherapy for locally advanced non-small-cell cancer of the lung. Report of a clinical trial and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy | 1991 |
Altretamine.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1991 |
Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C | 1985 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Primary choriocarcinoma of the lung: report of a case treated with intensive multimodality therapy and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Combined Modality | 1989 |
[Current views of the treatment of non-microcellular carcinoma of the lungs].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyc | 1985 |
Neurologic complications of systemic cancer.
Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse | 1985 |
[Tumors].
Topics: Antigens; Bleomycin; Daunorubicin; Fetal Proteins; Fluorouracil; Glycolipids; Glycoproteins; Humans; | 1972 |
The role of chemotherapy in the treatment of lung cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinom | 1974 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
293 trials available for fluorouracil and Lung Neoplasms
| Article | Year |
|---|---|
Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prol | 2022 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2020 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2022 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2019 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 | 2019 |
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chem | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorou | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorou | 2015 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chem | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2015 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr | 2008 |
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Long-term survival following chemoradiation for inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposid | 2008 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es | 2011 |
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; F | 2012 |
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2011 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, | 2012 |
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Carcinoma, Non-Small-Ce | 2012 |
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell | 2013 |
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Res | 2002 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
[Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drugs, Chinese Herbal; Etopo | 2001 |
[Study on effect of moxibustion and guben yiliu III combined with chemotherapy in treating middle-late stage malignant tumor].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell | 2001 |
[Influence of combined therapy of guben yiliu III, moxibustion and chemotherapy on immune function and blood coagulation mechanism in patients with mid-late stage malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Carboplatin; Cisplatin; Cyclophos | 2002 |
[Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astragalus propinquus; CD4-CD8 Ratio; Cisplatin; Cyc | 2002 |
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2003 |
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorodeoxyglucose F18; Fluoro | 2003 |
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2004 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
[Randomised study to evaluate the chronotolerance of a combination infusional chemotherapy with 5-fluorouracil, folinic acid and carboplatin in non small cell lung cancer (NSCLC) patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non- | 2003 |
Intratumoural chemotherapy with 5-fluorouracil for palliation of bronchial cancer in patients with severe airway obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Antimetabolites, Antineoplastic; Bronchoscopy; F | 2003 |
Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2003 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2004 |
5-Fluorouracil induces arterial vasocontractions.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brachial Artery; Endothelins; Fluor | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Canada; | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2005 |
[Short-term curative effect observation on treatment of tumor by Shengling liquid combined with intervene therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Therapy, Combinati | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcin | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dis | 2006 |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administr | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Ne | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De | 2006 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2006 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2007 |
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combi | 2008 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Ther | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 2007 |
A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer.
Topics: Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Radiometry; Radiotherapy | 1967 |
Small cell carcinoma of the lung: results of combination chemotherapy and radiation therapy (COF vs. COFP randomized analyzed).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials | 1984 |
[Chemotherapy of the non-small cell bronchogenic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1983 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi).
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Therapy | 1980 |
Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung: a Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinic | 1982 |
Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neop | 1983 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a | 1984 |
[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1984 |
[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukocyte Cou | 1984 |
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cyclop | 1980 |
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; Drug Therapy, Combination; Fluo | 1982 |
Comparison of radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil in bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Doxorubicin; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Age | 1981 |
Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Combined Modality | 1994 |
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admini | 1994 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
Chemoradiation in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1995 |
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch | 1995 |
[Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combi | 1994 |
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 1995 |
Cisplatin-5-fluorouracil in small cell lung cancer. A phase II study in 109 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; | 1994 |
A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Fluorouracil; H | 1995 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
[Efficacy of intrahepatic arterial chemotherapy to prevent recurrence of residual liver in metastatic liver cancer patients after hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epirubicin; Female; Fluorou | 1994 |
[Studies of guben quyu No I combined with chemotherapy in treating cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-CD8 Ratio; Cyclop | 1994 |
A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; beta-Alanine; Carcinoma, | 1994 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Death, Su | 1994 |
Alpha interferon, leucovorin, and 5-fluorouracil (ALF) in advanced cancer: results of a dose-finding study and evidence of activity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1994 |
Rationale for the combination therapy of 5FU and CDDP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Col | 1993 |
Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1994 |
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; F | 1993 |
Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical.
Topics: Adenocarcinoma; Administration, Inhalation; Aerosols; Aged; Animals; Bronchial Neoplasms; Carcinoma, | 1993 |
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi | 1993 |
[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; | 1993 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
Postoperative complications after combined neoadjuvant treatment of lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1993 |
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1993 |
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
Non-uniform dose/time fractionated radiation therapy and chemotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1995 |
Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma | 1995 |
Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1996 |
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Bone Marrow Tr | 1996 |
Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcino | 1996 |
[Evaluation of chemotherapy for stage IV non-small cell lung cancer employing a regression tree type method for quality-adjusted survival analysis to determine prognostic factors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1996 |
[Effect of leucovorin and 5-FU for advanced colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 1996 |
[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Stud | 1996 |
Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Fluorouracil; | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1996 |
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Antineo | 1996 |
Continuous infusion cisplatin and 5-fluorouracil with bolus vinorelbine in the treatment of advanced nonsmall cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
[A study of combination chemotherapy using, 5-FU and CDDP in patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 1996 |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1996 |
A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Com | 1997 |
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasm | 1997 |
A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 1997 |
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1997 |
[Optimization of combined radiotherapy and chemotherapy in treatment of non-small cell lung carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non | 1997 |
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents | 1997 |
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
[Usefulness of CA 15-3 antigen determination for evaluation of response to second-line chemotherapy in patients with breast cancer: preliminary study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclopho | 1997 |
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1997 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
[Combination therapy of daily intramuscular injection of interferon-alpha and oral administration of fluorouracil for advanced renal cell carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1998 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 1998 |
Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 1998 |
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Prot | 1998 |
[Clinical study on effect of kang' aibao oral liquid in treating 103 malignant tumor patients].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
Chemoradiation for inoperable non small cell lung cancer: a phase II study using a regimen with acceptable toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1999 |
A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 1999 |
Alpha interferon-2b, leucovorin, and 5-fluorouracil (ALF) in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1996 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2000 |
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma, Non-Small-Cell | 2000 |
Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2001 |
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2001 |
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2001 |
[The combined therapy of carboplatin, fluorouracil and radiotherapy for moderate and advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 1999 |
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2002 |
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluo | 2001 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Continuous infusion low-dose CDDP/5-FU plus radiation in inoperable or recurrent non-small-cell lung cancer: preliminary experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2002 |
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epiru | 2002 |
Conservative treatment of patients with small-cell lung cancer.
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lu | 1976 |
Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carcinoma, S | 1978 |
Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with ftorafur, adriamycin, and cis-dichlorodiammineplatinum(II).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin | 1978 |
[Results of the radiation therapy of lung cancer by different methods of dosage fractionation in combination with chemical preparations].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Gamma Rays; Humans; | 1978 |
[Joint radiation and chemotherapy of squamous cell lung cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; | 1979 |
Results of two sequential chemotherapy studies in WHO Types I, III and IV lung cancer: cyclophosphamide-5-fluorouracil (CF) and cyclophosphamide-5-fluorouracil-adriamycin (CAF).
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fem | 1979 |
Experience with combination chemotherapy and radiotherapy for undifferentiated lung cancer.
Topics: Adult; Aged; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil | 1976 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
[Phase II trial of concomitant cyclic radio-chemotherapy combination (ARCCC) in unoperable non-small cell lung cancer (CBNPCI)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1992 |
A study of oral etoposide, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small-cell lung cancer. A Mid-Atlantic Oncology Program study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1992 |
Phase II trial of high-dose 24-hour continuous intravenous 5-fluorouracil for advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fluorouracil; Humans; Lung Neoplasms | 1992 |
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
Advanced non-small-cell lung cancer (NSCLC) treated with folinic acid (F), fluorouracil (FU), vincristine (O), and mitomycin-C (Mi), (F-FOMi).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; | 1992 |
Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
[The combined chemotherapy with platinum of patients with inoperable non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac | 1992 |
A phase II clinical trial evaluating the use of two sequential, four-drug combination chemotherapy regimens in ambulatory bronchogenic adenocarcinoma patients.
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchog | 1992 |
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1992 |
A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluatio | 1992 |
Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intrav | 1992 |
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 1992 |
Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1991 |
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1991 |
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 1991 |
Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. A MAOP study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-S | 1991 |
A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1991 |
Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; C | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
Concurrent radiotherapy and chemotherapy for locally advanced non-small-cell cancer of the lung. Report of a clinical trial and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy | 1991 |
Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1991 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
[Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squam | 1989 |
[Results of cooperative studies on the combined treatment of cancer of the lungs including postoperative polychemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; F | 1989 |
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Topics: Aged; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Interaction | 1989 |
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1989 |
Concurrent chemotherapy and radiation therapy for limited unresectable non-small cell carcinoma of the lung. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1988 |
[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Ca | 1985 |
Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cl | 1986 |
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; | 1988 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1987 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Combined treatment including postoperative chemotherapy in lung cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1988 |
Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 1986 |
[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1986 |
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous | 1973 |
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials.
Topics: Antineoplastic Agents; Blood Platelets; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1972 |
Combined radiotherapy and chemotherapy for treatment of unresectable and or metastatic cancer.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Lu | 1974 |
Experience with furanidyl-fluorouracil in advanced tumours of the breast.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Feeding and Eating Disorde | 1974 |
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top | 1972 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1968 |
Sequential analysis of constant and prolonged regional chemotherapy for cancer of the lung.
Topics: Aged; Carcinoma, Squamous Cell; Catheterization; Clinical Trials as Topic; Decision Making; Female; | 1969 |
Long-term chemotherapy for cancer of the lung.
Topics: Aged; Carcinoma, Squamous Cell; Catheterization; Clinical Trials as Topic; Fluorouracil; Humans; Inj | 1968 |
996 other studies available for fluorouracil and Lung Neoplasms
| Article | Year |
|---|---|
N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis lung carcinoma.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Doxorubicin; Guanidines; Lung Neoplas | 1991 |
2'-Fluorinated isonucleosides. 1. Synthesis and biological activity of some methyl 2'-deoxy-2'-fluoro-2'-pyrimidinyl-D-arabinopyranosides.
Topics: Animals; Arabinonucleosides; Chemical Phenomena; Chemistry; Chemistry, Physical; Chlorine; Female; F | 1989 |
Intercedensides A-C, three new cytotoxic triterpene glycosides from the sea cucumber Mensamaria intercedens Lampert.
Topics: Animals; Antineoplastic Agents; China; Drug Screening Assays, Antitumor; Glycosides; Lung Neoplasms; | 2003 |
Synthesis of 6-cinnamoyl-2H-benzo[b][1,4]oxazin-3(4H)-ones and their effects on A549 lung cancer cell growth.
Topics: Antineoplastic Agents; Autophagy; Benzoxazines; Cell Cycle; Cell Proliferation; Cinnamates; Crystall | 2014 |
Biological activities of novel pyrazolyl hydroxamic acid derivatives against human lung cancer cell line A549.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; G1 Phase Cell Cycle Checkpoi | 2014 |
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-C | 2016 |
Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
Topics: Amidines; Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Pro | 2018 |
Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discover | 2018 |
Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-κB pathway inhibition.
Topics: A549 Cells; Antineoplastic Agents; Curcumin; Drug Design; Humans; Lung Neoplasms; MAP Kinase Signali | 2018 |
The design of 1,4-naphthoquinone derivatives and mechanisms underlying apoptosis induction through ROS-dependent MAPK/Akt/STAT3 pathways in human lung cancer cells.
Topics: Acetylcysteine; Apoptosis; Cell Line, Tumor; Drug Design; G1 Phase Cell Cycle Checkpoints; Humans; L | 2019 |
Discovery of a new autophagy inducer for A549 lung cancer cells.
Topics: A549 Cells; Autophagy; Humans; Lung Neoplasms; Molecular Structure | 2019 |
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, T | 2020 |
Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neopla | 2022 |
Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Topics: A549 Cells; Adenocarcinoma of Lung; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell | 2021 |
Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Hum | 2022 |
Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Erlotinib Hydrochloride; Fl | 2021 |
5-Fluorouracil-Impregnated PLGA Coated Gold Nanoparticles for Augmented Delivery to Lung Cancer: In Vitro Investigations.
Topics: Antineoplastic Agents; Drug Carriers; Fluorouracil; Gold; Humans; Lung Neoplasms; Metal Nanoparticle | 2022 |
Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil.
Topics: Angiotensin Receptor Antagonists; Animals; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasm | 2023 |
[A Case of Rectal Cancer and Multiple Lung Metastases That Had Complete Response Treated by XELOX plus Bevacizumab after Primary Lesion Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Hum | 2022 |
The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice.
Topics: Animals; Anthocyanins; Carcinoma, Large Cell; Cell Line, Tumor; Fluorouracil; Glucosides; Inflammati | 2022 |
Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Fluorouracil; Ginsenosides; Humans; Lung Neoplasms | 2022 |
Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Drug Repositioning; Drug Synergism; Fluor | 2022 |
[A Case of Long-Term Survival by Multidisciplinary Surgical Treatment for Metastatic Multi-Organ Metastasis after Radical Resection of Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagectomy; Fluoroura | 2022 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
In vivo self-assembled small RNA targets H19 lncRNA for the treatment of colorectal cancer.
Topics: Animals; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Micro | 2023 |
5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Fluorouracil; Immunotherapy; Lung Neoplasms; | 2023 |
Design, synthesis, antibacterial/antitumor activity and in vitro stability of novel cordycepin derivatives with unsaturated fatty acid chain.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Ce | 2023 |
Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Germ Cells; Humans | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
[A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2023 |
Jin-Fu-An decoction manipulation of macrophage polarization via β-catenin (CTNNB1) synergizes with cisplatin in lung cancer.
Topics: beta Catenin; Cell Line, Tumor; Cisplatin; Fluorouracil; Humans; Lung Neoplasms; Macrophages; Tumor | 2023 |
A rectal cancer organoid platform to study individual responses to chemoradiation.
Topics: Animals; Chemoradiotherapy; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Neoplasm Me | 2019 |
[A Case of Lung Metastases from Rectal Cancer Treated for Quite Long with FOLFIRI plus Ramucirumab as a Late Line of Therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2019 |
Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag
Topics: A549 Cells; Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Cetuximab | 2019 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Combined use of
Topics: Andrographis; Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cisplatin; Esop | 2019 |
Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report.
Topics: Adenocarcinoma of Lung; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lung Neoplasms; Pyridines; | 2020 |
Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2020 |
Discovery of new fluorescent thiazole-pyrazoline derivatives as autophagy inducers by inhibiting mTOR activity in A549 human lung cancer cells.
Topics: A549 Cells; Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chick Embryo; F | 2020 |
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithe | 2020 |
Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.
Topics: A549 Cells; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2020 |
Matrine Inhibitory Effect on Self-renewal and Re-sensitization of 5-FU Resistant NSCLC Stem Cells were through Let-7b dependent Downregulation of CCND1.
Topics: A549 Cells; Alkaloids; Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cyc | 2020 |
Unusual case of cannonball opacities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Fluorouracil; Humans; Laryngea | 2020 |
Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dendritic Cells; Female; | 2021 |
Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2021 |
Visualization of the cancer cell cycle by tissue-clearing technology using the Fucci reporter system.
Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell | 2021 |
Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug C | 2021 |
Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Disease Progression; Drug Carr | 2017 |
[Subacute cutaneous lupus erythematosus induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Car | 2017 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemoembolization, Therapeutic; Epirubicin; Fe | 2017 |
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; C | 2017 |
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Carcinoma; Carcinoma, | 2018 |
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl | 2018 |
Targeting PRPK Function Blocks Colon Cancer Metastasis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic N | 2018 |
Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL2; Cyclophosphamide; D | 2018 |
[A Case of Colon Cancer with Brain, Liver and Lung Metastasis Successfully Treated with Bevacizumab plus Xelox Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Deoxycyt | 2018 |
KAP1 inhibits the Raf-MEK-ERK pathway to promote tumorigenesis in A549 lung cancer cells.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Carcinogenesis; Extracellular Signal-Regulated MAP Kina | 2018 |
[Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated
with More Than Two Lines of Chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Fluor | 2018 |
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
[Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Intestinal Neoplasms; | 2018 |
Chemotherapeutic drug targeting to lungs by way of microspheres after intravenous administration.
Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Drug Delivery Systems; Fluoro | 2018 |
Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Fluorour | 2021 |
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplasti | 2018 |
Case of purpuric drug eruption probably induced by panitumumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Colonic Neoplasms; Drug Erupti | 2019 |
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Clini | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Etoposid | 2019 |
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2019 |
Impact of Perioperative Chemotherapy on Prognosis of Patients with Esophageal Carcinoma Undergoing Pulmonary Metastasectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2019 |
Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lu | 2019 |
Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tu | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; C | 2013 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2002 |
Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
Topics: Animals; Antineoplastic Agents; Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2013 |
[Neuroendocrine tumors: analysis of 252 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2013 |
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2013 |
[Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Fluorouracil; Humans; Laparoscopy; Le | 2013 |
Serum tumor markers, hypoxia-inducible factor-1α HIF-1α and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Non- | 2013 |
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Topics: Aminoglycosides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Capecit | 2013 |
Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell | 2013 |
Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic | 2014 |
A preclinical murine model for the detection of circulating human tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Disease | 2013 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2014 |
Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Doxorubicin; Female; Fluorou | 2013 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
[A case of recurrent duodenal carcinoma successfully controlled with FOLFOX treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Female; Fluorouracil; Humans; Le | 2013 |
[Recurrent rectal cancer with multiple liver and lung metastases treated effectively with oxaliplatin and capecitabine plus bevacizumab chemotherapy-a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Sq | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
[Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil].
Topics: Adenocarcinoma; Antimetabolites; Fluorouracil; Humans; Hyperammonemia; Lung Neoplasms; Male; Middle | 2014 |
Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antime | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
[A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
[Adenoid cystic carcinoma of the breast:report of 25 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 2014 |
5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, | 2014 |
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2013 |
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2014 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2014 |
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester | 2014 |
GFP stable transfection facilitated the characterization of lung cancer stem cells.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coculture Techniq | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Preliminary detection of the anti‑tumour activity of indoline‑2,3‑dione derivative DH‑12a targeting aminopeptidase N.
Topics: Animals; Antineoplastic Agents; CD13 Antigens; Cell Line, Tumor; Cell Movement; Dose-Response Relati | 2014 |
Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Drug R | 2014 |
Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistan | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Therapeutic effects of 5-fluorouracil sustained-release particles in 81 malignant pericardial effusion patients.
Topics: Antimetabolites, Antineoplastic; Delayed-Action Preparations; Female; Fluorouracil; Humans; Lung Neo | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2015 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorouracil | 2015 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Dual Drug Conjugate Loaded Nanoparticles for the Treatment of Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemistry, Pharmaceutical | 2015 |
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, Adjuv | 2015 |
Development of lattice-inserted 5-Fluorouracil-hydroxyapatite nanoparticles as a chemotherapeutic delivery system.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antimetabolites, Antineoplastic; Cell Li | 2015 |
5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumo | 2015 |
Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorouracil; Lung Neoplasms; Melanoma, Ex | 2015 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
[Rapidly Growing Interval Colon Cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cytoreduction | 2015 |
Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug | 2015 |
[A Case of Radical Resection of Rectal Cancer with Multiple Liver and Lung Metastases after Preoperative Chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 2015 |
Prostate Cancer Heterogeneous High-Metastatic Multi-Organ-Colonizing Chemo-Resistant Variants Selected by Serial Metastatic Passage in Nude Mice Are Highly Enriched for Multinucleate Giant Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubi | 2015 |
Pneumatosis intestinalis due to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2015 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
[A Patient with Rectal Cancer and Multiple Lung Metastases Treated with XELOX plus Bevacizumab (Bev) Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Deoxycyt | 2015 |
[A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Chemotherapy, Adjuvant; Fl | 2015 |
Carbon dots incorporated polymeric hydrogels as multifunctional platform for imaging and induction of apoptosis in lung cancer cells.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carb | 2016 |
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Li | 2016 |
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Deoxycytidine; Disease | 2016 |
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dihydrouracil Dehydrogenase (NADP); | 2016 |
Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac | 2017 |
The role of ZNRF2 in the growth of non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line, T | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta | 2017 |
rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFκB upon 5-FU treatment.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movem | 2016 |
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Topics: A549 Cells; Adenosine Triphosphate; Animals; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cell Cyc | 2016 |
Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis.
Topics: Animals; cdc42 GTP-Binding Protein; Cell Line, Tumor; Chemokine CXCL12; Disease Models, Animal; Drug | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorec | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2017 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cet | 2017 |
Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; b | 2017 |
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cetuximab; Colorectal Neop | 2017 |
Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Prolif | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; F | 2008 |
[Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cisplatin; C | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2009 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
[Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptotheci | 2008 |
Fatal pneumonitis induced by oxaliplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehyd | 2009 |
Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colo | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms | 2008 |
[Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; | 2008 |
Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carcinoma, Signet Ring Cell; Etoposide; Fl | 2008 |
[Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Epi | 2008 |
rNAPc2 inhibits colorectal cancer in mice through tissue factor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; C | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2008 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2008 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combin | 2009 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
[A case of hepatocellular carcinoma rapidly progressing after percutaneous radiofrequency ablation successfully treated with low-dose 5-FU and CDDP].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2009 |
Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Com | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Expression of 5-fluorouracil-related enzymes in lung cancer: ELISA characterizes enzyme activity and messenger RNA expression.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbe | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C | 2009 |
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2009 |
Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Bleomycin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2009 |
Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Drug | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do | 2010 |
Hepatocellular carcinoma in membranous obstruction of the inferior vena cava--a causal or a casual presentation.
Topics: Adult; Angioplasty, Balloon; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Flu | 2009 |
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxy | 2009 |
Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell C | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2009 |
[The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplat | 2009 |
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.
Topics: Aged; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Fluo | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2009 |
Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineop | 2009 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2010 |
[A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2009 |
[A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
Liposomes modified with YIGSR peptide for tumor targeting.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Drug Delivery Systems; Endothelium, Vascular; Fluor | 2010 |
[Two resected cases of pulmonary metastasis from post operative colorectal cancer after preoperative chemotherapy with FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2009 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents | 2010 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; F | 2010 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2009 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; C | 2010 |
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Scre | 2010 |
Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Cyclin D1; Fibroblasts; F | 2010 |
[Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2010 |
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line; Cell L | 2010 |
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cy | 2010 |
Metastatic urachal cancer responding to FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cystectom | 2010 |
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemistr | 2010 |
A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); | 2011 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, D | 2011 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
[A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Colonic Neoplasms; Female; | 2010 |
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Low dosage 5-fluorouracil increases the transfection efficiency of Ad/VEGF-A in mouse lung carcinoma cell line LA795 and inhibits tumor growth.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proli | 2010 |
A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Brea | 2010 |
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cisplatin; Colonic Ne | 2011 |
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 2011 |
[A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Comb | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2010 |
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dihydrouracil De | 2010 |
[A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; | 2010 |
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2010 |
Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi | 2011 |
Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.
Topics: Animals; Antineoplastic Agents; Chromatography, Supercritical Fluid; Drug Delivery Systems; Fluorour | 2010 |
Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Neuroendocr | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 2010 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2010 |
[An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[A case of sigmoid colon cancer with synchronous multiple liver and lung metastases, who survived 25-month after combination of chemotherapy and metastasectomy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[A case of lung metastasis from colon cancer controlled effectively by the stereotactic radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2010 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2011 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Antitumor effect of Croatian propolis as a consequence of diverse sex-related dihydropyrimidine dehydrogenase (DPD) protein expression.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (N | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2011 |
Primary lung cancer surgery after curative chemoradiotherapy for esophageal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Isolation and identification of side population cells in human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; ATP-Binding Cassette Transporters; Cell Cycle; Cell | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Ce | 2011 |
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2011 |
Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Cell Migration Assays; Cell Mo | 2011 |
[End results of combined treatment in metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemot | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; | 2011 |
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2012 |
Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Colonic Neoplasms; Fluorourac | 2012 |
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
The value of palliative gastrectomy in gastric cancer with distant metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2012 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase Inhi | 2012 |
Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouraci | 2011 |
[Repeated resections for originally unresectable liver metastasis from colorectal cancer after multiagent chemotherapy].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucov | 2011 |
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cel | 2012 |
[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2011 |
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo | 2012 |
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Topics: Animals; Brain Neoplasms; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engi | 2012 |
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Topics: Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line | 2012 |
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza | 2014 |
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Co | 2012 |
Lung metastases of epithelial-myoepithelial carcinoma of the parotid gland successfully treated with chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Fluorouracil | 2013 |
[A case of pathologically by complete response in advanced sigmoid colon cancer with multiple metastases of lung and Liver, left hydronephrosis after chemotherapy including bevacizumab/FOLFOX6].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fema | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemoth | 2013 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2012 |
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; De | 2013 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Topics: Adjuvants, Immunologic; Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Proto | 2012 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2013 |
[Two cases of long-term survival of metastatic colorectal cancer following treatment with polysaccharide K and mFOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2012 |
[A case of lung metastasis from esophageal cancer resistant to fluorouracil and cisplatin combination therapy but responsive to radiation therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2012 |
[A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone | 2012 |
[A case report of recurrent lung metastasis after surgery for rectal cancer for which lung radiofrequency ablation therapy and long-term administration of FOLFIRI were effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Fluorouracil; Human | 2012 |
Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, We | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
[Simultaneaous bilateral pulmonary metastasectomy of carcinoma of the sweat glands].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Axilla; Chemotherapy, Adjuva | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Ce | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc | 2002 |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac | 2001 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2002 |
[Resection of pancreatic cancer and simultaneous lung metastasis--a case report of successful in tumor dormancy mainly by postoperative 5-fluorouracil-based chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcin | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Admini | 2003 |
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcino | 2003 |
Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Gene Expression R | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; C | 2003 |
Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome.
Topics: Adult; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fatal Outcome; Fluorouracil; Hum | 2003 |
[Clinical observation of chemotherapy combined with yiqi xiaozheng granule in treating advanced malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combination; Drugs, Chinese | 2003 |
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide | 2003 |
[First-line metastatic cancer of the colon].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2003 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Resistance, | 2003 |
[A case of multiple lung metastases from colon cancer after sigmoidectomy treated effectively by chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Drug Administration Sc | 2003 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
Combined therapy of inoperable lung carcinoma with 5-fluorouracil and irradiation.
Topics: Antineoplastic Agents; Fluorouracil; Lung Neoplasms; Psychotherapy, Multiple; Uracil | 1961 |
Combination therapy with 5-fluorouracil and cobalt-60 for inoperable carcinoma of the lungs.
Topics: Antineoplastic Agents; Carcinoma; Cobalt; Cobalt Radioisotopes; Combined Modality Therapy; Fluoroura | 1962 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
[TRIAL OF COMBINED CHEMOTHERAPY IN LUNG CANCER. COMBINATION OF CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL].
Topics: Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms | 1963 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
COMBINED SPLIT-COURSE THERAPY WITH 5-FLUOROURACIL AND MEGAVOLTAGE IRRADIATION.
Topics: Colonic Neoplasms; Drug Therapy; Fluorouracil; Lung Neoplasms; Neoplasms; Radiography, Thoracic; Rad | 1964 |
N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213) IN TREATMENT OF SOLID TUMORS.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy; Fluorouracil; Humans; Injections, Intra-Arter | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
[RESULTS OF COMBINED TREATMENT OF LUNG CANCER (5-FLUOROURACIL AND ROENTGENTHERAPY)].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Lung Neoplasms; Neoplasms | 1965 |
Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, | 2003 |
[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; D | 2003 |
[A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2003 |
Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models | 2003 |
EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Transformation, | 2004 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
[Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Cisplatin; Colorectal Neoplasms; | 2003 |
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A | 2003 |
[Metastatic oropharyngeal cancer successfully treated with docetaxel, cisplatin, 5-FU and l-leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2004 |
[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dru | 2004 |
Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil.
Topics: Administration, Inhalation; Aerosols; Animals; Anticarcinogenic Agents; Carcinogens; Carcinoma, Squa | 2004 |
Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem | 2004 |
Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery.
Topics: Animals; Bone Neoplasms; Bystander Effect; Carcinoma, Lewis Lung; Cell Hypoxia; Cytosine Deaminase; | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2004 |
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Topics: Aged; Base Sequence; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Case-Control | 2004 |
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorourac | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2004 |
Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cel | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphami | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemo | 2005 |
Long-term survival after salvage surgery for colorectal lung metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2005 |
Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2005 |
Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA; Fluorouracil; Humans; Lung | 2005 |
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2005 |
[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 2005 |
[Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Dru | 2005 |
Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA | 2005 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell L | 2005 |
Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrog | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung | 2005 |
Rectal cancer clinical practice guidelines in oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
[A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Drug Admin | 2005 |
Patient with angina secondary to capecitabine.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
[A case of sclerosing cholangitis trigered by 5-FU/leucovorine combination therapy and rapidly deteriorated].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis, Sclerosing; Colonic Neoplasms; Co | 2005 |
[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2005 |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Topics: Aged; Antimetabolites, Antineoplastic; beta-Alanine; Cardiovascular Diseases; Colonic Neoplasms; Dru | 2005 |
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 2006 |
Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Fluorouracil; Genetic Vector | 2006 |
Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2006 |
[A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].
Topics: Adult; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles.
Topics: Administration, Inhalation; Aerosols; Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous | 2006 |
Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carc | 2006 |
Pancreatoblastoma in a teenage patient.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother | 2006 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
State of central and peripheral pools of hemopoietic precursor cells in patients with malignant neoplasms during chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neo | 2005 |
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
[Blood supply of pulmonary metastases and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Che | 2006 |
Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small | 2006 |
Epithelial-myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyc | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Topics: Animals; Antimitotic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 2007 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenas | 2006 |
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phas | 2006 |
Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Atrasentan; Cell Prolife | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
[Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C | 2006 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2006 |
[A case of metastatic lung cancer responding well from tongue carcinoma using a combination of stereotactic radiation therapy and docetaxel/cisplatin/5-FU chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2006 |
[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2006 |
[Management and prognosis in stage IV gestational trophoblastic neoplasia patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Fema | 2006 |
Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfam | 2006 |
Inhibitory effect of pulmonary carcinoma by adenovirus-mediated CD/UPRT gene.
Topics: Adenocarcinoma; Adenoviridae; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; | 2006 |
MRP8/ABCC11 directly confers resistance to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Calgranulin A; Cell Death; Drug Resistance, Neoplasm; Fluorodeoxyur | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2007 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |
Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2007 |
[Outcome of gestational trophoblastic neoplasia patients with residual lung tumor after completion of treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
[A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitab | 2008 |
Bevacizumab in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2007 |
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2007 |
[A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycyti | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxy | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; ErbB R | 2007 |
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cispl | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2007 |
A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Prolifer | 2008 |
[A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Combined Modality Th | 2007 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.
Topics: Animals; Antineoplastic Agents; Bifidobacterium; Cell Line, Tumor; Cytosine Deaminase; Drug Delivery | 2007 |
Oxaliplatin-induced immune mediated thrombocytopenia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Plat | 2008 |
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylas | 2008 |
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2008 |
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
Topics: Antineoplastic Agents; Digestive System Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp | 2008 |
Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Systemic therapy for metastatic colorectal cancer: current questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trial | 2008 |
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2008 |
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Topics: Amidohydrolases; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell | 2008 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2008 |
The unanswered question: what is the determinant of S-1 pharmacokinetics?
Topics: Alleles; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asian People; Body Size; Ca | 2008 |
[Use of radiochemotherapy for inoperable non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2008 |
Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Topics: Acitretin; Alitretinoin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2008 |
[A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Lung Neopl | 2008 |
[Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors].
Topics: Eye Neoplasms; Female; Fluorouracil; Humans; Infant; Infusions, Parenteral; Lung Neoplasms; Male; Mi | 1966 |
Serum enzymes in patients with carcinoma of lung: lactic-acid dehydrogenase, phosphohexose isomerase, alkaline phosphatase and glutamic oxaloacetic transaminase.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Clinical Enzyme Tests; Fluorouracil; Glucose-6-Ph | 1967 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha | 1967 |
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Liver | 1981 |
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga | 1981 |
Mitomycin-associated lung disease.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Cisplatin; Cyclophosphamide; Drug Therapy, Combinatio | 1983 |
An active chemotherapy regimen for squamous cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1984 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma--a pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Child; Fluor | 1984 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
Chemotherapy for adenocystic carcinoma.
Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Fluorouracil; Humans; Lung Neop | 1980 |
Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Com | 1980 |
Cytologic characteristics of oat-cell carcinoma of the lung in relation to the effect of chemotherapy.
Topics: Aged; Antineoplastic Agents; Bronchoscopy; Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Co | 1981 |
Fulminant lung metastases from cancer of the breast.
Topics: Adult; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophosphamide; Female; Fluorour | 1981 |
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Sched | 1982 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 1982 |
The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung: preliminary report of a Southwest Oncology Group study.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Drug T | 1982 |
Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.
Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Fluorouracil; Guanine Nucleotides; Guanosine Mon | 1983 |
[Pre- and intra-operative chemotherapy using FT-207 suppositories--with special reference to lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Fluorouracil | 1982 |
[Chemotherapy of small cell carcinoma of the lung in relation to lymph node metastasis and extending pattern of tumor].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neopl | 1983 |
[Chemotherapy of small cell carcinomas of the lung].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Co | 1983 |
[Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1983 |
An atypical endocrine tumor of the lung responsive to radiation therapy and 5-fluorouracil-streptozotocin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bombesin; Carcinoma, | 1984 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Small Cell; Drug Hypersensitivity; Erythema Multiforme | 1984 |
The significance of ascorbic acid, thiamin and retinol in cancer.
Topics: Animals; Ascorbic Acid; Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Neoplasms; Neo | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
[Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Cell Line; Cyclophosphamid | 1984 |
Radiation and concurrent chemotherapy for the treatment of Lewis lung tumor and B16 melanoma tumor in C57/BL mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cesium Radioisotopes | 1984 |
[Antitumor effect of FU-O-G, new antitumor agent, following long term administration].
Topics: Animals; Antineoplastic Agents; Carbazilquinone; Drug Administration Schedule; Drug Synergism; Femal | 1984 |
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met | 1984 |
[Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
[Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Female; Fluorouracil; Gangliosides; Lung Neoplasms; Mamma | 1984 |
Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, | 1984 |
Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum/5-fluorouracil treatment.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transit | 1984 |
Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1984 |
[Use of adriamycin in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Castr | 1984 |
[Chemotherapeutic responses of a primary tumor and its pulmonary metastases in murine tumor systems in relation to its proliferative properties].
Topics: Animals; Carcinoma; Fluorouracil; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Ne | 1984 |
Phase I-II study of 120-hour infused 5-FU and split-course radiation therapy in localized non-small cell lung cancer.
Topics: Aged; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; Humans; Lung Neoplasms; Male | 1983 |
Role of corticosteroid hormones in the control of cell proliferation in residual tumor after surgical cytoreduction.
Topics: Animals; Cell Cycle; Corticosterone; Dexamethasone; DNA Replication; Female; Fluorouracil; Kinetics; | 1983 |
Effects on metastases of drug therapy during developing and established tumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Imm | 1983 |
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors.
Topics: Adenocarcinoma; Age Factors; Animals; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Fluorou | 1984 |
5-fluorouracil metabolism monitored in vivo by 19F NMR.
Topics: Animals; Female; Fluorine; Fluorouracil; Liver; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mic | 1984 |
Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Female; Fluorouracil; Lung Neoplas | 1981 |
Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)- 5-fluorouracil (tegafur) in human tumor tissues.
Topics: Biotransformation; Fluorouracil; Humans; In Vitro Techniques; Lung Neoplasms; Tegafur | 1981 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
[Renal cell carcinoma].
Topics: Adenocarcinoma; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Lung | 1982 |
[Radiation and combination treatment of breast cancer metastases to the lungs].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as To | 1983 |
Therapeutic activity of pretazettine, standard drugs, and the combinations on intraperitoneally implanted Lewis lung carcinoma in mice.
Topics: Alkaloids; Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, | 1983 |
[Pulmonary metastasis of renal cell carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Co | 1983 |
Schedule-dependent cytotoxicity of 5-fluorouracil and cyclophosphamide in experimental cancer chemotherapy.
Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Fluorouracil; Leukemia L1210; Lung Neoplasm | 1980 |
5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling.
Topics: Animals; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Leukemi | 1981 |
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N | 1982 |
Spontaneous pneumothorax in gynecologic malignancies.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drainage; Drug Therapy, | 1982 |
[Results of chemo- and radiotherapy of poorly differentiated and undifferentiated lung cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Radi | 1982 |
Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases.
Topics: Adult; Fluorouracil; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Metastasis | 1982 |
Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Colonic Neoplasms; Complement Fixation Tests; Female; Fluorouracil; | 1982 |
Non-invasive methods for detection of cardiomyopathy in the course of antineoplastic treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiomyopathies; Doxorubicin; Drug Therapy, Combination; F | 1982 |
Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.
Topics: Biotransformation; Breast Neoplasms; Fluorouracil; Half-Life; Humans; Kinetics; Lung Neoplasms | 1982 |
[Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy].
Topics: Adult; Aged; Breast Neoplasms; Coenzymes; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 1982 |
[Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluo | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; I | 1982 |
Castration--chemotherapy treatment of prostate cancer model.
Topics: Animals; Carmustine; Castration; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Disea | 1981 |
Platinum-based combination chemotherapy in non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluor | 1981 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil; | 1980 |
5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; F | 1981 |
Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fema | 1981 |
Investigations into sister chromatid exchange in patients under cytostatic therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Child; Child, Preschool; Cr | 1981 |
Response of metastatic cloacogenic carcinoma to treatment with semustine.
Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu | 1981 |
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques | 1980 |
[5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Fluorouracil; Lung Neoplasms; Mi | 1980 |
The non-hormone chemotherapy of prostatic cancer.
Topics: Bone Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; M | 1980 |
Chemotherapeutic activity and histopathologic feature of BCNU + 5-FU effect on Lewis lung carcinoma.
Topics: Animals; Carmustine; Drug Therapy, Combination; Fluorouracil; Lung; Lung Neoplasms; Mice; Neoplasms, | 1980 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis | 1995 |
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1994 |
[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplat | 1995 |
[Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubic | 1995 |
Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 1995 |
5-Fluorouracil and cisplatin sequential chemotherapy; mechanism of action and clinical application in advanced, unresectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Synergism; Female; Fluorouracil; Humans | 1995 |
Cross-resistance to thymidylate synthase inhibitors in P-glycoprotein and non-P-glycoprotein cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 1994 |
Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause o | 1995 |
[Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Servic | 1994 |
[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1994 |
[Effect of fagopyrum cymosum rootin on clonal formation of four human tumor cells].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drugs, Chinese Herbal; | 1993 |
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplas | 1994 |
Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil and interferon in experimental liver metastases.
Topics: Animals; Combined Modality Therapy; Drug Synergism; Female; Fluorouracil; Interferon alpha-2; Interf | 1994 |
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Dru | 1994 |
Enhancement of antitumor effects of combined chemoimmunotherapy.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Chemotherapy, Adjuvant; | 1993 |
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; | 1994 |
High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Brain Neoplasms; | 1994 |
Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carcinoma, Non-Sm | 1994 |
[A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura | 1993 |
[Successful treatment of recurrent multiple lung metastasis from colon cancer with combination chemotherapy using methotrexate, 5-fluorouracil, and high-dose leucovorin: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Hu | 1993 |
[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
[A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1993 |
[A case of postoperative pulmonary metastasis of colon cancer which responded to treatment with leucovorin and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1993 |
[Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Car | 1993 |
Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Survival; Cisplatin; Drug Synergism; Fluorouracil; Humans; Leuc | 1993 |
[A new cell line derived from a nude mouse resembling human large cell lung cancer].
Topics: Adult; Animals; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Gen | 1993 |
Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cel | 1993 |
Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1993 |
In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 1993 |
[5-fluorouracil + low-dose leucovorin and cisplatin sequential chemotherapy with dipyridamole for advanced nonresectable squamous cell carcinoma of the lung: a case report].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1993 |
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; | 1993 |
[Experimental and clinical study in vitro chemosensitivity test for succinate dehydrogenase inhibition test].
Topics: Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopla | 1993 |
[A case of complete remission of breast cancer with bilateral multiple lung metastases by combination therapy of MPA, THP, CPM and 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1993 |
Serum cytokine level fluctuations in chemotherapy-induced myelosuppression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Carcino | 1996 |
[Contribution of an induction treatment in the surgical treatment of locally advanced non-small-cell cancers].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1995 |
Surgical resection of pulmonary metastases from nasopharyngeal carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Flu | 1996 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1996 |
[Possibilities of adoptive immunochemotherapy in the treatment of non-small-cell lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophospham | 1996 |
[A case report of small cell carcinoma of the esophagus with remarkable response to neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cispl | 1996 |
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1996 |
[Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; I | 1996 |
[A combination chemotherapy with CDDP and 5-FU effective for pulmonary metastases in a case of parotid gland carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 1996 |
[A case of recurrent breast carcinoma with metastatic foci in the lung and pleura treated successfully with biochemical modulation of 5-fluorouracil by low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administrati | 1996 |
[Individual therapeutic procedure in metastatic carcinoid of the small intestine].
Topics: Carcinoid Tumor; Colectomy; Combined Modality Therapy; Female; Fluorouracil; Humans; Ileal Neoplasms | 1996 |
[Selective arterial catheterization in the management of drug-resistant choriocarcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Drug Resistance, Neoplasm; Female; | 1996 |
Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
Topics: Animals; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Erythrocytes; Female; Fluo | 1996 |
Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1996 |
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 1996 |
How should cancer presenting as a malignant pleural effusion be managed?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma; Cisplatin; Epi | 1996 |
[A case of lung metastasis from breast cancer successfully treated by FLEP (5-FU leucovorin, etoposide CDDP) combined arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administrat | 1996 |
[Concurrent radiotherapy and chemotherapy for non-small-cell lung cancer--continuous infusion of low dose cisplatin and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 1996 |
Assessing whether to perform a confirmatory randomized clinical trial.
Topics: Adjuvants, Immunologic; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Combined M | 1996 |
Interferon-alpha inhibits CFU-GM mobilization following chemotherapy and G-CSF administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Evaluatio | 1996 |
Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Carcinoma, Lewis Lung; Combined Modalit | 1996 |
[A two-year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Drug Administr | 1997 |
Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobuta | 1997 |
Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line.
Topics: Animals; Antineoplastic Agents; Cell Death; Cisplatin; DNA Damage; Drug Synergism; Fluorouracil; Hum | 1997 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplati | 1997 |
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 1997 |
[Percutanous trans-catheter intervention for the diagnosis and treatment of malignant pericardial effusion, with a report of 50 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Catheteriz | 1996 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1997 |
Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1998 |
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; H | 1998 |
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo | 1998 |
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 1998 |
[Significance of full-thickness chest wall resection as a local treatment for sternum metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1998 |
Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1998 |
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Moda | 1997 |
Forty-five year's experience of the treatment of choriocarcinoma and invasive mole.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Choriocarcinoma; Female; Fluorouracil; Humans; Hyd | 1998 |
[An experimental study of local chemotherapy for metastatic lung tumor--isolated lung perfusion and pulmonary artery infusion].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perf | 1998 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1999 |
Evaluation of individual sensitivity to cytostatic drugs of in vitro cultured lung tumor cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
[A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1999 |
The effects of two different cisplatin-based chemotherapy regimens on advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relations | 1999 |
Malar metastasis from rectal carcinoma: a case report.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fatal Outcome; Female | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
Primary lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagno | 2000 |
Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weigh | 1999 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, N | 2000 |
Successful low-dose concurrent chemotherapy and radiation for locally advanced or inoperable non-small cell lung carcinoma: a report of six cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Comb | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non- | 2000 |
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cis | 2000 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2000 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Drug Resistance; | 2000 |
Tubulocystic clear cell adenocarcinoma arising within the prostate.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluor | 2000 |
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2000 |
Chemoradiotherapy for advanced lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cisplatin; Female; Fluorou | 2000 |
[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
[Hepatocellular carcinoma with tumor thrombus in the portal and hepatic veins treated successfully with hepatectomy and chemotherapy--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
[A case of pulmonary metastases of breast cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Ad | 2000 |
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2000 |
Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Carci | 2000 |
[Postoperative complications after radiochemotherapy or chemotherapy for bronchial cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carcinoma, Bronchoge | 2000 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec | 2001 |
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitum | 2001 |
[Intermittent administration of 5-FU and isovorin to patients with advanced and recurrent colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2001 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dr | 1999 |
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrog | 2001 |
Experience in treatment of metastatic pulmonary carcinoid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoi | 2001 |
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Renal C | 2001 |
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clone Ce | 2002 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2002 |
[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh | 2002 |
Bleomycin combination chemotherapy in the management of testicular neoplasia.
Topics: Abdominal Neoplasms; Adult; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Dysgerminoma; Fl | 1975 |
Effect of antitumor agents on sarcoma-180 tumor cells transplanted to liver, kidney, and lung.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Dactinomycin; Daunorubicin; Fluorouraci | 1975 |
[Chemoradiation therapy of inoperable lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Fl | 1975 |
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1976 |
Mallory-Weiss lesion following cancer chemotherapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; Male; Mallory-Weiss Syndrome; Methy | 1977 |
Chemotherapy for lung cancer.
Topics: Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Cytarabine; Dactinomyci | 1978 |
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Topics: Antineoplastic Agents; Autoradiography; Breast Neoplasms; Cell Count; Cell Division; Culture Techniq | 1975 |
Susceptibilities of normal and malignant human lung cells in culture to the cytocidal action of antitumor agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Doxorubicin; Drug Evaluat | 1978 |
A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
[After care in bronchial carcinoma. Results of postoperative polychemotherapy].
Topics: Aftercare; Aged; Antineoplastic Agents; Austria; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorour | 1976 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Combination chemotherapy with methyl-CCNU, 5-fluorouracil, and vincristine in adenocarcinoma and large cell carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Small cell carcinoma of the lung: clinical and cytomorphological studies in relation to its response to chemotherapy.
Topics: Adult; Aged; Carcinoma, Small Cell; Cell Nucleus; Cyclophosphamide; Cytoplasm; Female; Fluorouracil; | 1977 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li | 1978 |
COMF-radiotherapy treatment of small cell carcinoma of the lung.
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neopl | 1979 |
Schedule dependent effectiveness of CCNU and 5-fluorouracil in experimental chemotherapy.
Topics: Animals; Cell Survival; Drug Therapy, Combination; Fluorouracil; Hematopoietic Stem Cells; Lomustine | 1977 |
Current trends and prospects in surgical adjuvant trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dianhydroga | 1978 |
Heparinized chemotherapy in the treatment of disseminated lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouraci | 1979 |
Treatment of advanced bronchogenic carcinoma with adriamycin, 5-fluorouracil and methotrexate.
Topics: Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leuco | 1977 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
[Importance of the analysis of the carcinoembryonic antigen in clinical oncology].
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1979 |
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Drug | 1979 |
[Chemotherapy-radiotherapy combination in lung neoplasms].
Topics: Adolescent; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins | 1979 |
Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC).
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophospham | 1979 |
Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models--I. 6-[3H]-5-fluorouracil.
Topics: Animals; Carcinoma, Ehrlich Tumor; Fluorouracil; Half-Life; Lung Neoplasms; Male; Mice; Models, Biol | 1979 |
Effects of combination drug therapy on the subcutaneous and pulmonary growth of a slow and a fast-growing C3H/He mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combin | 1979 |
Heparin and polychemotherapy for treatment of lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1977 |
Immunological responsiveness and adjunct immunotherapy in lung cancer.
Topics: Aged; Animals; Cell Migration Inhibition; Female; Fluorouracil; Humans; Immunotherapy; Lung Neoplasm | 1978 |
The intrapleural instillation of nitrogen mustard and 5-fluorouracil in the management of malignant pleural effusions in Nigerians.
Topics: Adolescent; Adult; Aged; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Mechlorethamine; Middle | 1978 |
Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Topics: Animals; Carcinoma; Cell Line; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Leu | 1976 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
[Chemotherapy of bronchial carcinomas (author's transl)].
Topics: Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Therapy, | 1975 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo | 1977 |
[Five-drug therapy in addition to hormonal treatment in advance breast cancer metastatic to the lung (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1976 |
[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)].
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Follow-Up Studi | 1976 |
Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; | 1976 |
The role of nonspecific immunotherapy in the treatment of breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
[Treatment of osteosarcoma: an end to the present impasse?].
Topics: Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; International Cooperation; Lung Neoplasms; Mito | 1976 |
Anti-tumour and anti-metastatic activity of 3-(P-Chlorophenyl)-2,3-Dihydro-3-Hydroxythiazolo (3,2-A)-Benzimidazole-2-acetic acid (WY-13,876).
Topics: Animals; Anthelmintics; Antilymphocyte Serum; Antineoplastic Agents; Benzimidazoles; Cyclophosphamid | 1976 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
[Conservative treatment of lung cancer].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Drug-Related | 1975 |
[Chemo-radiotion treatment of undifferentiated lung cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Radi | 1975 |
[Progress in chemotherapy of lung neoplasms].
Topics: Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Humans; Lun | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
Heparin and chemotherapy in the management of inoperable lung carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Drug Tolerance; Female; Fluorouracil; Heparin; Humans; Lung Neoplasms | 1975 |
Resolution of pulmonary lymphangitic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Castration; Female; Fluorouracil; Humans; Lung Neoplasms; L | 1976 |
Multi-modality therapy for epidermoid carcinoma of the anus.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle | 1976 |
The inhibition of DNA synthesis by cannabinoids.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cannabidiol; Cannabis; Cyclophosphamide; Cytarabine; DNA; D | 1976 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
Progress against rare and not-so-rare cancers.
Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1992 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcino | 1992 |
Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.
Topics: Adenocarcinoma; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Damage; Drug Re | 1992 |
Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
[Diagnosis and treatment of hemothorax in malignant trophoblastic tumors].
Topics: Female; Fluorouracil; Hemothorax; Humans; Lung Neoplasms; Pregnancy; Trophoblastic Neoplasms; Uterin | 1992 |
Combination of 5-FU cisplatinum and hypofractionated irradiation followed by split-course radiotherapy in 47 patients with unresectable non small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 1992 |
5-Fluorouracil-induced pseudoporphyria.
Topics: Adenocarcinoma; Diagnosis, Differential; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Mid | 1992 |
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1992 |
Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Fluorouracil; Glycine; Leukemia L | 1992 |
[Inoperable brain metastases from bronchogenic cancers. Value of combined chemotherapy with cisplatin and 5 fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Bronchogeni | 1992 |
[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colorectal Neoplasms; Dose-Response R | 1992 |
[CT guided direct intervention chemotherapy of lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
[5-FU-leucovorin and cisplatin sequential chemotherapy with dipyridamole for non-small cell lung cancer (NSCLC). A pilot study for 5 cases].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1991 |
Treatment of malignant trophoblastic tumors. An analysis of 209 cases.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1991 |
Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1991 |
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1991 |
Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluoroura | 1991 |
Alpha-interferon and oral fluorouracil in the treatment of unremovable and/or metastatic renal cancer.
Topics: Adult; Aged; Bone Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alp | 1991 |
[Chemotherapy with cisplatin and 5-fluorouracil in inoperable brain metastases of bronchopulmonary cancers].
Topics: Adult; Aged; Brain Neoplasms; Cisplatin; Drug Therapy, Combination; Echoencephalography; Fluorouraci | 1991 |
Establishment and biochemical properties of cis-diamminedichloroplatinum(II)-resistant A549 lung cancer cells.
Topics: Cell Division; Cisplatin; Drug Resistance; Fluorouracil; Humans; Kinetics; Lung Neoplasms; S Phase; | 1991 |
[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1991 |
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1991 |
Inhibitory effect of a biscoclaurine alkaloid, cepharanthin, on lung metastasis of Lewis lung carcinoma.
Topics: Alkaloids; Aminopyrine N-Demethylase; Aniline Hydroxylase; Animals; Benzylisoquinolines; Drug Therap | 1991 |
In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Do | 1991 |
[Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Screening Assays, | 1991 |
The effect of cancer and chemotherapy on monocyte function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell; Cyclophosph | 1990 |
[High-dose Tegafur (FT) for primary lung cancer: a phase I trial].
Topics: Drug Administration Schedule; Drug Evaluation; Fluorouracil; Humans; Infusions, Intravenous; Lung Ne | 1991 |
Metastatic basal cell carcinoma: report of a case presenting with respiratory failure.
Topics: Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neopla | 1991 |
5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1991 |
Carmofur-induced organic mental disorders.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Electroencephalography; Female; Fluorouracil; Follow-U | 1990 |
Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherap | 1990 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas.
Topics: Adenocarcinoma; Carbon-Nitrogen Ligases; Carcinoma, Squamous Cell; DCMP Deaminase; DNA-Directed DNA | 1990 |
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1990 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo | 1990 |
Long-term complete remission of stage IV breast cancer after high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1990 |
Combined modality therapy for locally advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Negative phase II study of 5-fluorouracil with high-dose leucovorin in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Fluorouracil; Humans; Leucovor | 1990 |
5-Fluorouracil carcinogenesis in BALB/c mice.
Topics: Animals; Carcinogenicity Tests; Female; Fluorouracil; Injections, Intraperitoneal; Leukemia, Lymphoc | 1990 |
[A case of esophageal carcinoma with the lung and liver metastases surviving more than 3 years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Ci | 1990 |
Pulmonary carcinoid presenting as multiple subcutaneous nodules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Female; Fluorouracil; Humans; Leuco | 1990 |
[Assessment of individual sensitivity to chemotherapy of human pulmonary tumors transplanted to subrenal capsule of CBA mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1990 |
[Drug therapy of pulmonary metastases of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans | 1990 |
[The treatment of refractory choriocarcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomyc | 1990 |
[Current perspectives in the management of non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Evaluation; | 1985 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
[Effect of combination immunochemotherapy with an organogermanium compound, Ge-132, and antitumor agents on C57BL/6 mice bearing Lewis lung carcinoma (3LL)].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Fluoroura | 1986 |
[Chemotherapy combined with selective resection in small cell lung cancer--analysis of 239 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Combined Modality | 1986 |
[Combination therapy of advanced choriocarcinoma--an analysis of 60 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality | 1986 |
Conventional fractionation radiotherapy combined with 5-fluorouracil for metastatic malignant melanoma.
Topics: Abdominal Neoplasms; Adult; Aged; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Liver Neoplasm | 1987 |
Toxicity of FED chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carcinoma, Non-Small-Cell | 1987 |
[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1988 |
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor | 1989 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
The use of simultaneous radiotherapy and 5-flurouracil in patients with inoperable squamous cell lung cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Lung Neopla | 1989 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
[Effect of uracil on the both reactions, 5-fluorouracil degradation into 2-fluoro-beta-alanine and 5-fluorouracil splitting from tegafur in human tumor].
Topics: Adenocarcinoma, Papillary; Alanine; beta-Alanine; Fluorouracil; Humans; Lung Neoplasms; Tegafur; Tum | 1989 |
[Serum and tissue concentration of tegafur and 5-FU after administration of tegafur suppository in patients with lung cancer--correcting the influence of residual blood in the tissue].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Suppositories; T | 1989 |
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom | 1989 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1989 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation in unresectable non-small cell lung cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 1989 |
5-Fluorouracil infusion and mitomycin combination chemotherapy in the management of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ev | 1989 |
[Current status in the treatment of inoperable non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Ca | 1985 |
Advanced prostatic carcinoma: pulmonary manifestations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Fluorouracil; Hum | 1985 |
[Continuous venous infusion in cancer chemotherapy].
Topics: Bleomycin; Bone Marrow; Breast Neoplasms; Cytarabine; Doxorubicin; Drug Administration Schedule; Flu | 1985 |
Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Cell Survival; Cells, Cultured; Cisplatin; Doxor | 1985 |
Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1989 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
[A case of non-functioning adrenal cortical carcinoma with pulmonary and bony metastases].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Agents; Bone Neoplasms; Combined Modality Th | 1989 |
Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1989 |
Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1989 |
[A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Kidney Neopla | 1989 |
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.
Topics: Amphotericin B; Animals; Antimetabolites, Antineoplastic; Dipyridamole; Drug Evaluation, Preclinical | 1989 |
Increased contraenvironmental-pressure cell division capability: a decisive force in metastasis and invasion of mouse lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Clone Cells; Fluorouracil; Lung Neoplasms; Mice; | 1989 |
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Dr | 1989 |
Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
[5-FU intra-arterial infusion and simultaneous irradiation in the treatment of esophageal cancer and metastatic lung cancer].
Topics: Adult; Aorta, Thoracic; Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Female; Fluorour | 1989 |
[Antitumor effects of 5-fluorouracil-bound organic silicon compound].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Ethyla | 1989 |
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo | 1989 |
[Evaluation of combined chemotherapy including high-dose cisplatin in the treatment of malignant tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell L | 1987 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
Phase II pilot study with cisplatin, etoposide, and continuous-infusion 5-fluorouracil in metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1988 |
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell L | 1988 |
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1988 |
Multimodality treatment of non-small cell lung cancer: response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cel | 1988 |
Simultaneous chemotherapy-radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 1988 |
Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1988 |
[State III large cell carcinoma of the lung cured by radiotherapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Cytarabine; | 1988 |
Role of small doses of radiotherapy combined with chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1988 |
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorou | 1989 |
Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.
Topics: Animals; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Leukemia L1210; Lung N | 1986 |
Pharmacological modulation of photodynamic therapy with hematoporphyrin derivative and light.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Syner | 1987 |
Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Topics: Animals; Antimetabolites; Deoxycytidine; Female; Floxuridine; Fluorouracil; Lung Neoplasms; Mice; Te | 1987 |
[Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouraci | 1988 |
Stem cell defects after cytoreductive therapy in man.
Topics: Animals; Antineoplastic Agents; Blood Cells; Bone Marrow; Breast Neoplasms; Carcinoma, Small Cell; C | 1985 |
[Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1986 |
[Combination therapy of small cell anaplastic carcinoma of the lung and the role of prophylactic whole brain irradiation--report of 39 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinoma, Small Cell | 1985 |
Adenoid cystic carcinoma of the esophagus. Complete response to combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Adenoid Cystic; Cisplati | 1986 |
Phase II trial of 5-FU, vincristine, and mitomycin (FOMi) in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Eval | 1985 |
Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1987 |
[UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; | 1987 |
Five-year survival following chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubic | 1987 |
5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1987 |
Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisp | 1988 |
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Fluorouracil; Follow- | 1986 |
Combination chemotherapy for advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
[5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 1986 |
[Serum and tissue concentrations of UFT in patients with lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymph No | 1986 |
[Effects of intravenous feeding on adjuvant chemotherapy--an experimental study on the distribution of 5-FU after injection of tegafur (1)].
Topics: Animals; Fluorouracil; Liver; Lung Neoplasms; Male; Parenteral Nutrition; Rats; Rats, Inbred Strains | 1987 |
[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Fluor | 1987 |
[FO-152].
Topics: Absorption; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Dogs; Drug Evaluation; Female | 1987 |
[Effects of intravenous alimentation on adjuvant chemotherapy--an experimental study on the distribution of 5-FU after injection of tegafur (2)].
Topics: Animals; Fluorouracil; Injections, Intravenous; Lung Neoplasms; Parenteral Nutrition, Total; Rats; T | 1987 |
[Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Flu | 1988 |
[Experimental and clinical study of interactions between fluorinated pyrimidine derivatives and anticoagulants].
Topics: Animals; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug | 1988 |
[Intra-arterial drug infusion via the bronchial artery in the treatment of bronchogenic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Bronchog | 1988 |
[Experimental results of survivals with different dose schedule of 5-FU and 5'-DFUR].
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Floxuridine; Fluorouracil; Lung Neopla | 1985 |
Role of dose, schedule and route of administration of 5-formyltetra-hydrofolate: preclinical and clinical investigations.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1988 |
Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy.
Topics: Bronchial Fistula; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Fluorouraci | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
[Experimental and clinical studies of nebulization chemotherapy in the treatment of lung cancer].
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Animals; Dogs; Female; Fluorouracil; Humans; Lu | 1988 |
[Central squamous cell carcinoma of the lung and its management by transbronchoscopic topochemotherapy and combination radiotherapy].
Topics: Adult; Aged; Bronchoscopy; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy | 1987 |
[Complete regression of breast cancer and its lung metastases after chemohormonotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1986 |
[Clinical study of clonogenic assays--with reference to adjuvant cancer chemotherapy after operation].
Topics: Antineoplastic Agents; Colonic Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Flu | 1986 |
[Pharmacokinetics of 1-phthalidyl-5-fluorouracil (PH-FU)].
Topics: Administration, Oral; Animals; Biological Assay; Fluorouracil; Kinetics; Liver Neoplasms, Experiment | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Effects of a blended Chinese medicine, xiao-chai-hu-tang, on Lewis lung carcinoma growth and inhibition of lung metastasis, with special reference to macrophage activation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Complement C3; Cyclo | 1986 |
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Combined Modalit | 1986 |
[Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional Cell; | 1986 |
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1986 |
Inhibition of experimental pulmonary metastasis in mice by beta-cyclodextrin-benzaldehyde.
Topics: Animals; Benzaldehydes; beta-Cyclodextrins; Cyclodextrins; Cytotoxicity, Immunologic; Dextrins; Fluo | 1986 |
[4-component chemotherapy and radiation therapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1986 |
Verapamil enhances antitumor activity without increasing myeloid toxicity.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Drug Synergism; Drug Therapy, Combination; Female; Fluo | 1987 |
[Antimetastatic properties of aloe juice].
Topics: Aloe; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyc | 1986 |
Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours.
Topics: Aerobiosis; Animals; Combined Modality Therapy; Fluorouracil; Lung Neoplasms; Mammary Neoplasms, Exp | 1987 |
[Chemotherapy of bronchopulmonary and pleural adenocarcinoma. Apropos of 31 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 1985 |
[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cell Membrane Permeability; Female; Fluoroura | 1985 |
Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: comparison of two FAM schedules.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
[Treatment of metastasized breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1986 |
[Experimental studies with the use of metastatic clones isolated from mouse tumors].
Topics: Adenocarcinoma; Animals; Clone Cells; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; | 1985 |
Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evalu | 1985 |
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Ev | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.
Topics: Animals; Carcinoma 256, Walker; Carcinoma, Squamous Cell; Cell Line; Dose-Response Relationship, Dru | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1985 |
Effects of anticancer drugs on folate disposition and excretion.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Folic Acid; Liver; Lung Neoplasms; M | 1985 |
Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
[Palliative treatment in patients with lung cancer].
Topics: Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Methenolone; Palliative Care; Radiation Inju | 1971 |
[Experiences in the palliative chemotherapy of 228 cases of unmeasurable and 52 measurable intrapulmonary tumors].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neopla | 1971 |
[Mitomycin alone and in therapeutic association in the palliative treatment of solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Drug Combinations; Femal | 1971 |
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenicals; Benzoates; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Ch | 1972 |
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso | 1973 |
Alternative approaches to radiotherapy alone and radiotherapy as a part of a combined therapeutic approach for lung cancer.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neop | 1973 |
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
Topics: Adenocarcinoma; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Doxorubicin; Fluoroura | 1973 |
Effect of anticancer chemotherapy on the lymphocyte blastoid transformation.
Topics: Adult; Aged; Animals; Bleomycin; Cyclophosphamide; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1973 |
Potentially useful combinations of chemotherapy detected in mouse tumor systems.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Azauridine; Bleomycin; Camptothecin; Cyclic P-Oxides | 1974 |
Metastatic basal cell carcinoma: review, report of a case, and chemotherapy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bleomycin; Carcinoma, Basal Cell; Cyclophosphamide; Dru | 1974 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
[On the question of preclinical selection of cytostatics in the area of treatment of human tumors].
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Culture Te | 1969 |
Chemotherapy for lung cancer at the Institute of Experimental and Clinical Oncology, Academy of Medical Sciences, USSR.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcino | 1973 |
[Postoperative bronchopleural complications in the combined treatment of lung cancer].
Topics: Adult; Antineoplastic Agents; Bronchial Fistula; Cyclophosphamide; Dose-Response Relationship, Radia | 1974 |
Conservative management of malignant pericardial effusion.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cardiomegaly; Female; Fluorouracil; Follow-Up Studies | 1974 |
Hypercalcemia in cancer: response to therapy.
Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil; | 1974 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Metabolically active liver metastases treated by 5-fluorouracil hepatic artery infusion.
Topics: Adenoma, Islet Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Hepatic Artery; Hormones, Ectop | 1970 |
Hepatoma: long-term survival with disseminated tumor treated with 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Long-Term Care; Lung Neoplasms; Ma | 1970 |
Widespread extracranial metastases of glioblastoma multiforme. Report of case and clinicopathological review of cases in literature.
Topics: Adolescent; Autopsy; Biopsy; Bone Neoplasms; Brain Neoplasms; Carotid Arteries; Cauda Equina; Cerebr | 1972 |
The role of heparin in the chemotherapy of solid tumors: preliminary clinical trial in carcinoma of the lung.
Topics: Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Fibrinogen; Fluorouracil; H | 1972 |
Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Blood Coagulation; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Small | 1974 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
Chemotherapy for adenocarcinoma and alveolar cell carcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Female; Fluorouracil; Follow-Up Studies; | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
[Combined treatment methods in operable breast and lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Female; Flu | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Chemotherapy for recurrent carcinoma of the breast.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Injections, | 1972 |
[Polychemotherapy of broncho-pulmonary cancer: report of clinical research].
Topics: Adenocarcinoma; Adult; Aged; Bronchial Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Hu | 1972 |
[Features of regressive changes during chemotherapy of breast cancer metastases to the lungs].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neopl | 1972 |
[Experimental anc clinical studies on the sensitivity test for carcinostatic agent from the cytological point of view].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cells, Cultur | 1972 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
[Topical administration of carcinostatics to mediastinal lymph node lesion metastasized lung cancer--an adjuvant therapy in surgery of lung cancer].
Topics: Animals; Dogs; Fluorouracil; Gold Colloid, Radioactive; Humans; Injections; Injections, Intra-Arteri | 1972 |
[Results of single- and multiple-drug treatment of 183 cases of inoperable bronchopulmonary cancer].
Topics: Bronchial Neoplasms; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Lung Neoplasms; Methods | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
[Immediate results of polychemotherapy of patients with 3-4 stage lung cancer].
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Injections, Intravenous; Lung Neoplas | 1973 |
Chemotherapeutic studies in bronchogenic carcinoma by the Austrian study group.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Austria; Carcinoma, Bronchogenic; Cyclophosphamide; | 1973 |
The problems of drug treatment of breast cancer.
Topics: Age Factors; Alkylating Agents; Androgens; Bone Neoplasms; Breast Neoplasms; Corticosterone; Drug Co | 1973 |
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide | 1973 |
[Intra-aortic infusion of 5-fluorouracil and mitomycin-C and cobalt-60 radiation in progressive lung cancer].
Topics: Adult; Aged; Aorta, Thoracic; Cobalt Isotopes; Fluorouracil; Humans; Injections, Intra-Arterial; Lun | 1973 |
Timing of administration of 5-fluorouracil in combination with irradiation in the treatment of advanced adenocarcinoma. Comparison of methods used to assess radiological response to the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Lung Neoplasms; Male; Methods; Middle Ag | 1973 |
[Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen resistant metastases].
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Therapy, Combination; Estrogens; Fluorouracil; Fol | 1973 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
[Recent advances in the treatment of Ewing's sarcoma (author's transl)].
Topics: Adolescent; Adult; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Synergism; Female; Fluorouracil | 1974 |
[Combination chemotherapy with cyclophosphamide, methotrexate, 5-fluoro-uracil, and vincristine in solid metastasized tumours (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lung Neoplas | 1974 |
[Effect of 5-fluorouracl on the intestinal flora in oncological patients].
Topics: Biological Products; Enterobacteriaceae; Escherichia coli; Fluorouracil; Gastrointestinal Neoplasms; | 1966 |
Selective bronchial artery catheterization for diagnostic and physiologic studies and chemotherapy for bronchogenic carcinoma.
Topics: Adult; Aged; Angiography; Bronchial Arteries; Carcinoma, Bronchogenic; Catheterization; Fluorouracil | 1966 |
[Are combinations more effective than monotherapy in the matter of antiocancer chemotherapy?].
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Synergism; Female; Fluorouracil; Fl | 1968 |
[Antineoplastic polychemotherapy in thoracic pathology].
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cortisone; Cyclop | 1968 |
[3 years of polychemotherapy of pleuro-pulmonary cancer. Apropos of 95 cases].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Ne | 1968 |
[The chemotherapy of cancer].
Topics: Adult; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Dactinomycin; Female; Fluorouracil | 1967 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
The use of chemotherapy in lung cancer (controlled trials).
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Dactinomycin; Drug Synergism; Female; Fluorouraci | 1971 |
[Radiation and complex therapy of inoperable low-differentiated lung cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Time | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |
Combination chemotherapy in the treatment of metastatic hemangiopericytoma.
Topics: Administration, Oral; Cyclophosphamide; Dactinomycin; Fluorouracil; Hemangiopericytoma; Humans; Inje | 1972 |
Expectations and pitfalls of chemotherapy in a university cancer clinic.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Gastrointestinal Neoplasms; Hospitals, Tea | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
[Treatment of poorly differentiated lung cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Radi | 1972 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
Calusterone in the therapy for advanced breast cancer.
Topics: Adenocarcinoma; Axilla; Bone Neoplasms; Breast Neoplasms; Castration; Drug Synergism; Female; Fluoro | 1972 |
[The functional state of the liver during conservative treatment of oncologic patients].
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Esophageal Neoplasms; Fluorouracil; H | 1972 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
[Lung cancer].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Cobalt Isotopes; Cyclop | 1971 |
Complete regression of metastases following chemotherapy.
Topics: Aged; Cecal Neoplasms; Colectomy; Fluorouracil; Humans; Injections, Intravenous; Lung Neoplasms; Lym | 1971 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
Treatment of metastatic breast cancer with a combination of adrenalectomy and 5-fluorouracil. Progress report.
Topics: Adrenalectomy; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Huma | 1971 |
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human | 1971 |
[Evaluation, in newborn Swiss mice, of the carcinogenic activity of some antineoplastic and immunosuppressive compounds].
Topics: Adenoma; Animals; Animals, Newborn; Antineoplastic Agents; Asparaginase; Azathioprine; Fluorouracil; | 1971 |
[On the treatment of bronchopulmonary cancer with various methods of monochemotherapy and polychemotherapy].
Topics: Antineoplastic Agents; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Lung Neoplasms; | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Bronchial artery infusion with anticancer agents in the treatment of osteosarcoma. Prevention of pulmonary metastasis and improvement of prognosis.
Topics: Adolescent; Adult; Angiography; Aortic Coarctation; Blood Cell Count; Bronchial Arteries; Catheteriz | 1971 |
Distant metastases from beta-naphthylamine induced vesical tumors in dogs.
Topics: Animals; Carcinogens; Carcinoma, Transitional Cell; Dogs; Female; Fluorouracil; Lung Neoplasms; Naph | 1969 |
Bronchial artery infusion therapy for lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Bronchial Arteries; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cath | 1969 |
[Cytological control of expectoration in primary broncho-pulmonary cancers treated by chemotherapy, radiotherapy or surgical exeresis].
Topics: Bronchial Neoplasms; Carcinoma, Squamous Cell; Cobalt; Cyclophosphamide; Cytodiagnosis; Female; Fluo | 1969 |
New approaches in administration of anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans | 1969 |
Combined 5-fluoro-uracil and procarbazin in the treatment of lung metastases from different carcinomas.
Topics: Adult; Aged; Benzoates; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms | 1969 |
[Polychemotherapy of bronchial carcinoma].
Topics: Aged; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; | 1970 |
[Our experience with Vinca alkaloids in the poly-chemotherapy of inoperable bronchopulmonary cancer].
Topics: Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Fluorouracil; Humans; Lung Neoplasms; | 1970 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
The influence of treatment on the survival of patients with hepatic metastases diagnosed by liver scanning.
Topics: Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Hepatectomy; Humans; | 1970 |
Preferential attack on cancer by selected SH inhibitors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor; | 1970 |
Combination chemotherapy in the management of breast cancer metastases.
Topics: Adult; Aged; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Fe | 1970 |
Immunosuppression by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel | 1970 |
An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzoates; Blood Cell Count; Carcinoma; Carcinoma, Bro | 1970 |
[Polychemotherapeutic treatment of pulmonary neoplasms].
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Drug Synergism; Evaluation Studies as Topic; Fluorouracil | 1970 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[Combined therapy with 5-fluorouracil and irradiation in the treatment of lung cancer].
Topics: Adult; Aged; Cobalt Isotopes; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 1967 |
[Anticancer chemotherapy with evaluation of combined treatments].
Topics: Adolescent; Adult; Aged; Alkylating Agents; Amides; Antibiotics, Antineoplastic; Antineoplastic Agen | 1968 |
[The results of attack polychemotherapy in broncho-pleuro-pulmonary cancer. Phytohemagglutinin in the prevention and treatment of hematologic complications of antimitotics].
Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; | 1968 |
[Trial polychemotherapy of inoperable cancer (apropos of 71 cases)].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamo | 1968 |
[Clinical trial of polychemotherapy of inoperable bronchopulmonary cancers].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Cyclophosphamide; Drug Synergism; Fluorouracil | 1968 |
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms | 1968 |
[Polychemotherapy of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophos | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop | 1968 |
[Chemotherapy of lung cancer].
Topics: Adult; Aged; Cobalt Isotopes; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
[Topical intra-arterial infusion of antineoplastic agents].
Topics: Adult; Aged; Antimetabolites; Catheterization; Female; Femoral Neoplasms; Fluorouracil; Humans; Inje | 1968 |
[A case of successful use of 5-fluorouracil and cyclophosphane in metastasis of cancer of the breast].
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neopl | 1968 |
[Combined therapy of lung carcinoma with 5-fluorouracil and 60Co irradiation].
Topics: Adult; Aged; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; F | 1968 |
Response to 5-fluorouracil of lung metastases from bladder and breast cancers.
Topics: Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastas | 1969 |
Relation of thymidine index to pulmonary tumor response in mice receiving urethan and other carcinogens.
Topics: Animals; Autoradiography; Carbamates; Carcinogens; Cytarabine; Dactinomycin; DNA; Fluorouracil; Inje | 1969 |
[Cytostatic therapy of lung and pleural neoplasms].
Topics: Cyclophosphamide; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleu | 1965 |
[The use of 5-fluorouracil in the therapy of some epithelial tumors].
Topics: Adenocarcinoma; Breast Neoplasms; Carcinosarcoma; Fluorouracil; Humans; Intestinal Neoplasms; Lung N | 1966 |
Chemotherapy for lung cancer by intra-aortic infusion.
Topics: Aorta; Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intra-Ar | 1966 |